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Abstract 
Ihe occurrence of various forms of cancer has been recorded since 
prehistoric era, modern lifestyle has only aggravated its incidence to 
gargantuan levels. The types and complexity of cancer are mind-boggling. 
Despite worldwide efforts being made to find ways to stop this scourge, 
an effective cure of cancer remains an uphill task. One in every twelve 
persons up to 64 years of age is likely to be afflicted by one or other form 
of cancer in his/her lifetime. Global efforts continue to give rise to a wide 
range of anti-cancer agents with desirable therapeutic potential. 
However, many of these agents have solubility, stability or toxicity issues 
that retard or prevent their development into viable treatment strategies. 
In many cases, targeted delivery has been found to successfully tackle 
many of such issues. To date, many nano-sized systems such as 
liposomes, micelles, and nanoparticles have been explored for systemic 
delivery of anti-cancer agents. Among these technologies, liposomes have 
become the most well characterized and well established. With clinical 
implimentations of liposomes as drug delivery systems against cancer 
treatment, a series of strategies have been developed and modified to 
enhance the therapeutic efficacy of liposomised chemotherapeutic 
agents. A number of obstacles such as in vivo instability, short half-life in 
the blood circulation, and lack of target specificity have impeded the 
clinical application of liposomes as anticancer drug delivery systems. 
These obstacles have been partially resolved by significant efforts of 
researchers that ultimately resulted in development of clinically approved 
liposomal formulations. However, there is ample scope of further 
development, particularly in the enhancement of target specificity to 
improve the therapeutic efficacy of liposome-based drugs. The major 
clinical challenge for cancer therapy remains the eradication (or 
prevention) of metastatic disease. A principal barrier to destruction of 
disseminated cancer is its heterogeneous nature as most of the tumors 
contain subpopulations of cells that are able to subvert host defenses 
and recruit infiltrating cells that supply needed growth factors and blood 
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supply. Moreover, metastatic lesions can become autonomous with 
respect to homeostatic mechanisms of normal tissue architecture. This 
not only poses main obstacle to most of available chemotherapeutic 
agents but also affect the success of immunotherapy or the use of 
biological response modifiers in cancer treatment. 
The foreignness/nonself nature of cancer tissue can evoke immune 
system of the host. As first line of defense against cancer, the 
macrophages infiltrate the lesions. In general, presence of inflammatory 
macrophages in growing tumors is maintained through recruitment of 
circulating monocytes, and in certain tumors, these are developed by the 
proliferation of mononuclear phagocytes. In regressing murine sarcomas, 
tumor-associated macrophages (TAMs) are found throughout the tumors, 
whereas in progressing sarcomas, TAMs are confined to the periphery of 
the tumor. The presence of noncytotoxic (nonactivated) macrophages in 
neoplasms could actually enhance tumor growth. Macrophages (and 
lymphocytes) produce many diffusible growth, angiogenic, and cytotoxic 
factors. According to the type and level of such mediators, TAMs, 
therefore, may enhance or inhibit the growth of neoplasms. 
Macrophages recognize numerous molecules via a wide variety of 
their plasma membrane receptors that interact with a specific ligand, an 
extracellular protein as well as with adhesion molecules such as the 
integrins. Although carbohydrates and proteins have long been known to 
play an important role in cell-cell interactions, or as antigenic structures 
on cell surface, an increasing body of evidence suggests that 
phospholipids which comprise the cell membrane bilayer are also 
involved in macrophage mediated recognition of target cells. The 
mechanism for this recognition is nonimmunologic and requires cell-to-
cell contact. Because activated macrophages can destroy phenotypically 
diverse tumor cell populations including those resistant to killing by 
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other host-defense mechanisms and by anticancer drugs. Macrophage-
directed therapy represents a potential strategy for elimination of 
biologically heterogeneous metastatic cells. New therapies based upon 
stimulation of natural immune mechanisms must be able to circumvent 
tumor heterogeneity, killing of cells that are resistant to conventional 
cytotoxic therapies, and ability to provoke host-mediated defenses that 
favor eradication of metastatic tumor cells. Besides, there is an intense 
effort to develop newer specific cancer therapies that target altered 
genetic pathways in tumors. The benefit of such therapies lies in the 
exploitation of these alterations to achieve an improved therapeutic ratio. 
The ability to differentiate between normal and tumor cells is contingent 
upon the identification of an appropriate molecular target, development 
of modalities that address this target, and most importantly targeted 
delivery of the potent anticancer agent to the tumor cells. The tumor 
microenvironment is a critical factor in such development since it acts as 
a barrier for the delivery of effective treatment. Besides it can also 
influence the tumor cell phenotype, and thus the appropriateness of a 
given molecular target, and act as a barrier for the delivery of effective 
treatment 
It can be speculated that targeted delivery of chemotherapeutic 
agents in combination with immunomodulators may also offer a 
promising strategy to eliminate cancer. The activation of immune system 
could be made possible by certain chemical agents (mostly originated 
from natural sources) that can modulate immune function 
non specifically. Among various immunomodulators, tuftsin, a 
tetrapeptide fragment from IgG (289-292 residue of the Fc region) has 
been found to be effective against cancer as well as infectious diseases. 
In the present work, its liposomised form has been used extensively for 
prophylaxis and chemotherapy against polycyclic aromatic 
hydrocarbons-induced hepatic alterations and fibrosarcoma in model 
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animals. We have evaluated augmentation of antitumor potential of 
liposomal etoposide (ETP) by tuftsin against benzo (a) pyrene induced 
fibrosarcoma in Swiss albino mice. The efficacy of the free form of ETP, 
liposomised ETP (Lip-ETP) as well as tuftsin-bearing liposomised ETP 
(Tuft-Lip-ETP) formulations was evaluated on the basis of tumor 
regression, effect on expression level of p53wt and p53mut as well as 
survival of the treated animals. Tuft-Lip-ETP (ETP dose 10 mg/kg body 
weight/day) when administered for 5 days, significantly reduced tumor 
volume, delayed tumor growth and also up-regulated the expression of 
p53wt. In contrast, though Lip-ETP delayed tumor growth, it could not 
decrease tumor size. We also tried to understand the multiple signaling 
pathways involved in the regression of tumor by liposomal etoposide 
associated tuftsin against fibrosarcoma by monitoring changes at mRNA 
as well as protein level. The treatment with liposomised tuftsin was 
found to modulate both p53 and p21 /waf 1 in dose dependent manner. A 
single-dose of tuftsin-bearing liposomal etoposide (Tuft-Lip-ETP) was 
found to normalize level of p53wt, p53mut and p21/waf-l in the animals 
that were preexposed to benzo (a) pyrene treated animals. On the other 
hand, the effect of tuftsin-bearing liposomal etoposide on expression of 
bcl-2, bax and caspase-3 was same as observed in animals treated with 
tuftsin-free liposomal etoposide (Lip-ETP) but significantly distinct from 
that induced by free etoposide as well as sham tuftsin-liposomes. The 
results suggest that tuftsin-bearing liposomal etoposide, a novel 
chemotherapeutic formulation, is capable of favorably regulating the 
tumor suppressor p53 along with its downstream effective molecule, 
p21/wafl in the treatment of various forms of cancer. 
In the next phase of study, we tried to evaluate the 
hepatoprotective properties of tuftsin against 7,12 dimethylbenz (a) 
anthracene (DMBA) induced alteration in liver of Swiss albino mice. 
Administration of tuftsin effectively alleviates DMBA induced oxidative 
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stress, characterized by reduction in apoptotic cell population in 
hypodiploid region. The inhibition of apoptosis was preceded by decrease 
in reactive oxygen species (ROS) level and restoration of mitochondrial 
transmembrane potential. To further elucidate the mechanism of anti-
apoptotic effect of tuftsin, we tried to understand its effect on signaling 
pathways. In DMBA-treated animals down-regulation of antiapoptotic 
Bcl-2 and up-regulation of proapoptotic Bax and Caspase 3 was observed 
in mouse liver. The reduced expression level of phosphatidylinositol 3-
kinase (PI3-K) followed by the activation of Akt were also observed. These 
alterations were restored by tuftsin, indicating Akt-mediated inhibition of 
apoptosis by tuftsin. The data of the present study demonstrate that 
tuftsin is effective in combating oxidative stress induced cellular injury of 
liver cells by modulating Akt, a cell-growth regulator. 
We also tried to understand the chemopreventive effect of various 
liposomal formulation of a dietary constituent diallyl sulphide (DAS) 
isolated from garlic. The use of chemicals as an alternative to the 
conventional medicines in the form of food and food products is an 
effective approach for the treatment of chronic diseases, including 
cancer. The intervention of chemopreventive strategies for controlling 
genetic diseases using dietary constituents provides a strong rationale to 
arrest or reverse the process of carcinogenesis before metastasis occur. 
During the past few years, cancer chemoprevention by dietary 
constituents has received a great deal of attention and as a means of 
effective control over cancer. Studies on the tumor inhibitory compounds 
of plant origin have yielded an impressive array of novel structures. 
Besides, epidemiological studies suggest that consumption of diets 
including fruits and vegetables may reduce the risk of developing cancer. 
Garlic (Allium sativum) has been shown to possess potential health 
benefits (cf. lipid lowering, antimicrobial, chemo-preventive and 
anticarcinogenic properties) since beginning of recorded history and is 
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probably one of the most widely studied medicinal plants. The 
chemotherapeutic and antitumor activity associated with garlic has been 
attributed to the presence of various organosulfide based active 
compounds including DAS. Of the various options available for 
administration of medicaments, topical application is the most promising 
approach for treating skin tumors as it leads to localized release of drug 
at desired site with minimal side effects. However, retention of drugs 
administered by this mode is low because of extensive diffusion that is 
more apparent in case of small sized molecules such as DAS. This 
warrants development of formulations that can modulate 
pharmacokinetics as well as pharmacodynamic properties of DAS 
thereby making it more efficacious. 
Among various novel drug delivery systems, micro-particulate-
based carrier systems viz. micro-emulsion, nano-emulsion, 
nanoparticles, liposomes, etc. have been reported to improve delivery of 
drug to the skin. Interestingly, liposome-based formulations, when 
employed for topical delivery, have been shown to be extremely promising 
for enhancement of drug penetration, improved pharmacological effects, 
decreased side effects, controlled drug release and above all their own 
biodegradable nature. In this regard, considerable attention has been 
focused on the use of natural as well as tailor-made phospholipid 
vesicles or liposomes to enhance the therapeutic potential of anticancer 
agents. 
In the present study, we have evaluated chemo-preventive effects 
of liposomised-DAS (conventional egg PC, pH-sensitive liposomes and 
escheriosomes) against DMBA-induced skin papilloma. Various 
liposome-based novel formulations of DAS (250 |ig/mouse) were applied 
topically to the animals after 1 hour of exposure to DMBA (52 
|ng/mouse/dose). The animals were treated thrice weekly for a total 
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period of 12 weeks. The efficacy of the various liposomal formulations of 
DAS was evaluated on the basis of parameters such as incidence of 
tumorogenesis, total numbers and sizes of induced tumor nodules. The 
liposomised DAS formulations were also assessed for their effect on the 
expression of p53wt, p53mut as well as p21/Wafl. The results of the 
present study showed that liposomised DAS could effectively delay the 
onset of tumorogenesis and reduce the cumulative numbers and size of 
tumor papillomas in treated mice. Treatment of DMBA exposed animals 
with liposomal formulation of DAS ensued in up-regulation of p53wt and 
p21/Wafl, while level of p53mut expression was reduced. The promising 
chemo-preventive nature of liposomal DAS may form the basis for 
establishing effective means of controlling various forms of cancer 
including skin papilloma. 
The cytosol of cells is an important but relatively inaccessible 
compartment for many therapeutic macromolecules. Due to unfavorable 
physicochemical characteristics, in particular large size, or preferential 
solubility, molecules often show restricted ability to pass through plasma 
membranes. There is a strong need for a carrier that can deliver 
membrane-impermeable molecules into the cytosol of target cells. 
Although liposomes have been widely used for the delivery of therapeutic 
compounds, their ability to deliver entrapped molecules into cytosol of 
the target cell remains inefficient. This problem was circumvent was 
using pH-sensitive liposomes, which release their contents into 
cytoplasm of the target cells. This approach relies on their selective 
destabilization in the endolysosomal compartment under acidic pH of the 
surrounding medium. In fact, pH sensitive liposomes undergo 
phosphatidyl-ethanolamine (main constituent of these liposomes) 
mediated phase transition at acidic pH, thereby delivering their content 
to the cytosol of the tumor cells. The polar head group of PE gets less 
hydrated as compared to repulsive hydration layer associated with the 
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head group of PC. Thus PE provides a more hydrophobic bilayer surface 
that is susceptible to energetically more favorable interbilayer 
interactions. The phospholipids facilitate not only the close approach of 
bilayers, there may also be directly involved in the merging process. In 
this context PE can form the hexagonal Hn phase, the formation of which 
involves the development of non-lamellar structure, an intermediate in 
membrane fusion. The operative mechanism seems to form the basis of 
the observed higher efficacy of pH sensitive liposomes over egg PC 
neutral liposomes. 
Keeping into consideration, significance of cytosolic delivery of 
drugs to effectively control various forms of cancer, we have also 
developed fusogenic liposomes using lipids isolated from Eschericia coli. 
The lipids were shown to induce strong membrane-membrane fusion as 
evident from Resonance Energy Transfer and Content Mixing Assays. 
Further, the fusion of these liposomes with model living cells (J774 A.l) 
was demonstrated to result in effective transfer of fluorescent lipid probe 
to the plasma membrane of the cells. Moreover, these liposomes 
effectively delivered encapsulated ricin A molecule to the cytosol of the J 
774A. 1 cells, which ultimately resulted in the inhibition of cellular 
protein synthesis. Interestingly, the liposomes were also found to be 
efficient vehicles for the in vivo delivery of the drugs to cytosol of the 
target cells resulting in the destruction of tumor cells more efficiently. We 
entrapped DAS in escheriosomes (EC-Lip-DAS) and evaluate the efficacy 
of EC-Lip-DAS in chemoprevention against skin papilloma in model 
animals. These results imply usage of liposome based drug formulation 
in prophylaxis as well as chemotherapy against various forms of cancer. 
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lhe occurrence of various forms of cancer has been recorded since 
prehistoric era, modern lifestyle has only aggravated its incidence to 
gargantuan levels. The types and complexity of cancer are mind-boggling. 
Despite worldwide efforts being made to find ways to stop this scourge, 
an effective cure of cancer remains an uphill task. One in every twelve 
persons up to 64 years of age is likely to be afflicted by one or other form 
of cancer in his /her lifetime. Global efforts continue to give rise to a wide 
range of anti-cancer agents with desirable therapeutic potential. 
However, many of these agents have solubility, stability or toxicity issues 
that retard or prevent their development into viable treatment strategies. 
In many cases, targeted delivery has been found to successfully tackle 
many of such issues. To date, many nano-sized systems such as 
liposomes, micelles, and nanoparticles have been explored for systemic 
delivery of anti-cancer agents. Among these technologies, liposomes have 
become the most well characterized and well established. With clinical 
implimentations of liposomes as drug delivery systems against cancer 
treatment, a series of strategies have been developed and modified to 
enhance the therapeutic efficacy of liposomised chemotherapeutic 
agents. A number of obstacles such as in vivo instability, short half-life in 
the blood circulation, and lack of target specificity have impeded the 
clinical application of liposomes as anticancer drug delivery systems. 
These obstacles have been partially resolved by significant efforts of 
researchers that ultimately resulted in development of clinically approved 
liposomal formulations. However, there is ample scope of further 
development, particularly in the enhancement of target specificity to 
improve the therapeutic efficacy of liposome-based drugs. The major 
clinical challenge for cancer therapy remains the eradication (or 
prevention) of metastatic disease. A principal barrier to destruction of 
disseminated cancer is its heterogeneous nature as most of the tumors 
contain subpopulations of cells that are able to subvert host defenses 
and recruit infiltrating cells that supply needed growth factors and blood 
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supply. Moreover, metastatic lesions can become autonomous with 
respect to homeostatic mechanisms of normal tissue architecture. This 
not only poses main obstacle to most of available chemotherapeutic 
agents but also affect the success of immunotherapy or the use of 
biological response modifiers in cancer treatment. 
The foreignness/nonself nature of cancer tissue can evoke immune 
system of the host. As first line of defense against cancer, the 
macrophages infiltrate the lesions. In general, presence of inflammatory 
macrophages in growing tumors is maintained through recruitment of 
circulating monocytes, and in certain tumors, these are developed by the 
proliferation of mononuclear phagocytes. In regressing murine sarcomas, 
tumor-associated macrophages (TAMs) are found throughout the tumors, 
whereas in progressing sarcomas, TAMs are confined to the periphery of 
the tumor. The presence of noncytotoxic (nonactivated) macrophages in 
neoplasms could actually enhance tumor growth. Macrophages (and 
lymphocytes) produce many diffusible growth, angiogenic, and cytotoxic 
factors. According to the type and level of such mediators, TAMs, 
therefore, may enhance or inhibit the growth of neoplasms. 
Macrophages recognize numerous molecules via a wide variety of 
their plasma membrane receptors that interact with a specific ligand, an 
extracellular protein as well as with adhesion molecules such as the 
integrins. Although carbohydrates and proteins have long been known to 
play an important role in cell-cell interactions, or as antigenic structures 
on cell surface, an increasing body of evidence suggests that 
phospholipids which comprise the cell membrane bilayer are also 
involved in macrophage mediated recognition of target cells. The 
mechanism for this recognition is nonimmunologic and requires cell-to-
cell contact. Because activated macrophages can destroy phenotypically 
diverse tumor cell populations including those resistant to killing by 
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other host-defense mechanisms and by anticancer drugs. Macrophage-
directed therapy represents a potential strategy for elimination of 
biologically heterogeneous metastatic cells. New therapies based upon 
stimulation of natural immune mechanisms must be able to circumvent 
tumor heterogeneity, killing of cells that are resistant to conventional 
cytotoxic therapies, and ability to provoke host-mediated defenses that 
favor eradication of metastatic tumor cells. Besides, there is an intense 
effort to develop newer specific cancer therapies that target altered 
genetic pathways in tumors. The benefit of such therapies lies in the 
exploitation of these alterations to achieve an improved therapeutic ratio. 
The ability to differentiate between normal and tumor cells is contingent 
upon the identification of an appropriate molecular target, development 
of modalities that address this target, and most importantly targeted 
delivery of the potent anticancer agent to the tumor cells. The tumor 
microenvironment is a critical factor in such development since it acts as 
a barrier for the delivery of effective treatment. Besides it can also 
influence the tumor cell phenotype, and thus the appropriateness of a 
given molecular target, and act as a barrier for the delivery of effective 
treatment 
It can be speculated that targeted delivery of chemotherapeutic 
agents in combination with immunomodulators may also offer a 
promising strategy to eliminate cancer. The activation of immune system 
could be made possible by certain chemical agents (mostly originated 
from natural sources) that can modulate immune function 
nonspecifically. Among various immunomodulators, tuftsin, a 
tetrapeptide fragment from IgG (289-292 residue of the Fc region) has 
been found to be effective against cancer as well as infectious diseases. 
In the present work, its liposomised form has been used extensively for 
prophylaxis and chemotherapy against polycyclic aromatic 
hydrocarbons-induced hepatic alterations and fibrosarcoma in model 
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animals. We have evaluated augmentation of antitumor potential of 
liposomal etoposide (ETP) by tuftsin against benzo (a) pyrene induced 
fibrosarcoma in Swiss albino mice. The efficacy of the free form of ETP, 
liposomised ETP (Lip-ETP) as well as tuftsin-bearing liposomised ETP 
(Tuft-Lip-ETP) formulations was evaluated on the basis of tumor 
regression, effect on expression level of p53wt and p53mut as well as 
survival of the treated animals. Tuft-Lip-ETP (ETP dose 10 mg/kg body 
weight/day) when administered for 5 days, significantly reduced tumor 
volume, delayed tumor growth and also up-regulated the expression of 
p53wt. In contrast, though Lip-ETP delayed tumor growth, it could not 
decrease tumor size. We also tried to understand the multiple signaling 
pathways involved in the regression of tumor by liposomal etoposide 
associated tuftsin against fibrosarcoma by monitoring changes at mRNA 
as well as protein level. The treatment with liposomised tuftsin was 
found to modulate both p53 and p21/wafl in dose dependent manner. A 
single-dose of tuftsin-bearing liposomal etoposide (Tuft-Lip-ETP) was 
found to normalize level of p53wt, p53mut and p21/waf-l in the animals 
that were preexposed to benzo (a) pyrene treated animals. On the other 
hand, the effect of tuftsin-bearing liposomal etoposide on expression of 
bcl-2, bax and caspase-3 was same as observed in animals treated with 
tuftsin-free liposomal etoposide (Lip-ETP) but significantly distinct from 
that induced by free etoposide as well as sham tuftsin-liposomes. The 
results suggest that tuftsin-bearing liposomal etoposide, a novel 
chemotherapeutic formulation, is capable of favorably regulating the 
tumor suppressor p53 along with its downstream effective molecule, 
p21/wafl in the treatment of various forms of cancer. 
In the next phase of study, we tried to evaluate the 
hepatoprotective properties of tuftsin against 7,12 dimethylbenz (a) 
anthracene (DMBA) induced alteration in liver of Swiss albino mice. 
Administration of tuftsin effectively alleviates DMBA induced oxidative 
Jl6stract 
stress, characterized by reduction in apoptotic cell population in 
hypodiploid region. The inhibition of apoptosis was preceded by decrease 
in reactive oxygen species (ROS) level and restoration of mitochondrial 
transmembrane potential. To further elucidate the mechanism of anti-
apoptotic effect of tuftsin, we tried to understand its effect on signaling 
pathways. In DMBA-treated animals down-regulation of antiapoptotic 
Bcl-2 and up-regulation of proapoptotic Bax and Caspase 3 was observed 
in mouse liver. The reduced expression level of phosphatidylinositol 3-
kinase (PI3-K) followed by the activation of Akt were also observed. These 
alterations were restored by tuftsin, indicating Akt-mediated inhibition of 
apoptosis by tuftsin. The data of the present study demonstrate that 
tuftsin is effective in combating oxidative stress induced cellular injury of 
liver cells by modulating Akt, a cell-growth regulator. 
We also tried to understand the chemopreventive effect of various 
liposomal formulation of a dietary constituent diallyl sulphide (DAS) 
isolated from garlic. The use of chemicals as an alternative to the 
conventional medicines in the form of food and food products is an 
effective approach for the treatment of chronic diseases, including 
cancer. The intervention of chemopreventive strategies for controlling 
genetic diseases using dietary constituents provides a strong rationale to 
arrest or reverse the process of carcinogenesis before metastasis occur. 
During the past few years, cancer chemoprevention by dietary 
constituents has received a great deal of attention and as a means of 
effective control over cancer. Studies on the tumor inhibitory compounds 
of plant origin have yielded an impressive array of novel structures. 
Besides, epidemiological studies suggest that consumption of diets 
including fruits and vegetables may reduce the risk of developing cancer. 
Garlic [Allium sativum) has been shown to possess potential health 
benefits (c/. lipid lowering, antimicrobial, chemo-preventive and 
anticarcinogenic properties) since beginning of recorded history and is 
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probably one of the most widely studied medicinal plants. The 
chemotherapeutic and antitumor activity associated with garlic has been 
attributed to the presence of various organosulfide based active 
compounds including DAS. Of the various options available for 
administration of medicaments, topical application is the most promising 
approach for treating skin tumors as it leads to localized release of drug 
at desired site with minimal side effects. However, retention of drugs 
administered by this mode is low because of extensive diffusion that is 
more apparent in case of small sized molecules such as DAS. This 
warrants development of formulations that can modulate 
pharmacokinetics as well as pharmacodynamic properties of DAS 
thereby making it more efficacious. 
Among various novel drug delivery systems, micro-particulate-
based carrier systems viz. micro-emulsion, nano-emulsion, 
nanoparticles, liposomes, etc. have been reported to improve delivery of 
drug to the skin. Interestingly, liposome-based formulations, when 
employed for topical delivery, have been shown to be extremely promising 
for enhancement of drug penetration, improved pharmacological effects, 
decreased side effects, controlled drug release and above all their own 
biodegradable nature. In this regard, considerable attention has been 
focused on the use of natural as well as tailor-made phospholipid 
vesicles or liposomes to enhance the therapeutic potential of anticancer 
agents. 
In the present study, we have evaluated chemo-preventive effects 
of liposomised-DAS (conventional egg PC, pH-sensitive liposomes and 
escheriosomes) against DMBA-induced skin papilloma. Various 
liposome-based novel formulations of DAS (250 (ig/mouse) were applied 
topically to the animals after 1 hour of exposure to DMBA (52 
(ig/mouse/dose). The animals were treated thrice weekly for a total 
fl.6stract 
period of 12 weeks. The efficacy of the various liposomal formulations of 
DAS was evaluated on the basis of parameters such as incidence of 
tumorogenesis, total numbers and sizes of induced tumor nodules. The 
liposomised DAS formulations were also assessed for their effect on the 
expression of p53wt, p53mut as well as p21/Wafl . The results of the 
present study showed that liposomised DAS could effectively delay the 
onset of tumorogenesis and reduce the cumulative numbers and size of 
tumor papillomas in treated mice. Treatment of DMBA exposed animals 
with liposomal formulation of DAS ensued in up-regulation of p53wt and 
p21/Wafl, while level of p53mut expression was reduced. The promising 
chemo-preventive nature of liposomal DAS may form the basis for 
establishing effective means of controlling various forms of cancer 
including skin papilloma. 
The cytosol of cells is an important but relatively inaccessible 
compartment for many therapeutic macromolecules. Due to unfavorable 
physicochemical characteristics, in particular large size, or preferential 
solubility, molecules often show restricted ability to pass through plasma 
membranes. There is a strong need for a carrier that can deliver 
membrane-impermeable molecules into the cytosol of target cells. 
Although liposomes have been widely used for the delivery of therapeutic 
compounds, their ability to deliver entrapped molecules into cytosol of 
the target cell remains inefficient. This problem was circumvent was 
using pH-sensitive liposomes, which release their contents into 
cytoplasm of the target cells. This approach relies on their selective 
destabilization in the endolysosomal compartment under acidic pH of the 
surrounding medium. In fact, pH sensitive liposomes undergo 
phosphatidyl-ethanolamine (main constituent of these liposomes) 
mediated phase transition at acidic pH, thereby delivering their content 
to the cytosol of the tumor cells. The polar head group of PE gets less 
hydrated as compared to repulsive hydration layer associated with the 
fl.6stract 
head group of PC. Thus PE provides a more hydrophobic bilayer surface 
that is susceptible to energetically more favorable interbilayer 
interactions. The phospholipids facilitate not only the close approach of 
bilayers, there may also be directly involved in the merging process. In 
this context PE can form the hexagonal Hn phase, the formation of which 
involves the development of non-lamellar structure, an intermediate in 
membrane fusion. The operative mechanism seems to form the basis of 
the observed higher efficacy of pH sensitive liposomes over egg PC 
neutral liposomes. 
Keeping into consideration, significance of cytosolic delivery of 
drugs to effectively control various forms of cancer, we have also 
developed fusogenic liposomes using lipids isolated from Eschericia coli. 
The lipids were shown to induce strong membrane-membrane fusion as 
evident from Resonance Energy Transfer and Content Mixing Assays. 
Further, the fusion of these liposomes with model living cells (J774 A. 1) 
was demonstrated to result in effective transfer of fluorescent lipid probe 
to the plasma membrane of the cells. Moreover, these liposomes 
effectively delivered encapsulated ricin A molecule to the cytosol of the J 
774A.1 cells, which ultimately resulted in the inhibition of cellular 
protein synthesis. Interestingly, the liposomes were also found to be 
efficient vehicles for the in vivo delivery of the drugs to cytosol of the 
target cells resulting in the destruction of tumor cells more efficiently. We 
entrapped DAS in escheriosomes (EC-Lip-DAS) and evaluate the efficacy 
of EC-Lip-DAS in chemoprevention against skin papilloma in model 
animals. These results imply usage of liposome based drug formulation 
in prophylaxis as well as chemotherapy against various forms of cancer. 
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The 20 t h century heralded modern life as we witness, ironically 
it also brought share of misery by the upsurge of degenerative 
diseases. Today the disease that is most feared and which possesses a 
challenge to the entire scientific community is neoplasma (Pitot 1978). 
Cancer is a popular generic term for malignant neoplasms, various 
types of the diseases occurring in all human and animal populations 
involving vital t issues composed of potentially dividing cells. The basic 
characteristic of cancer is the transmissible abnormality of cells that 
is manifested by reduced control over growth and functions leading to 
serious adverse effects on host through invasive growth and 
metastases. Over 0.7 million new cases and 0.3 million deaths occur 
annually due to cancer. Data from population-based registries under 
National Cancer Registry Programme, India, have indicated cancers of 
oral cavity, lungs, oesophagus and stomach amongst men; which 
account for over 50% of all cancer deaths in India. WHO has 
estimated that 91 per cent of oral cancers in South-East Asia as 
directly attributable to the use of tobacco and a leading cause of oral 
cavity and lung cancer in India. 
The word cancer means 'crab' in Latin. Cancers are transformed 
cells, which grow in uncontrolled fashion to become tumors. Many 
tumors are benign, meaning they remain confined to the part of the 
body where they are formed and can usually be removed while others 
are malignant meaning their growth show adverse manifestationss in 
the body, thereby disturbing its normal functioning. During its course 
of establishment, the malignant cells leave the local site and travel in 
the body fluids to a distant organ. This process is known as 
metastases. Dissemination of cancer cells throughout the body allows 
development of secondary tumors or neoplasms to be established in 
other organs. 
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Human cancer is probably as old as the human race. The oldest 
known description of human cancer is found in an Egyptian seven 
papyri written between 3000-1500 BC describing details of conditions 
that are consistent with modern descriptions of cancer. Hippocrates, 
the great Greek physician (460-370 B.C) who is considered the father 
of medicine, was the first person to clearly recognize difference 
between benign and malignant tumors. His writings include the 
description of cancers involving various body sites. The Renaissance, 
beginning in the 15th century, witnessed the advancement in surgery 
and development of rational therapies based on clinical observations. 
During this period the cancer was considered incurable, however, a 
variety of temporary measures were available including 'Arsenic' 
containing creams and pastes. The 19th century can boast of 
beginning of systematic study of oncology with the discovery and use 
of the modern microscope. Rudolf Virchow, often called the founder of 
cellular pathology, provided the scientific basis for the modern 
pathologic study of cancer. This method laid the foundation for the 
development of cancer surgery. The 20 t h century saw great progress in 
understanding of microscopic structure and functioning of the living 
cells. Researchers pursued different theories to the origin of cancer, 
subjecting their hypotheses to systematic research and 
experimentation. Better understanding of mechanism of cancer 
induction by various carcinogens showed tremendous improvement in 
understanding of the cellular mechanisms related to cell growth and 
division. Many factors that suppress and activate the cell growth and 
division were also identified. 
Causes of cancer 
From the ancient times physicians were not able to resolve the 
issue over induction of cancer. Various theories have been advocated 
in this regard like the Humoral Theory, Lymph Theory, Blastoma 
Theory, and Parasite Theory. Of late, many causes of cancer have been 
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discovered and documented. In 1911, Peyton Rous described a 
sarcoma in chickens caused by what later became known as the Rous 
sarcoma virus. In 1915, cancer was artificially induced in laboratory 
animals for the first time by coal tar, a chemical applied to rabbit skin 
at Tokyo University. Today we recognize and avoid many specific 
substances that cause cancer. Coal tars and their derivatives such as 
benzene, hydrocarbons, aniline (a substance used to make dyes), 
asbestos, and others are known to induce cancer. Various type of 
radiation from a variety of sources, including the sun, can lead to 
cancer. Viruses have been reported to link with various forms of 
cancer. 
1. Long-standing liver infection with the hepatitis virus that can 
lead to cancer of the liver. 
2. Herpes virus, the Epstein-Barr virus, causes infectious 
mononucleosis and has been implicated in non-Hodgkin's 
lymphomas and nasopharyngeal cancer. 
3. The human immunodeficiency virus (HIV) is associated with an 
increased risk of developing several cancers, especially Kaposi's 
Sarcoma and non-Hodgkin's lymphoma. 
4. Human papilloma viruses (HPVs) have been linked to cancers of 
the cervix, vulva, and penis. 
5. HTLV type 1 (HTLV-1) appears to contribute directly to the 
development of adult T-cell leukemia (ATL). 
Types of cancer 
Cancer is a disease that occurs much more frequently in the old 
age people. Cancer is not a single disease but rather a conglomeration 
of range of diseases with different causes that share many common 
characteristics. About two hundred distinct types of cancers have 
been recognized. Malignant tumors or cancers are classified according 
3 
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Figure 1.1.1: Causes and growth of cancer. 
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to their embryonic origin of the tissue from which the tumor is 
derived. The following are the various types of tumors: 
Carcinomas: 
Carcinomas are principally originated in epithelial cells of 
ectodermal and endodermal origin. The solid tumors in nerve tissue 
and t issues of body surfaces or their attached glands are examples of 
carcinomas. These include cervical, breast, skin and brain 
carcinomas. About 85% of cancers are carcinomas. 
Sarcomas: 
Sarcomas principally involve connective t issues cells, which are 
of mesodermal origin. They are solid tumors growing from connective 
tissue, cartilage, bone and muscle. Although they account for most of 
the cancers studied in laboratory animals, constitute only about 2% of 
human cancers. 
Lymphomas: 
Lymphomas are cancers in which there is excessive production 
of lymphocytes by the lymph nodes and spleen. Hodgkin's disease is 
an example of lymphoma. Lymphomas constitute about 5% of human 
cancers. 
Leukemias: 
Leukemias are neoplastic growth of leukocytes (WBC) and are 
characterized by excessive production of the cells. They constitute 
about 4% of human cancer. 
Classification of tumors 
The tumors can also be classified on the basis of their aetiology, 
anatomy, histology, function or behaviour. 
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The classification given by Willis (1960) is based on the 
histogenesis and behaviour of the tumors and embraces all the 
usually recognized classes of tumors without involving any great 
change in existing nomenclature. 
Group I - Tumors of epithelial t issues 
If benign, the tumors could be papillomas or adenomas. If 
malignant, such tumors are called as carcinomas. 
Group II - Tumors of non-haemopoietic mesenchymal t issues 
Benign tumors of connective, skeletal, vascular, meningeal, and 
muscular t issues are described as fibroma, myxoma, lipoma, 
chondroma, osteoma, benign osteoclastoma, synovinoma, angiomas 
(haemangioma, tlymphangioma and glomangioma), and meninginoma, 
leiomyoma and rhabdomyoma. A suffix sarcoma is used for malignant 
members of same classes corresponding to the benign counterpart, 
e.g. fibrosarcoma, osteosarcoma liposarcoma and haemangiosarcoma 
etc. 
Group III - Tumors of haemopoietic t issues 
Free circulatory or mobile cells are peculiar characteristic of 
haemopoietic tissues and their tumors. These tumors are grouped 
into: 
Tumors of lymphoid tissue 
(i) Follicular lymphoma 
(ii) Lymphosarcoma and lymphatic leukaemia 
(iii) Hodgkin' s disease 
(iv) Re ticulo sarcoma 
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with some other compound can potentiate the neoplastic conversion 
and are termed as 'Cocarcinogens'. A number of compounds have 
been found to be carcinogens and cocarcinogens in various 
epidemiological and experimental studies. Based upon the properties 
of carcinogenesis at present IARC (1994) has categorized them into 
different categories: 
• With sufficient evidence for carcinogenicity in humans , 
• With limited evidence for carcinogenic potential in humans and 
more evidences are required with scientifically performed 
epidemiological studies, 
• With sufficient evidence for carcinogenicity in animals, 
• With limited evidence of carcinogenesis in animals, 
• Suspected carcinogens and 
• Non carcinogens 
The carcinogens can further be divided on the basis of their 
metabolic fate into 'procarcinogens' and 'proximate carcinogens' 
(direct acting carcinogens). 'Procarcinogens' are active only after their 
metabolic conversion by the host. The 'proximate carcinogens' do not 
require the participation of enzyme(s) from the host organism to 
generate the key reactive intermediates or the 'ultimate carcinogens', 
which eventually binds to biomacromolecules and causes mutations 
or initiate the process of carcinogenesis (Miller 86 Miller 1976). Most of 
the direct acting carcinogens are synthetic chemicals developed as 
laboratory tools for research or used in industries and because of 
their high reactivity they are not generally present in the environment. 
In contrast procarcinogens are comparatively stable and maintain 
their chemical cutting exist in environment until they reach their 
target site and get activated. Some procarcinogens are chemically or 
spontaneously converted to ultimate carcinogens by hydrolytic 
reactions and often exhibit a broad spectrum of activity in many 
species and target organs (Miller 85 Miller 1976). Other 
procarcinogens, which require host controlled biochemical activation, 
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dependent on specific enzymes systems (Grover el al. 1974) may 
exhibit more specific and/or restricted carcinogenicity (Falk 1976). 
The procarcinogens may also be subjected to deactivation reactions, 
which can lead to the formation of products with either no or less 
carcinogenic potential than the parent molecule (Miller & Miller, 
1976). The ultimate reactive metabolites are "electron deficient" 
reactants. They are the compounds, which reacts with "electron rich" 
sites in the nucleic acids and proteins causing mutagenic effects, 
frequently paralleled by the onset of DNA repair processes (Miller & 
Miller 1976). Fig. 1.1.2, illustrates the generalized scheme of the 
metabolic activation of chemical carcinogens and their possible 
mechanisms of action. 
'Chemical carcinogenesis' is an operational process during which a 
normal cells and their progeny are converted into cancer cells over a 
period of time i.e. cells which fail to respond to the normal growth 
controlling factors in the environment. Despite the diversity in 
chemical structures of known carcinogens and mutagens such as 
alkylating agents, N-nitrosamines and N-nitrosamides, nitroaryl and 
furan derivatives, aromatic heterocyclic amines and azo dyes, 
polycyclic aromatic hydrocarbons (PAHs), chlorinated hydrocarbons 
and some naturally occurring compounds (e.g. aflatoxins, pyrolizidine, 
alkaloids etc.), their basic mode of action remain the same. These 
agents are capable of inducing mutations that ultimately ensue in the 
development of cancer. 
During cancer development, the transformation of a normal 
somatic cell into a malignant tumor cell occur via a complex 
multistage process involving various biochemical and genetic changes 
(Slaga et al. 1995, Greenwald 1996). As depicted in Fig. 1.1.2, the 
whole process of cancer development consists of three distinct 
sequences. In the first step the normal cell gets converted into a 
neoplastic cell (initiation), which is followed by transformation into an 
9 
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overt neoplasm known as 'promotion' phase that finally led to final 
progression stage (Marks & Furstenberger 1984, DiGiovanni 1992). 
Initiation: 
The initial sequence of events in carcinogenesis consists of the 
transformation of a normal cell into a neoplastic cell through 
development of genetic defects that are required for the expression of 
transformation (Elenbaas et al. 2001). The initiation stage is rapid, 
irreversible, and results in carcinogen-induced mutational events. The 
initiator may be chemical (eg. polycyclic hydrocarbon, nitrosamine), 
biological (eg. certain viruses) or physical (eg. X-rays, Ultra violet 
radiation) capable of inducing permanent genetic alterations in the 
cells of the target tissues. Carcinogens, which can cause the 
development of malignant tumors, when used in high doses or with 
repeated exposures are called complete carcinogens, as they are active 
in all three stages. Initiation is generally brought about by a single, 
topical/intragastric (Boutwell 1964) or transplacental (Shukla 85 Arora 
2001) application of a chemical carcinogen at a very low 
"subthreshold" (sub carcinogenic) dose (Fig. 1.1.2), which is generally 
used in order to determine the critical physiological and biochemical 
events necessary for the completion of the subsequent stages of 
carcinogenesis. Since successful induction of tumor growth can be 
accomplished at almost any time after initiation (from few days to life 
long), the alterations caused by the initiating agent in the tissue are 
t hus regarded as irreversible (Boutwell et al. 1982). The target cells for 
initiation stage of chemically induced skin carcinogenesis have great 
analogy to the stem cells, since these cells undergo 'differentiation' 
and 'dedifferentiation' which is a prerequisite for genetic alteration 
(Perez-Losada 85 Balmain 2003). 
The genetic alterations leading to tumor initiation appear to be 
the result of one or more simple mutations such as transitions, 
transversions or small deletions (Devereux et al. 1999). Other 
10 
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modifications, such as alteration of the normal pattern of cytosine 
methylation occur in growth control genes, protooncogenes, tumor 
suppressor genes and their regulatory genes (Vogelstein & Kinzler 
1993, Weinberg 1995, Hussain & Harris 1998), resulting in loss of 
genetic control in the cell (Sherr 1996, Weinstein et al. 1997). 
Some chemical carcinogens require metabolic activation within the 
cell to form the "ultimate" carcinogen, which is the bioactive molecule 
able to bind covalently to DNA (Pitot 86 Dragan 1991). Although 
interactions of the ultimate carcinogen with DNA may be necessary 
for initiation, they are not sufficient (Farber 1984). Due to the 
irreversible nature of initiation, cells can persist for the lifetime of the 
animal (Solt et al. 1980, Loehrke et al. 1983). 
Promotion: 
Promotion can be characterized by the "phenotypic clonal expansion 
of the initiated cell, which eventually leads to the development of a 
neoplasm" (Slaga et al. 1980). Tumor promotion is comparatively a 
long (Fig. 1.1.2) and reversible event, at least u p to a point. The 
cessation of promoter treatments causes regression and 
disappearance of the induced, benign lesions (yuspa, 1994, Pitot 8s 
Dragan 1995, McClain 1995). Agents promoting it, include silica 
fibres (physical agent), and a variety of chemicals such as 
polypeptides, steroid (endogenous) hormones (Henderson et al. 1988), 
growth factors, numerous synthetic and naturally occurring 
chemicals and other compound such as cytotoxic drugs and bile acids 
etc. (Reddy et al. 1978). These promoters usually exhibit the 
properties of the alteration of genetic expression, stimulation of cell 
replication and inhibition of apoptosis etc. (Morse 8B Stoner, 1993). At 
the molecular level, tumor promotion is characterized by the changes 
in the expression of genome rather than the structural alterations in 
11 
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DNA (Pitot 1997). Virtually, all known promoting agents like 12-o-
tetradecanoyl phorbol-13-acetate (TPA), 2,3,7,8-tetrachloro-dibenzo-p-
dioxin (TCDD), phenobarbital etc. mediate effects through receptor 
mechanisms. These agents directly interact with plasma membrane 
receptors causing an activation of the tyrosine protein kinase 
component of the receptor, which in turn phosphorylates critical 
proteins, leading ultimately to altered expression of genes. The other 
biochemical responses to tumor promoters include increased 
synthesis of DNA, RNA, protein, phosholipids, histidine 
decarboxylase, and protease etc. and decreased activities of 
superoxide dismutase and catalase (Pitot et al. 1997). Other events in 
the course of hyperplastic transformation include expression of the 
proto-oncogenes c-fos and c-myc (Rose and Doms 1988, Angel et al. 
1999), desensitization of epidermal cells to antiproliferative 
endogenous signals (such as catecholamine and chalcone), and an 
impairment of intercellular communication (Nishizuka 1992). 
Progression: 
'Progression' or 'conversion' during chemical carcinogenesis 
refers to the rapid cell division and ultimately conversion into a 
malignant neoplasm from existing benign tumor, which is irreversible 
stage (Fig. 1.1.2). Progression is probably the most complex of 
multistage carcinogenesis, because of acquired genetic and 
phenotypic changes, as well as rapid cellular expansion. Spontaneous 
progression is relatively rare and probably results from spontaneous 
karyotypic changes that occur in the mitotically active cells during 
promotion. It includes histopathologic changes from well differentiated 
and poorly differentiated to anaplastic, biochemical changes such as 
increased or inappropriate expression of metabolic enzymes and 
chromosomal changes. Progression appears to be the consequence of 
a mutator phenotype which introduces further mutations in 
replicating neoplastic cells endowing growth advantage (Loeb 1991). 
13 
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Early in progression, the karyotype of neoplastic cells may be diploid 
but with very subtle structural alterations. Mechanisms that can lead 
to karyotypic instability are numerous and include disruption of the 
mitotic apparatus , alteration in telomere function (Blackburn 1994), 
DNA hypomethylation, recombination, gene amplification and gene 
transposition (Cheng & Loeb 1993). Many malignant neoplasms 
exhibit one or more of these events, which very likely play a role in the 
evolution of process (Fearson 8s Vogelstein 1990). Thus clastogenesis 
and karyotypic instability result from a number of mechanisms, any 
one, many or all of which may be involved in the initial transition from 
the stage of promotion to that of progression, as well as the evolution 
of the final stage of neoplastic conversion. 
Hallmarks of cancer 
The vast catalog of cancer cell genotypes is a manifestation of at 
least six essential alterations in cell physiology that collectively dictate 
malignant growth (Figure 1.1.3) 
1. Self-competent growth signals. 
2. Tolerance to antigrowth signals. 
3. Apoptosis evasion. 
4. Limitless replicative potential 
5. Sustained angiogenesis 
6. Tissue invasion and metastasis. 
Each of these physiologic changes— novel capabilities acquired 
during tumor development represents the successful breaching of an 
anticancer defense mechanism imposed by cells and tissues. These 
properties are shared in common by most and perhaps all types of 
human tumors. The multiplicity of defenses may explain why cancer 
is relatively rare during an average human lifetime. 
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1. Self-competent growth signals. 
Normal cells require mitogenic growth signals (GS) before they 
can move from a quiescent state into an active proliferative state. 
These signals are transmitted into the cell by transmembrane 
receptors that bind distinctive classes of signaling molecules: 
diffusible growth factors, extracellular matrix components, and cell-
to-cell adhesion /interaction molecules. Normal cell cannot proliferate 
in the absence of such stimulatory signals. Many of the oncogenes in 
the cancer catalog act by mimicking normal growth signaling in one 
way or another. The tumor cells generate many of their own growth 
signals to which they are responsive creating a positive feedback 
signaling loop often termed autostimulation (Fedi et al. 1997), thereby 
reducing their dependence on stimulation from their normal tissue 
microenvironment. This liberation from dependence on exogenously 
derived signals disrupts a critically important homeostatic mechanism 
that normally operates to ensure a proper behavior of the various cell 
types within a tissue. The production of PDGF (platelet-derived growth 
factor) and TGF-a (tumor growth factor-a) by glioblastomas and 
sarcomas respectively are two illustrative examples (Fedi et al. 1997). 
The cell surface receptors that transduce growth stimulatory signals 
into the cell interior are themselves targets of deregulation during 
tumor pathogenesis. Growth factor (GF) receptors, often carrying 
tyrosine kinase activities in their cytoplasmic domains, are 
overexpressed in many cancers. Intact receptor overexpression may 
enable the cancer cell to become hyperresponsive (Fig. 1.1.4). For 
example, the epidermal growth factor receptor (EGF-R/erbB) is 
upregulated in stomach, brain, and breast tumors, while the 
HER2/neu receptor is overexpressed in stomach and mammary 
carcinomas (Slamon et al. 1987, Yarden and Ullrich 1988). 
Additionally, gross overexpression of GF receptors can elicit ligand-
independent signaling (DiFiore et al. 1987). Such ligand-independent 
signaling can also be achieved through structural alteration of 
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receptors; for example, truncated versions of the EGF receptor lacking 
much of its cytoplasmic domain fire constitutively (Fedi et al. 1997). 
Cancer cells can also switch the types of expressed extracellular 
matrix receptors (integrins), favoring those, which that transmit 
progrowth signals (Lukashev and Werb 1998, Giancotti and Ruoslahti 
1999). These bifunctional, heterodimeric cell surface receptors 
physically link cells to extracellular superstructures known as the 
extracellular matrix (ECM). Successful binding to specific moieties of 
the ECM enables the integrin receptors to transduce signals into the 
cytoplasm that influence cell behavior, ranging from quiescence in 
normal tissue to motility, resistance to apoptosis, and entrance into 
the active cell cycle. Conversely, the failure of integrins to forge these 
extracellular links can impair cell motility, induce apoptosis, or cause 
cell cycle arrest (Giancotti and Ruoslahti, 1999). 
The most complex mechanisms of acquired GS autonomy derive 
from alterations in components of the down-stream cytoplasmic 
circuitry that receives and processes the signals emitted by ligand-
activated GF receptors and integrins. The SOS-Ras-Raf-MAPK cascade 
plays a central role here. In about 25% of human tumors, Ras 
proteins are present in structurally altered forms that enable them to 
release a flux of mitogens into cells, without ongoing stimulation by 
their normal upstream regulators (Medema and Bos 1993). 
S 
2. Tolerance to antigrowth signals. ,
 t j . 
Within a normal tissue multiple antiproliferative signals operate 
to maintain cellular quiescence and tissue homeostasis; these signals 
include both soluble as well as immobilized inhibitors embedded in 
the extracellular matrix and on the surfaces of nearby cells. The 
growth-inhibitory signals, like their positively acting counterparts, are 
perceived by transmembrane cell surface receptors coupled to 
intracellular signaling circuits. Normaly, antigrowth signals can block 
proliferation by two distinct mechanisms. Cells may be forced out of 
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the active proliferative cycle into the quiescent (GO) state from which 
they may reemerge on some future occasion when extracellular 
signals permit. Alternatively, cells may be induced to permanently 
relinquish their proliferative potential to enter into post mitotic states, 
usually associated with acquisition of specific differentiation-
associated traits. Incipient cancer cells must evade these 
antiproliferative signals if they are to prosper. At the molecular level, 
many and perhaps all antiproliferative signals are funneled through 
the retinoblastoma protein (pRb) and its two relative analogs, p i 0 7 
and p l 3 0 . In hypophosphorylated state, pRb blocks proliferation by 
sequestering and altering the function of E2F transcription factors 
that control the expression of banks of genes essential for progression 
from Gl into S phase (Weinberg 1995). Disruption of the pRb pathway 
liberates E2Fs and thereby allows cell proliferation, rendering cells 
insensitive to antigrowth factors that normally operate along this 
pathway to block advancement to the Gl phase of the cell cycle. The 
soluble signaling molecule TGF-(3 causes synthesis of the pl5INK4B 
and p21 proteins that block the cyclin:CDK complexes responsible for 
pRb phosphorylation (Hannon and Beach 1994, Datto et al. 1997). 
The pRb signaling circuit, as governed by TGF-(3 and other extrinsic 
factors, can be disrupted in a variety of ways in different types of 
human tumors (Fynan and Reiss 1993). Some tumor cells lose TGF-f3 
responsiveness through downregulation of their TGF-(3 receptors, 
while others display mutant or dysfunctional receptors (Fynan and 
Reiss 1993, Markowitz et al. 1995). Moreover the cytoplasmic Smad4 
protein which transduces signals from ligand activated TGF-p 
receptors to downstream targets may be eliminated through mutation 
of its encoding gene (Schutte et al. 1996). Also the locus encoding 
pl5INK4B may be deleted (Chin et al. 1998). Alternatively, the 
immediate downstream target of its actions, CDK4, may become 
unresponsive to the inhibitory actions of pl5INK4B because of 
mutations that create amino acid substitutions in its INK4A/B-
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interacting domain; the resulting cyclin D:CDK4 complexes are then 
given a free hand to inactivate pRb by hyperphosphorylation (Zuo et 
al. 1996). Finally, functional pRb, the end target of this pathway, may 
be lost through mutation of its gene. Alternatively, in certain DNA 
virus-induced tumors, conspicuously cervical carcinomas, pRb 
function is eliminated through sequestration by viral oncoproteins, 
such as the E7 oncoprotein of human papillomavirus (Dyson et al. 
1989). In addition, cancer cells can also turn off expression of 
integrins and other cell adhesion molecules that send antigrowth 
signals, favoring instead those that convey progrowth signals. 
' Cell proliferation also depends on signals towards irreversible 
postmitotic, differentiated states, using diverse mechanisms that are 
not well understood. Tumor cells use various strategies to avoid this 
terminal differentiation. One strategy for avoiding differentiation 
directly involves the c-myc oncogene, which encodes a transcription 
factor. Normally, the growth-stimulating action of Myc in association 
with another factor, Max, can be supplanted by alternative complexes 
of Max with a group of transcription factors called Mad; the Mad-Max 
complexes elicit differentiation-inducing signals (Foley and Eisenman 
1999). Overexpression of the c-Myc oncoprotein, as is seen in many 
tumors shifts the balance back to favor Myc-Max complexes, thereby 
impairing differentiation and promoting growth. 
3. Apoptosis evasion: 
The ability of tumor cell populations to expand in number is 
determined not only by the rate of cell proliferation but also by the 
rate of cell attrition. Programmed cell death (apoptosis) represents a 
major source of this attrition. The apoptotic program is present in 
latent form in virtually all cell types throughout the body. Once 
triggered by a variety of physiologic signals, this program unfolds in a 
precisely choreographed series of steps (Fig. 1.1.5): cellular 
membranes are disrupted, the cytoplasmic and nuclear skeletons are 
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broken down, the cytosol is extruded, the chromosomes axe degraded, 
and the nucleus is fragmented, all in a span of 30-120 min. In the 
end, the shriveled cell corpse is engulfed by nearby cells and 
disappears, typically within 24 hr (Wyllie et al. 1980). 
The apoptotic machinery comprises sensors and effectors. The 
sensors are responsible for monitoring the extracellular and 
intracellular environment for conditions of normality or abnormality 
that influence whether a cell should live or die. These signals regulate 
the second class of components which function as effectors of 
apoptotic death. The sentinels include cell surface receptors that bind 
survival or death factors. Examples of these ligand/receptor pairs 
include survival signals conveyed by IGF-l/IGF-2 through their 
receptor, IGF-1R, and by IL-3 and its cognate receptor, IL-3R (Lotem 
and Sachs 1996, Butt et al. 1999). Death signals are conveyed by the 
FAS ligand binding the FAS receptor and by TNF-oc binding TNF-R1 
(Ashkenazi and Dixit 1999). The life of most cells is in part maintained 
by cell-matrix and cell-cell adherence-based survival signals whose 
abrogation elicits apoptosis (Ishizaki et al. 1995, Giancotti and 
Ruoslahti 1999). Many of the signals that elicit apoptosis converge on 
the mitochondria, which respond to proapoptotic signals by releasing 
cytochrome C, a potent catalyst of apoptosis (Green and Reed 1998). 
Members of the Bcl-2 family of proteins, which have either 
proapoptotic (Bax, Bak, Bid, Bim) or antiapoptotic (Bcl-2, Bcl-XL, Bcl-
W) function, act in part by governing mitochondrial death signaling 
through cytochrome C release. The p53 tumor suppressor protein can 
elicit apoptosis by upregulating expression of proapoptotic Bax in 
response to sensing DNA damage; Bax in turn stimulates 
mitochondria to release cytochrome C. The ultimate effectors of 
apoptosis include an array of intracellular proteases termed caspases 
(Thornberry and Lazebnik 1998). Two "gatekeeper" caspases, viz. 
capase 8 and caspase 9 are activated by death receptors such as FAS 
or by the cytochrome C released from mitochondria, respectively. 
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These proximal caspases trigger the activation of a dozen or more 
effector caspases that execute the death program, through selective 
destruction of subcellular structures and organelles, and of the 
genome. Therefore apoptosis is a major barrier to cancer that must be 
circumvented by rapidly growing tumors containing low numbers of 
apoptotic cells (Symonds et al. 1994). Collectively, these observations 
argue that altering components of the apoptotic machinery can 
dramatically affect the dynamics of tumor progression, providing a 
rationale for the inactivation of this machinery during tumor 
development. 
Resistance to apoptosis by cancer cell can be acquired through 
a variety of strategies. Surely, the most commonly occurring loss of a 
proapoptotic regulator through mutation involves the p53 tumor 
suppressor gene. The resulting functional inactivation of its product, 
the p53 protein, is seen in greater than 50% of human cancers and 
results in the removal of a key component of the DNA damage sensor 
that can induce the apoptotic effector cascade (Harris 1996). Signals 
evoked by other abnormalities, including hypoxia and oncogene 
hyperexpression, are also funneled in part via p53 to the apoptotic 
machinery; these too are impaired at eliciting apoptosis when p53 
function is lost (Levine 1997). Additionally, the PI-3 kinase-AKT/PKB 
pathway, which transmits antiapoptotic survival signals, is likely to be 
involved in mitigating apoptosis in a substantial fraction of human 
tumors. This survival signaling circuit can be activated by 
extracellular factors such as IGF-1/2 or IL-3 (Evan and Littlewood 
1998), by intracellular signals emanating from Ras (Downward 1998), 
or by loss of the pTEN tumor suppressor, a phospholipid phosphatase 
that normally attenuates the AKT survival signal (Cantley and Neel, 
1999). Recently, a mechanism for abrogating the FAS death signal has 
been revealed in a high fraction of lung and colon carcinoma cell 
lines: a nonsignaling decoy receptor for FAS ligand is upregulated, 
titrating the death-inducing signal away from the FAS death receptor 
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(Pitti et al. 1998). It is presumable that virtually all cancer cells harbor 
alterations that enable evasion of apoptosis. 
It is now possible to layout a provisional apoptotic signaling 
circuitry (Figure 1.1.4); while incomplete, it is evident that most 
regulatory and effector components are present in redundant form. 
This redundancy holds important implications for the development of 
novel types of antitumor therapy, since tumor cells that have lost 
proapoptotic components are likely to retain other similar ones. 
4. Limitless Replicative Potential 
Many and perhaps all types of mammalian cells carry an 
intrinsic, cell-autonomous program that limits their multiplication 
and this program appears to operate independently of the cell-to-cell 
signaling pathways described as above. It too must be disrupted in 
order expansion of clone of cells to a size that constitutes a 
macroscopic, life-threatening tumor. The early work of Hayflick 
demonstrated that cells in culture have a finite replicative potential 
(Hayflick 1997). Once such cell populations have progressed through 
a certain number of doublings, they stop growing: a process termed 
senescence. The senescence of cultured human fibroblasts can be 
circumvented by disabling their pRb and p53 tumor suppressor 
proteins, enabling these cells to continue multiplying for additional 
generations until they enter into a second state termed crisis. The 
crisis state is characterized by massive cell death, karyotypic disarray 
associated with end-to-end fusion of chromosomes, and the 
occasional emergence of a variant (1 in 107) cell that has acquired the 
ability to multiply without limit, the trait termed immortalization 
(Wright etal 1989). 
Provocatively, most types of tumor cells that are propagated in culture 
appear to be immortalized, suggesting that limitless replicative 
potential is a phenotype that was acquired in vivo during tumor 
progression and was essential for the development of their malignant 
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growth state (Hayflick 1997). This result suggests that at some point 
during the course of multistep tumor progression, evolving 
premalignant cell populations exhaust their endowment of allowed 
doublings and can only complete their tumorigenic agenda by 
breaching the mortality barrier and acquiring unlimited replicative 
potential. 
The counting device for cell generations has been discovered 
over the past decade: the ends of chromosomes, telomeres, which are 
composed of several thousand repeats of a short 6 bp sequence 
element. Replicative generations are counted by the 50-100 bp loss of 
telomeric DNA from the ends of every chromosome during each cell 
cycle. This progressive shortening has been attributed to the inability 
of DNA polymerases to completely replicate the 3' ends of 
chromosomal DNA during each S phase. The progressive erosion of 
telomeres through successive cycles of replication eventually causes 
them to lose their ability to protect the ends of chromosomal DNA. 
The unprotected chromosomal ends participate in end-to-end 
chromosomal fusions, yielding the karyotypic disarray associated with 
crisis and resulting, almost inevitably, in the death of the affected cell 
(Counter et al. 1992). Telomere maintenance is evident in virtually all 
types of malignant cells (Shay and Bacchetti 1997); 85%-90% of them 
succeed in doing so by upregulating expression of the telomerase 
enzyme, which adds hexanucleotide repeats onto the ends of telomeric 
DNA (Bryan and Cech 1999), while the remainder have invented a way 
of activating a mechanism, termed ALT, which appears to maintain 
telomeres through recombination-based interchromosomal exchanges 
of sequence information (Bryan et al. 1995). By one or the other 
mechanism, telomeres are maintained at a length above a critical 
threshold, and this in turn permits unlimited multiplication of 
descendant cells. Both mechanisms seem to be strongly suppressed 
in most normal human cells in order to deny them unlimited 
replicative potential. The role of telomerase in immortalizing cells 
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demonstrated directly by ectopically expressing the enzyme in cells, 
where it convey unlimited replicative potential onto a variety of normal 
early passage, presenescent cells in vitro (Bodnar et al. 1998, Vaziri 
and Benchimol 1998). Further, late passage cells poised to enter crisis 
continue to proliferate without giving any evidence of crisis when 
supplied with this enzyme (Counter et al. 1998, Halvorsen et al. 1999, 
Zhu et al. 1999). Additional clues into the importance of telomere 
maintenance for cancer come from analysis of mice lacking 
telomerase function. For example, mice carrying a homozygous 
knockout of the cell cycle inhibitor pl6INK4A are tumor prone, 
particularly when exposed to carcinogens; the tumors that arise show 
comparatively elevated telomerase activity. When carcinogens were 
applied to pl6INK4A-null mice that also lacked telomerase, tumor 
incidence was reduced, concomitant with substantial telomere 
shortening and karyotypic disarray in those tumors that did appear 
(Greenberg et al. 1999). 
While telomere maintenance is clearly a key component of the 
capability for unlimited replication, the circumvention of cellular 
senescence remains unceretain. The phenomenon of senescence was 
originally observed as a delayed response of primary cells to extended 
propagation in vitro and has thus been associated with mechanisms 
of divisional counting (Hayflick 1997). More recently, the senescent 
state has been observed to be inducible in certain cultured cells in 
response to high-level expression of genes such as the activated ras 
oncogene (Serrano et al. 1997). 
Thus, these observations might argue that senescence, much like 
apoptosis, reflects a protective mechanism that can be activated by 
shortened telomeres or conflicting growth signals that forces aberrant 
cells irreversibly into a GO-like state, thereby rendering them 
incapable of further proliferation. If so, circumvention of senescence 
in vivo may indeed represent an essential step in tumor progression 
that is required for the subsequent approach to and breaching of the 
crisis barrier. 
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5. Sustained Angiogenesis 
Oxygen and nutrients supplied by the vasculature are crucial 
for cell function and survival, obligating virtually all cells in a tissue to 
reside within 100 mm of a capillary blood vessel. During 
organogenesis, this closeness is ensured by coordinated growth of 
vessels and parenchyma. Once a tissue is formed, the growth of new 
blood vessels—the process of angiogenesis—is transitory and carefully 
regulated. The cells within aberrant proliferative lesions initially lack 
angiogenic ability, curtailing their capability for expansion. In order to 
progress to a larger size, incipient neoplasias mus t develop angiogenic 
ability (Bouck et al. 1996, Hanahan and Folkman 1996, Folkman 
1997). Counterbalancing positive and negative signals encourage or 
block angiogenesis. One class of these signals is conveyed by soluble 
factors and their receptors, the latter displayed on the surface of 
endothelial cells; integrins and adhesion molecules mediating cell-
matrix and cell-cell association also play critical roles. The 
angiogenesis-initiating signals are exemplified by vascular endothelial 
growth factor (VEGF) and acidic and basic fibroblast growth factors 
(FGF1/2). Each binds to transmembrane tyrosine kinase receptors 
displayed by endothelial cells (Fedi et al. 1997, Veikkola and Alitalo 
1999). A prototypical angiogenesis inhibitor is thrombospondin-1, 
which binds to CD36, a transmembrane receptor on endothelial cells 
coupled to intracellular Src-like tyrosine kinases (Bull et al. 1994). 
There are currently more than two-dozen angiogenic inducer factors 
known and a similar number of endogenous inhibitor proteins. 
Experimental evidence for the importance of inducing and sustaining 
angiogenesis in tumors is both extensive and compelling (Bouck et al. 
1996, Hanahan and Folkman 1996, Folkman 1997). The anti-VEGF 
antibodies proved able to impair neovascularization and growth of 
subcutaneous tumors in mice (Kim et al. 1993), as did a dominant-
interfering version of the VEGF receptor-2 (flk-1) (Millauer et al. 1994); 
both results have motivated the development of specific VEGF/VEGF-
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R inhibitors now in late stage clinical trials. The essential role of 
angiogenesis is further supported by the ability of an increasing 
catalog of antiangiogenic substances to impair the growth of tumor 
cells inoculated subcutaneously in mice (Folkman, 1997). Tumors 
arising in cancer-prone transgenic mice are similarly susceptible to 
angiogenic inhibitors (Bergers et al. 1999). 
Tumors appear to activate the angiogenic switch by changing 
the balance of angiogenesis inducers and countervailing inhibitors 
(Hanahan and Folkman 1996). One common strategy for shifting the 
balance involves altered gene transcription. Many tumors evidence 
increased expression of VEGF and/or FGFs compared to their normal 
tissue counterparts. In others, expression of endogenous inhibitors 
such as thrombospondin-1 or p-interferon is downregulated. 
Moreover, both transitions may occur, and indeed be linked, in some 
tumors (Singh et al. 1995, Volpert et al. 1997). 
The mechanisms underlying shifts in the balances between 
angiogenic regulators remain incompletely understood. In one well-
documented example, the inhibitor thrombospondin-1 has been found 
to positively regulated by the p53 tumor suppressor protein in some 
cell types. Consequently, loss of p53 function, which occurs in most 
human tumors, can cause thrombospondin-1 levels to fall, liberating 
endothelial cells from its inhibitory effects (Dameron et al. 1994). The 
VEGF gene is also under complex transcriptional control. For 
example, activation of the ras oncogene or loss of the VHL tumor 
suppressor gene in certain cell types causes upregulation of VEGF 
expression (Rak et al. 1995, Maxwell et al. 1999). Another dimension 
of regulation is emerging in the form of proteases, which can control 
the bioavailability of angiogenic activators and inhibitors. Thus, a 
variety of proteases can release bFGF stored in the ECM (Whitelock et 
al. 1996), whereas plasmin, a proangiogenic component of the clotting 
system, can cleave itself into an angiogenesis inhibitor form called 
angiostatin (Gately et al. 1997). The coordinated expression of pro-
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and anti-angiogenic signaling molecules, and their modulation by 
proteolysis, appear to reflect the complex homeostatic regulation of 
normal tissue angiogenesis and of vascular integrity. 
As is already apparent, tumor angiogenesis offers a uniquely 
attractive therapeutic target, indeed one that is shared in common by 
most and perhaps all types of human tumors. The already available 
evidence indicates that different types of tumor cells use distinct 
molecular strategies to activate the angiogenic switch. This raises the 
question of whether a single antiangiogenic therapeutic will suffice to 
treat all tumor types, or whether an ensemble of such therapeutics 
will need to be developed, each responding to a distinct program of 
angiogenesis that has been developed by a specific class of human 
tumors. 
6. Tissue Invasion and Metastasis 
Sooner or later during the development of most types of human 
cancer, primary tumor masses spawn pioneer cells that move out, 
invade adjacent tissues, and thence travel to distant sites where they 
may succeed in founding new colonies. These distant settlements of 
tumor cells—metastases—are the cause of 90% of human cancer 
deaths (Sporn 1996). The capability for invasion and metastasis 
enables cancer cells to escape the primary tumor mass and colonize 
new terrain in the body where, at least initially, nutr ients and space 
are not limiting. The newly formed metastases arise as amalgams of 
cancer cells and normal supporting cells conscripted from the host 
tissue. Like the formation of the primary tumor mass, successful 
invasion and metastasis depend upon all of the other five acquired 
hallmark capabilities. Invasion and metastasis are exceedingly 
complex processes, and their genetic and biochemical determinants 
remain incompletely understood. At the mechanistic level they are 
closely allied processes, which justifies their association with one 
another as one general capability of cancer cells. Both utilize similar 
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operational strategies, involving changes in the physical coupling of 
cells to their microenvironment and activation of extracellular 
proteases. 
Several classes of proteins involved in the tethering of cells to 
their surroundings in a tissue are altered in cells possessing invasive 
or metastatic capabilities. The affected proteins include cell-cell 
adhesion molecules (CAMs)—notably members of the immunoglobulin 
and calcium-dependent cadherin families, both of which mediate cell-
to-cell interactions—and integrins, which link cells to extracellular 
matrix substrates. Notably, all of these "adherence" interactions 
convey regulatory signals to the cell (Aplin et al. 1998). The most 
widely observed alteration in cell-to-environment interactions in 
cancer involves E-cadherin, a homotypic cell-to-cell interaction 
molecule ubiquitously expressed on epithelial cells. Coupling between 
adjacent cells by E-cadherin bridges results in the transmission of 
antigrowth and other signals via cytoplasmic contacts with ! -catenin 
to intracellular signaling circuits that include the Lef/Tcf 
transcription factor (Christofori and Semb 1999). E-cadherin function 
is apparently lost in a majority of epithelial cancers, by mechanisms 
that include mutational inactivation of the E-cadherin or p-catenin 
genes, transcriptional repression, or proteolysis of the extracellular 
cadherin domain (Christofori and Semb 1999). Forced expression of 
E-cadherin in cultured cancer cells and in a transgenic mouse model 
of carcinogenesis impairs invasive and metastatic phenotypes, 
whereas interference with E-cadherin function enhances both 
capabilities (Christofori and Semb 1999). Thus, E-cadherin serves as 
a widely acting suppressor of invasion and metastasis by epithelial 
cancers, and its functional elimination represents a key step in the 
acquisition of this capability. 
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Changes in expression of CAMs in the immunoglobulin 
superfamily also appear to play critical roles in the processes of 
invasion and metastasis (Johnson 1991). For example, N-CAM 
undergoes a switch in expression from a highly adhesive isoform to 
poorly adhesive (or even repulsive) forms in Wilms' tumor, 
neuroblastoma, and small cell lung cancer (Johnson, 1991; Kaiser et 
al. 1996) and reduction in overall expression level in invasive 
pancreatic and colorectal cancers (Fogar et al. 1997). Experiments in 
transgenic mice support a functional role for the normal adhesive 
form of N-CAM in suppressing metastasis (Perl et al. 1999). Changes 
in integrin expression are also evident in invasive and metastatic 
cells. Invading and metastasizing cancer cells experience changing 
tissue microenvironments during their journeys, which can present 
novel matrix components. Accordingly, successful colonization of 
these new sites (both local and distant) demands adaptation, which is 
achieved through shifts in the spectrum of integrin a or b subunits 
displayed by the migrating cells. These novel permutations result in 
different integrin subtypes (of which there are greater than 22) having 
distinct substrate preferences. Thus, carcinoma cells facilitate 
invasion by shifting their expression of integrins from those that favor 
the ECM present in normal epithelium to other integrins (e.g., cc3pi 
and aVp3) that preferentially bind the degraded stromal components 
produced by extracellular proteases (Varner and Cheresh, 1996, 
Lukashev and Werb 1998). Forced expression of integrin subunits in 
cultured cells can induce or inhibit invasive and metastatic behavior, 
consistent with a role of these receptors in acting a s central 
determinants of these processes (Varner and Cheresh 1996). 
The second general parameter of the invasive and metastatic 
capability involves extracellular proteases (Coussens and Werb 1996, 
Chambers and Matrisian 1997). Protease genes are upregulated, 
protease inhibitor genes are downregulated, and inactive zymogen 
forms of proteases are converted into active enzymes. Matrix-
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degrading proteases are characteristically associated with the cell 
surface, by synthesis with a trans-membrane domain, binding to 
specific protease receptors, or association with integrins (Werb 1997, 
Stetler-Stevenson 1999). It seems docking of active proteases on the 
cell surface can facilitate invasion by cancer cells into nearby stroma, 
across blood vessel walls, and through normal epithelial cell layers. 
Nevertheless, it is difficult to unambiguously ascribe the functions of 
particular proteases solely to this capability, given their evident roles 
in other hallmark capabilities, including angiogenesis (Stetler-
Stevenson 1999) and growth signaling (Werb 1997, Bergers and 
Coussens 2000), which in turn contribute directly or indirectly to the 
invasive/metastatic capability. 
A further dimension of complexity derives from the multiple cell 
types involved in protease expression and display. In many types of 
carcinomas, matrix-degrading proteases are produced not by the 
epithelial cancer cells but rather by conscripted stromal and 
inflammatory cells (Werb 1997); once released by these cells, they 
may be wielded by the carcinoma cells. For example, certain cancer 
cells induce urokinase (uPA) expression in cocultured stromal cells, 
which then binds to the urokinase receptor (uPAR) expressed on the 
cancer cells (Johnsen et al. 1998). The activation of extracellular 
proteases and the altered binding specificities of cadherins, CAMs, 
and integrins are clearly central to the acquisition of invasiveness and 
metastatic ability. Unfortunately, the regulatory circuits and 
molecular mechanisms that govern these shifts remain elusive and, at 
present, seem to differ from one tissue environment to another. The 
acquired capability for invasion and metastasis represents the last 
great frontier for exploratory cancer research. 
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An enabling characteristic: Genome instability 
The acquisition of the enumerated six capabilities during the 
course of tumor progression creates a dilemma. The available 
evidence suggests that most are acquired, directly or indirectly, 
through changes in the genomes of cancer cells. However, mutation of 
specific genes is an inefficient process, reflecting the unceasing, 
fastidious maintenance of genomic integrity by a complex array of 
DNA monitoring and repair enzymes. These genome maintenance 
teams strive to ensure that DNA sequence information remains 
pristine. Karyotypic order is guaranteed by yet other watchmen, 
manning so-called check-points, that operate at critical times in the 
cell's life, notably mitosis. Together, these systems ensure that 
mutations are rare events, indeed so rare that the multiple mutations 
known to be present in tumor cell genomes are highly unlikely to 
occur within a human life span. Yet cancers do appear at substantial 
frequency in the human population, causing some to argue that the 
genomes of tumor cells must acquire increased mutability in order for 
the process of tumor progression to reach completion in several 
decades time (Loeb 1991). Malfunction of specific components of these 
genomic "caretaker" systems has been invoked to explain this 
increased mutability (Lengauer et al. 1998). The most prominent 
member of these systems is the p53 tumor suppressor protein, which, 
in response to DNA damage, elicits either cell cycle arrest to allow 
DNA repair to take place or apoptosis if the damage is excessive. 
Indeed, it is now clear that the functioning of the p53 DNA damage 
signaling pathway is lost in most, if not all, human cancers (Levine 
1997). Moreover, a growing number of other genes involved in sensing 
and repairing DNA damage, or in assuring correct chromosomal 
segregation during mitosis, is found to be lost in different cancers, 
labeling these caretakers as tumor suppressors (Lengauer et al. 1998). 
Their loss of function is envisioned to allow genome instability and 
variability and the generation of consequently mutant cells with 
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selective advantages. Interestingly, recent evidence suggests that 
apoptosis may also be a vehicle of genomic instability, in that DNA 
within apoptotic cell bodies can be incorporated into neighboring cells 
following phagoctytosis (Holmgren et al. 1999), in principle genetically 
diversifying any of the constituent cell types of a tumor. This acquired 
characteristic of genomic instability could be considered apart from 
the six acquired capabilities associated with tumor cell phenotype and 
tumor physiology: it represents the means that enables evolving 
populations of premalignant cells to reach these six biological 
endpoints. 
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Liposomes are vesicular structures of colloidal nature assembled 
when amphipathic lipids are dispersed in water (Fig. 1.2.1). The 
vesicular s tructures can be thought of as artificial lipid bilayer 
membranes enclosing aqueous inner core. These were first described by 
Alec D. Bangham in 1965 (Bangham et al. 1965), and initially used as 
models for studying dynamic properties such as fluidity, phase 
transitions etc. of biomembranes. However, potential of these vesicles 
was soon realized as versatile models, reagents and tools in various 
scientific disciplines including, biology, biochemistry, and biophysics 
(Table 1.2.1). 
Table 1.2.1: Role of liposomes in various disciplines 
Cell biology and 
physiology 
Biochemistry 
Biophysics 
Drug therapy and 
Enzyme therapy 
Immunology 
Excretion, cell function, trafficking and signaling, 
studies pertaining to function of genes 
Function of membrane proteins, catalysis, energj 
conversions etc. 
Properties of cell membranes, membrane channels, 
studies pertaining to topology of transmembrane 
proteins etc. 
Acts as a depot for sustained release of various 
anti-cancer and antifungal drugs as well as 
enzymes of therapeutic significance. 
Act as a vaccine carrier and adjuvants for 
increased humoral and CTL response. 
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Various liposome-associated features in context of drug/antigen 
delivery rely on their composition, colloidal, chemical, 
microencapsulating and surface properties. The applications of the 
liposomes range from their use as drug delivery systems (antimicrobial 
/ tumor drugs etc.), vaccines, cosmetic formulations (skin care 
products, shampoos), diagnostics, ecological cleansing modules, and 
food preparations to novel breakthroughs like gene and enzyme 
therapy. 
Composition 
Liposomes resemble cellular biomembranes in being composed of 
amphiphiles such as phospholipids and sphingolipids, which upon 
their exposure to aqueous environment, tend to self-organize to form 
ordered structures. The assemblage of amphipathic molecules to the 
vesicular entities minimizes the chances of interaction of hydrophobic 
moieties with surrounding water molecules. 
A careful examination at the process of self-organization in 
amphiphilic molecules reveals that there may be three geometric factors 
that determine the nature and sizes of the vesicles viz. 
• Area of the molecule -(A) 
• Volume of their hydrocarbon chain -(V) 
• Maximum length of the chains -(L) 
The crucial combination of these parameters is geometrically the 
packing parameter, I, such that i = (V/A*L). 
• If the value of i is < 1/3 then spherical micelles form. 
• If 1/2 < (i) < 1 then bilayers are formed. 
In fact, the molecules that form bilayers are mainly those with 
large hydrocarbon chains, which are too bulky to fit into smaller 
molecular assemblies like micelles. A quick look at the values of (V/A*L) 
36 
<Rfview of literature Liposomes 
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HydrophobJ 
tail 
Figure 1.2.1: Cross section view of unilamellar liposome. 
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for different structures shows that for the same head-group and 
maximum length of the chains, molecules with double the volume of 
the hydrocarbon chain form bilayers. Thus molecules with two 
hydrocarbon chains are likely to form bilayers. The most important 
class of bilayer forming molecules is phospholipids. It becomes 
energetically favorable for the bilayer to form closed spherical 
structures rather than very long planar s tructures. These closed 
spherical bilayers are called vesicles or liposomes. If (V/A*L) > 1 then 
usually inverted micellar structures are formed or the molecules 
precipitate out of the solution (eg. cholesterol). Vesicles (unilamellar -
single bilayer) are a Particular case from the family of spherically 
concentric multilamellar (many bilayers) s tructures called liposomes. 
The properties of these vesicular entities are also influenced by 
external parameters like the temperature and the presence of certain 
molecules nearby. The presence of proteins in the biological 
membranes influences their properties eg. improves the mechanical 
properties. The best-characterized liposomes are those with lipids 
having packing parameter close to 1.0. The lipid classes include 
phosphatidylcholine, phosphatidylserine, phosphatidylinositol, 
sphingomyelin, dicetylphosphate and DODAC. Other candidates are 
sulfatides, gangliosides, dialkylphosphates etc. Liposomes can also be 
prepared from mixture of phospholipids and the mean packing 
parameter is evaluated as weighted average of packing parameters of all 
the components. 
Additional constituents, apart from lipids, can also be 
incorporated during preparation of liposomes for various reasons. For 
example antioxidants, chelating agents or cholesterol (acts as fluidity 
buffer) are included to enhance stability of liposomes. Moreover, 
optimization of temperature, pH and ionic strength of the medium are 
also important to produce more stable liposomes. Similarly, addition of 
cryoprotectants allows storage of liposomes in frozen and lyophilized 
form, while coating with inert hydrophilic polymers led to increase in 
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stability. To avoid aggregation of liposomes charged lipids could be 
incorporated. For prolonged presence of these in blood circulation, 
polyethylene glycol coated 'stealth' liposomes are used. Fusogenic 
liposomes are constituted by including glycerol, polyvinyl alcohol or 
reconstituted viral-membrane (virosomes). Actually, liposomes can be 
custom designed for almost any need by varying lipid content, 
additional components, size, surface charge and method of preparation. 
Preparation 
Several strategies are available for the preparation of various types of 
liposomes and entrapment of various substances therein. All the 
procedures include the steps of lipid film hydration, formation of the 
lipid bilayer followed by removal of un-entrapped material (Fig. 1.2.2). 
The most common method employed is sonication either by a probe 
sonicator or a bath type sonicator (Huang, 1969), others being high-
pressure exclusion, rapid injection of an ethanolic solution of a lipid 
into an aqueous solution (Batzri and Korn, 1973) or by transgently 
increasing the pH of aqueous phospholipid dispersion (Hauser and 
Gains, 1982). Removal of detergents by dialysis, solvent infusion and 
reverse phase evaporation (Buboltz and Feigenson 1999) results in the 
formation of multi-lamellar vesicles (MLVs). The simplest procedure, 
however, involves hand shaking or stirring of aqueous phospholipid 
dispersion. Following dehydration/ rehydration method, the 
entrapment efficiency of liposomes can be increased to 40% of the 
compound to be entrapped which is fairly higher than 2-10% for MLVs 
prepared by hand shaking method. Since the size of liposome is an 
important factor in its stability and tissue distribution in wvo, exclusion 
through polycarbonate membranes is routinely used to obtain a more 
uniform size distribution in the liposome preparation. Homogenization 
of MLVs results in the formation of unilamellar vesicles. It involves 
some or the other form of energy to be dissipated into the system of 
lipids and aqueous solvent for preparing liposomes. 
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Phospholipids, 
lipid soluble drugs 
and organic solvent 
Lipid film Hydration with 
Water 
(hydrophyllic drug) 
Sonication 
Extrusion 
Homogenization 
Hydration 
Agitation 
Figure 1.2.2: Method of Liposome Preparation. 
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Nomenclature and Classification 
Initially, liposomes were classified on the basis of the name of the 
contributors who were directly involved in their development, eg.-
Banghamosomes for sonicated MLVs and Huangosomes for ULVs 
prepared by dispersion of the MLVs. More recently used nomenclature 
is based on composition, structure or method used in the preparation 
of liposomes. 
Nomenclature based on Structure 
The most widely accepted terminology is based on size and 
number of lamellae present in the liposomes. Thus liposomes with more 
than one bilayer are multilamellar (MLV) and with single layer are 
unilamellar (ULV). The ULVs can be further classified on the basis of 
out / in ratio i.e. ratio of number of lipid molecules present in outer Vs 
inner monolayer of the liposomes. 
Type 
MLVs 
M W s 
OLVs 
ULVs 
SUVs 
MUVs 
LUVs 
GUVs 
Specifications 
Multilamellar large vesicles 
Diameter Out/ in ratio 
>0.5 urn 
0.1-20 jim 
0.1-1.0 urn 
Multivesicular vesicles 
Oligolamellar vesicles 
Unilamellar vesicles 
Small unilamellar vesicles 20-40nm 
Medium unilamellar vesicles 40-80 nm 
Large unilamellar vesicles > 80 nm 
Giant unilamellar vesicles > 1 ^m 
2 to 2.4 
1.2 to 1.5 
1 to 1.2 
1 
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Nomenclature based on method of preparation 
The nomenclature does not provide information regarding 
properties of liposomes. Methods of preparation of liposomes used for 
naming liposomes, such as: 
Type 
REV 
MLV-REV 
SPLVs 
FAT MLVs 
VET 
DRVs 
Method 
Single or oligolamellar vesicles made by 
reverse phase evaporation method 
Multilamellar vesicles made by reverse 
phase evaporation method 
Stable plurilamellar vesicles 
Frozen and thawed MLV 
Vesicles prepared by extrusion technique 
Dehydration-rehydration made 
vesicles/dried reconstituted vesicles 
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Figure 1.2.3: Schematic illustration of liposomes of different size 
and number of lamellae. Small unilamellar vesicles (SUVs), Large 
unilamellar vesicles (SUVs), Multilamellar vesicles (MLVs), 
Multivesicular vesicles (MWs) 
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Nomenclature based on composition 
Various constituents included in preparation of liposomes as well 
as other characteristic features can also be used as criteria for their 
nomenclature: 
Type Characteristic 
Conventional liposomes (CL) 
Fusogenic liposomes 
Neutral or negatively charged 
phospholipids with/without 
Cholesterol 
Fusogenic lipids/viral components 
pH sensitive liposomes 
Stealth liposomes 
Archaeosomes 
Escheriosomes 
Proteoliposomes 
Immunoliposomes 
Genosomes 
Lipofectin 
Phosphatidyl-ethanolamine with 
cholesterol hemi-succinate or PE with 
oleic acid liposomes or Cationic lipids 
with DOPE 
Choi and 5-10% of PEG-DSPE or 
GM1 
Made of lipid from Archaebacteria 
Composed of E. coli membrane lipid 
Liposomes with encapsulated/surface 
attached proteins 
Liposomes with covalently attached 
mono/polyclonal antibodies 
DNA-liposomes/lipid complexes 
Lipid-DNA complex 
Fate of l iposomes inside host body 
Liposomes administered into host may disintegrate in bloodstream 
or may wander in the systemic circulation and picked up 
predominantly by macrophages. Actually, endothelial lining of healthy 
blood vessels forms an efficient barrier to the liposomal escape from 
circulation. However at the site of inflammation, endothelium is more 
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permeable and allows extravasations of small liposomes. This leads to 
the rapid clearance of liposomes from the blood circulation and their 
capture by the organs of reticulo-endothelial system (Poste 1983, Allen 
et al. 1988), corresponding to the tissue distribution pattern of some 
pathogenic microorganisms responsible for intracellular infections. 
Passive site-specific drug targeting with liposomes, as it is called, may 
facilitate lowering of the drug dosage relative to the amount of the free 
drug used, thereby reducing the potential toxic side effects exerted by 
higher doses of the drugs. However, this clearance is too fast to benefit 
other t issues from it. PEG-coated stealth liposomes have long half-life 
in blood circulation and may act as a reservoir for sustained release of 
the therapeutic agents for longer duration. Antibodies or other homing 
devices covalently attached to the surface make the liposome uptake 
tissue and cell specific. 
The applications of liposomes in drug delivery are based on 
physicochemical and colloidal characterization such as composition, 
size and loading efficiency and the stability of the carrier, as well as 
their biological interactions with the cells. The major interactions 
between the liposomes and cells are as follows. Lipid exchange is a 
long-range interaction that involves the exchange of liposomal lipids for 
the lipids of various cell membranes. It depends on the mechanical 
stability of the bilayer and can be reduced by alloying the membrane 
with the cholesterol (which gives rise to greatly improved mechanical 
properties, such as increased stretching elastic modulus, resulting in 
stronger membranes and reduced permeability). The second major 
interaction is adsorption onto cells, which occurs when the attractive 
forces (electrostatic, electrodynamic, Vander waals, hydrophobic 
interaction and hydrogen bonding etc.) exceed repulsive forces 
(electrostatic, steric, hydration, ondulation, protrusion etc.). Adsorption 
onto phagocytic cells is normally followed by endocytosis or rarely, by 
fusion. The fusogenic liposomes mimic the way by which several 
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viruses (HIV, Sendai virus) bind and merge with cell membranes at 
neutral pH and subsequently release their content into the cytoplasm. 
Liposomes - Applications 
Liposomes are being used for a range of therapeutic and 
pharmaceutical applications. Some of them are listed as below: 
• As drug/protein delivery vehicles 
• In anti-bacterial, anti-fungal and anti-viral therapy 
• As biological response modifiers 
• In tumor therapy 
• In Immunology 
• In enzyme replacement therapy 
• In gene delivery 
• In environmental cleansing 
• In cosmetics and dermatology 
• In enzyme immobilization and bioreactor technology 
• In Recombinant DNA technology 
• As artificial blood surrogates 
• As radiopharmaceutical and radiodiagnostic carriers. 
However, the most important and wider field, which has been 
revolutionized by liposomes, is drug-delivery and targeting. 
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Liposomes as drug carriers 
Advantages of using liposomes: 
Resemblance to bio-membranes: 
The liposomes are biodegradable, inert, non-toxic delivery 
systems usually composed of lipids isolated from plasma membranes of 
the living cells. Various types of liposomes can be prepared by varying 
size, morphology, and composition. 
Solubilisation: 
Liposomes may solubilise recalcitrant drugs/compounds. 
Versatile carriers: 
Amphipathic nature of liposomes facilitates the incorporation of 
both hydrophilic as well as hydrophobic drugs. The drugs of 
intermediate solubility can be associated with liposome interior by 
manipulation of liposomal internal pH (Mayer et al. 1986) or by addition 
of counter ions to form molecular complexes of the drug within the 
liposomes (Haran et al. 1993). 
Flexibility: 
Liposomes can be formulated as a suspension, as an aerosol or in 
a semisolid form such as gel or cream or dry powder, for their topical or 
potential in vivo administration. 
Targeting potential: 
Property of liposomes to be taken up by the macrophages and 
RES can be utilized for passive delivery of drugs to the liver and spleen. 
Surface engineered versions of liposomes have increased circulation 
time and deliver drugs to specific tissues by circumventing passive 
uptake by RES-predominant organs. 
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Duration of Action: 
Liposomes can help in maintaining relatively constant and 
sustained blood plasma levels of drugs and give rise to long lasting 
effects. 
Internalization: 
The endocytosis/phagocytosis of liposomes opens up 
opportunities for use in targeting of drugs, genes, enzymes etc. to the 
desired population of cells. 
Amplification: 
Liposomes can be used as adjuvants in vaccine formulations as 
well. The Liposomised antigen can evoke immune system of the host 
more efficiently as compared to free form of antigen. 
Protection: 
Liposomes-encapsulated drugs are inaccessible to metabolising 
enzymes. Conversely, body components like RBC and heart, are not 
exposed directly to toxic effects of drugs. 
Altered Pharmacokinetics: 
Relative to the same drug in free form, there are significant 
changes in absorption, bio-distribution and clearance of liposomes-
associated drugs, resulting in dramatic effects on both the efficacy and 
toxicity of the entrapped compound. 
Limitations of using liposomes 
o Liposomes tend to aggregate or lose entrapped drug during 
storage. 
o There is no suitable method of their sterilization by irradiation or 
by heat. 
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o The macrophages of RES can take up liposomes before reaching 
their target organs. 
o High-density lipoproteins tend to interact with liposomes, in vivo, 
leading to leakage of encapsulated species. 
o Liposome preparation techniques are difficult to scale up using 
traditional methods. 
Liposomes and control of multi drug resistance 
When used in treatment of infectious diseases, careful selection 
of proper antibiotics allows successful inhibition of multiplication as 
well as complete eradication of the pathogens from the host. Each kind 
of organism may be inhibited by specific antibiotic and also by specific 
drug dose. Therefore attributes made for selection of correct antibiotics 
are fundamental to the success of any treatment. When drug entrapped 
in liposomes is administered, liposomes act as a carrier transporting 
and directing antibiotics to the infected t issues where the drug attains 
fairly high concentration needed to kill the pathogens. Besides 
increasing the efficacy of the drug, liposome mediated delivery regresses 
chances for the development of resistance as the drug concentration at 
site of infection maintained throughout the treatment period. The 
targeted delivery also minimizes exposure of normal cells to the drug 
and thereby chances of toxic manifestation are minimal. In addition, 
this also facilitates the diffusion of the drug preferably into the infected 
locus and persistently maintains the effectiveness for a long time. 
Incidentally, multi-drug resistance in cancerous cells is often 
associated with the over expression of drug efflux pumps, known as P-
glycoprotein pump (PGP) (Kartner et al. 1985) and multi-drug 
resistance associated pumps (MRP), which expel the drug molecules 
outside the cells resulting in less accumulation inside the cells. Various 
delivery systems including liposomes have been used in chemotherapy 
of a number of refractory cancers both in animals and clinical models 
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(Endicott and Ling 1989). Several mechanisms proposed, through 
which liposomes control multi-drug resistance in tumors are: 
• Negatively charged phospholipids (phosphatidylserine or 
cardiolipin) used in the liposomal formulations may directly 
regulate the expression PGP and MRP. 
• After endocytosis of drug-loaded liposomes, the lysosomal 
localization of the drug protects it from outflow by PGP by 
avoiding immediate contact with the transporter that is present at 
plasma membrane. 
• Liposomes may provide sustained and high levels of drug to cells 
over long period of time to reduce the chances of cells to be 
converted into resistant ones. 
• Liposomal drug delivery may help to overcome a broader range of 
drug resistance due to favorable pharmacokinetics. 
Interestingly, the combination of liposome-encapsulated drug 
with some other chemotherapeutic agents or immunomodulators 
makes it more effective in combating the problem of resistance. This 
strategy opens new vistas in treating the infectious diseases not 
responding to free forms of the drugs in lower doses or moderately 
higher doses. In normal course, C. albicans isolates respond to the drug 
at 1 mg/Kg body weight dose of Amp B, however some of the strains 
were found to be less sensitive to the Amp B at lower doses and may 
need more than 5 mg/Kg dose for complete elimination. Incidentally, 
the higher doses of the Amp B are likely to impart untoward effects 
such as nephrotoxicity etc., and cannot be recommended for 
therapeutic purposes. 
Liposomes and antibacterial therapy 
Infections caused by intracellular pathogens, such as Brucella, 
Salmonella, Listeria, Legionella and Mycobacterium species, are difficult 
to treat with conventional anti-microbial chemotherapy because of the 
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unfulfilled requirement that antibiotics should accumulate therapeutic 
levels at the intracellular site of the infection. When antibiotics are 
incorporated in liposomes, these are readily delivered to the endosome 
of macrophages, thus targeting the drug to the site of infection. This 
approach provides a remarkable enhancement in the therapeutic index 
of antibiotics and reduction in toxic side effects. 
Liposomised streptomycin was shown to be more effective against 
Staphylococcus aureus and Escherichia coli (Fountain et al. 1985), as 
compared to the free drug. Gentamycin when encapsulated in positively 
charged liposomes could eliminate the Brucella melitensis (Harnandez-
Caselles et al. 1989) and Klebsiella pneumoniae (Swenson et al. 1990) 
loads from the liver and spleen of the infected animals. The same 
liposomal preparation of gentamycin with changed lipid composition 
has also helped treat Salmonella dublin infections. Gentamycin 
encapsulated in pH-sensitive liposomes was found to show increased 
efficacy against Salmonella typhimurium in model animal (Cordiero et 
al. 2000). The efficacy of liposomised preparation of other drugs such 
as amikacin, tobramycin and chloramphenicol against several gram-
negative bacteria has also been reported (Stevenson et al. 1983). 
Chronic listerosis infection can be managed by an injection of 
liposomised ampicillin (Bakker-Woundenberg et al. 1988) and has been 
90 fold more potent than the free drug (Fattal et al. 1991). 
The association of tuberculosis with HIV infection has 
significantly exacerbated the situation in developed and developing 
countries. HIV infection is the highest risk factor identified so far for 
latent tuberculosis infection to progress to an active disease. 
Mycobacterial infections have long been notorious for being difficult to 
eradicate by conventional chemotherapy, can also be controlled using 
liposomal preparations. Liposomal encapsulation of Streptomycin 
(Vladirmisky et al. 1983), Isoniazid and Rifampicin (Orozco et al. 1990) 
can enhance efficacy of these drugs against tuberculosis. While 
liposomised rifampicin was able to control Mycobactrium avium 
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infection in mice (Saito and Tomika, 1989). Different aminoglycoside 
classes of antimycobacterial drugs, amikacin and gentamycin, have 
also been shown to control mycobacterial infection more efficiently 
when encapsulated in liposomes (Bermudez et al. 1990; Kesavalu et al. 
1990, Klemens et al. 1990). 
Liposomes and antifungal therapy 
Systemic fungal infections occur at high frequency in the 
immuno-compromised patients such as those of cancer and AIDS 
patients as well as patients with organ transplantation (Landman and 
Saurina, 1998; Musial et al. 1988). Drug of choice for the most 
systemic mycoses is a polyene antibiotic Amphotericin-B, that interacts 
with ergosterol in fungal cell membranes thus creating transmembrane 
channels and permitting the escape of vital ions and metabolites. This 
drug although very promising, had limited use due to its systemic 
toxicity. Incorporation of Amp-B in liposomes successfully reduces its 
nephrotoxicity and thus improves the therapeutic index (Adler-Moore 
and Proffitt, 2002). Numerous reports of liposomal Amp-B having 
enhanced efficacy against murine aspergillosis and candidiasis (Van 
Etten et al. 1995; Otsubo et al. 1998), and against cryptococcosis, 
histoplasmosis, Fusarium infections etc. (Graybill et al. 1982; Adler-
Moore et al. 1991; Garcia et al. 2000) are available. Table. 1.2.2, gives 
some of the important commercially available liposomal preparations of 
Amp-B. 
Other polyene antibiotics like nystatin and hamycin have also 
been successfully liposomised to improve their therapeutic index 
(Mehta et al. 1991). This led to the development of the liposomal 
preparation of Itraconazole in management of experimental 
cryptococcosis and pulmonary aspergillosis (Leconte et al. 1992). 
Liposomes and antiprotozoal therapy 
The first successful use of the liposomal drug delivery system in 
infectious diseases was made in the treatment of leishmaniasis. This 
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protozoan parasite, endemic in many tropical and subtropical areas, 
enters and colonizes macrophages and thus can be readily targeted by 
liposomes. In mice, liposome encapsulated antimonies have been 
shown to be about 700-1800 times more effective than the free drug in 
controlling leishmaniasis (New et al. 1978). Stilbamine encapsulated in 
mannose bearing liposomes has been used in treatment of the 
experimental leishmaniasis. Interestingly, some of the anti-fungal drugs 
like griseofulvin (New et al. 1981), Amp-B (Adler-Moore et al. 2002) and 
5-fluorocytosine were demonstrated to exhibit an enhanced efficacy 
against leishmaniasis when used in the liposomal form. 
It has been shown that when MSP-1 i.e .Psurface protein -1 was 
incorporated into a synthetic monophosphoryl lipid A-liposome 
formulation, mice of different haplotypes produced anti MSP-1 
antibodies capable of inhibiting P. falciparum growth (Chang et al. 
1994). 
The life cycle of the malarial parasite gets completed in different 
body parts of the host. Depending on its different life cycle stages, 
specific liposomal formulations of antimalarials have been shown to be 
of great promise in the treatment of malarial infection. Primaquine 
when entrapped in liposomes can cure murine malaria by using a 
single intravenous injection. The efficacy of primaquine containing 
liposomes can be increased several fold when such liposomes are made 
more specific for their target by grafting galactosyl glycolipid on their 
surface (Alving 1982). Chloroquine, the most promising antimalarial, 
specific against intra erythrocytic stage of plasmodial life cycle, can be 
made very effective not only against drug sensitive but also drug 
resistant strains of P. berghei (Owais et al. 1995), by encapsulation in 
liposomes bearing antibodies directed against surface antigens of 
erythrocytes. 
Liposomes and antiviral therapy 
Liposome encapsulated macrophage stimulators, viz lymphokine, 
muramyldipeptide and its aminobuturyl analogue, were employed 
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against Herpes simplex virus type-2 (HSV-2) infection (Koff et al. 1983, 
Koff et al. 1984). Murine Rift Valley fever virus, rhinovirus and murine 
hepatitis virus could be controlled effectively by using liposomal 
preparations of ribavarin, enviroxime and y-interferon. Liposomal 
formulation of phosphonoformate, was shown to have an improved 
immunomodulation against Rausher Murine Leukemia retroviral 
infection (Szoka 1990). 
Intracellular delivery of novel drugs against HIV-1, including 
antisense oligodeoxynucleotides, ribozymes and therapeutic genes, may 
be achieved by encapsulation in or association with certain types of 
liposomes (Duzgunes et. al, 1999). The authors showed that EC50 of 
the reverse transcriptase inhibitor 9-(2-phosphonylmethoxyethyl) 
adenine (PMEA) was reduced by an order of magnitude when delivered 
to HIV-1 infected macrophages in pH sensitive liposome with the drug 
in liposomised form as effective as the free drug. 
CD4 receptors present on T cells are specifically recognized by 
glycoprotein 'gpl20 ' present on the HIV coat. CD4 inserted in the 
liposomal bilayer effectively cleared both free HIV and 'gp 120' bound to 
HIV infected cells (Nicolau et al. 1990). Liposome encapsulated 
azidothymidine has been shown to reduce the hematopoietic toxicity 
and enhance the activity of the drug against murine AIDS (Phillips and 
Tsoukas 1992). 
Liposomes and Immunology 
Besides its potential application in chemotherapy and gene 
therapy, liposome technology has established itself in the area of 
immunology as well. The major areas of interest from immunological 
point of view are: 
• Liposomes as adjuvants 
• Liposomal vaccines 
• Liposomes as carriers of inrnmnomodulators 
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• Liposomes as tools in imrqun<^agnosticS| _ [(discussed in 
'Liposomes & diagnostics' secltiori) 
Liposomes as adjuvants 
Adjuvants are substance injected together with antigens to 
enhance their immunogenicity. Owing to toxicity of all the known 
adjuvants, only one (alum) has hitherto been licensed for use in 
humans in spite of the fact that it is far from ideal. 
On the contrary, liposomes may offer an alternative, versatile and 
universal adjuvant system with high safety profiles. Liposomal 
immunoadjuvants passively accumulate within regional lymph nodes 
and act as antigen depot by slowly releasing encapsulated antigenic 
components. Table. 1.2.2, provides list of antigens with which 
liposomes have been used. Liposomes have been firmly established as 
immunoadjuvants by potentiating both antigen specific humoral 
(antibody production) (Alving et at 1995) as well as cell-mediated 
(cytotoxic T lymphocytes) (Owais and Gupta 2000) immunity. 
Some other advantages of using liposomes for 
immunopotentiation are as follows: 
• A non-immunogenic substance may be transformed to an 
immunogenic one. 
• Hydrophobic antigens may be reconstituted. 
• May incorporate multiple antigens and other adjuvants to provide 
strong immune response. 
• Toxicity of the antigens can be reduced or may be eliminated by 
inclusion into the liposomes. 
• Modulation of the immune system. 
• Liposomal vaccines produce higher titers of functional antibodies 
as well as prolonged duration of these antibodies. 
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Liposomal Vaccines 
Liposomal vaccines can be developed by incorporating microbes, 
soluble antigens, cytokines or deoxyribonucleic acid in liposomes. 
Alternatively, antigens can be covalently coupled to liposomal 
membrane for increasing their immunogenicity (Wassef et al. 1994). 
Also for enhanced immunopotentiation, some other agents such as 
muramyl dipeptide (MDP), lipopolysachharide, lipid A and tuftsin can 
also be incorporated into liposomes (Schroit and Fidler 1986, Singhal et 
al. 1984, Bennett-Guerrero et al. 2000, Richards et al 1998). 
Some of the commercially available liposomal vaccines are 
enlisted in Table. 1.2.3. Most of the liposomal vaccines investigated to 
date are based either on novasome or IRIV (immunopotentiating 
reconstituted influenza virosome). Vaccines based on novasomes (non-
phospholipid, biodegradable, pausilamellar vesicles formed from single 
chain amphiphiles, with or without other lipids) have been licensed for 
the immunization of the fowl against Newcastle disease virus and avian 
retrovirus (IGI, Vineland Laboratories, Vineland, NJ, USA) (Gregoriadis 
1995). 
IRIVs are spherical, unilamellar vesicles with a mean diameter of 
-150 nm (Gluck et al. 1992). IRIVs are prepared by detergent removal 
of influenza surface glycoproteins and a mixture of natural and 
synthetic phospholipids containing 70% egg phosphatidylcholine, 20% 
synthetic PE and 10% envelope phospholipids originating from H1N1 
influenza virus. Thus IRIV combines several components that are 
known to contribute to immunostimulation and at the same time are 
non-toxic and bioacceptable. The first liposome based vaccine (against 
hepatitis A) for human use is IRIV vaccine produced by Swiss serum 
and vaccine institute, Berne, Switzerland known as "Epaxal-Berna 
Vaccine" (Gluck, 1995). 
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CD4+ T helper and CD8+ T cytotoxic phenotype may be influenced 
by cytokine milieu, the differential expression of costimulatory 
molecules, antigen dose, differences in affinity at the TCR-peptide-MHC 
interface and adjuvants (Agrewala et al. 1996; Agrewala et al. 1998, 
Braciale et al. 1987, Liebana et al. 1999). In spite of activating the 
immune response of the host against exogenous antigenic substances, 
even the liposomised form of the antigen usually results in activation of 
CD4+ T cells, which helps in elicitation of antigen specific humoral 
immune response with enhanced production of antibodies. The 
induction of cell mediated immunity (CMI) to antigen is dependent on 
the activation of CD4+, MHC class II (T-helper cells) and CD8+, MHC 
class I (cytotoxic T cells) restricted T cells (Braciale et al. 1987; Unanue 
and Allen, 1987). T-helper cells (Th) facilitate cytotoxic T cell (CTL) and 
B cell responses, and help in the production of class switching and 
memory responses. Cytotoxic T cells represent the other effector arm of 
the cell-mediated immune response. T lymphocytes are of strategic 
importance in killing of the cells infected with intracellular pathogens 
and also towards surveillance mechanisms against cancer cells. The 
CD8+ T cell phenotype can considerably influence the outcome of 
infection by intracellular pathogens. The role of cytotoxic T cells has 
been established and found to be crucial for protecting the host against 
diseases caused by intracellular microbes and viruses (Unanue and 
Allen, 1987; Nickell et al. 1993; Muller et al. 1991; Flynn, et al. 1992; 
Deres et al. 1989). Since, both cytotoxic as well as T helper cells are 
crucial for protecting the host against intracellular pathogens, to mount 
an effective immunity against such infections, it is important to develop 
vaccines that generate strong CD4+ and CD8+ T cells responses (Flynn, 
etal. 1992; Tarleton etal. 1992; Bottomly, 1988). 
The lipid composition of plasma membrane of various organisms 
plays crucial role in various physiological activities, eg. fertilization, 
phagocytosis, exocytosis and cell division especially in perspective of 
membrane-membrane fusion (Voet et al. 1999, White 1992). Lower 
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organisms, such as bacteria and yeast, have many fusogenic (anionic) 
phospholipids in their membranes, presumably to cope with the high 
multiplication rate (Krishnan et al. 2000, Conlan et al. 2001, Rattray 
1988, Owais and Gupta 2000). Such lipids seem to facilitate the fusion 
of the two opposite sites of inner leaflets under physiological conditions. 
It was demonstrated that the E. coli lipid liposomes (escheriosomes) 
very effectively fused with the membrane of the macrophages leading to 
the delivery of entrapped solutes or antigens to their cytosol. 
Moreover, the studies have revealed that antigen entrapped in these 
liposomes could generate strong OVA-specific, CD4+ T-helper as well as 
CD8+ cytotoxic T cells. The T-helper response was chiefly of Th-2 type, 
as evident from the secretion of IL-4 and IgGl-isotype (Stevens et al. 
1988, Shaji et al. 1998). On the contrary, the same antigen after 
encapsulation in egg PC liposomes induced humoral immune response 
mainly (Owais & Gupta 2000). 
Protective immunity against intracellular bacteria (tuberculosis, 
leprosy), fungi (cryptococcosis, candidiasis), protozoans (leishmaniasis, 
malaria), viruses and cancer requires active involvement of the 
pathogen specific CD8+ T lymphocytes (Malik et al. 1993, Sasiain et al. 
1998, Liebana et al. 1999, Nickell et al. 1993, Muller et al. 1991, Deres 
et al. 1989). Ironically, prevalent immunization protocols result in the 
development of humoral immune response mainly; on the contrary 
generation of cytotoxic T cells always remains a major uphill task 
(Audibert and Lise 1993, Leclerc and Ronco 1998). Moreover, some of 
the presently available antigen delivery systems viz. Virosomes, pH 
sensitive liposomes or fusogenic protein bearing liposomes, which are 
claimed to induce strong immunogenic responses against entrapped 
antigen, cannot be recommended because of cost factor, toxicity as well 
as structural components (cf. carbohydrate) induced immunological 
complications (Mandal and Lee 2002, Polt-Frank et al. 1999, Lee- ki et 
al. 2002, Kunisawa et al. 2001, Babai et al. 2002, Harding et al. 1991). 
58 
<Rpview of literature I S P £ip°somes 
Liposomised antigens are avidly taken u p by the antigen 
presenting cells, and lead to the production of IL-4 mainly (Agrewala et 
al. 1996). Thus in spite of the adjuvant effect of liposomes in terms of 
increased humoral immunity, they miserably fail to activate the cell-
mediated immunity. To meet demand of the ordeal, escheriosomes and 
yeast lipid liposomes were evaluated for their ability to breach cell 
membrane barrier and deliver entrapped solutes in the cytosol of the of 
the target cells including macrophages. The potential of escheriosomes 
to activate the cell mediated arm of the immune response enables them 
as an ideal vaccine adjuvant against diseases caused by intracellular 
pathogens. 
Liposomes in immunomodulation 
Interestingly, incorporation of cytokines or other 
immunomodulators have been found to activate various immune 
components of the host. Activation of the immune system for the 
management of certain types of tumors like micrometastases and 
osteosarcoma is a well-accepted treatment modality. The main purpose 
is to activate macrophages and render them tumoricidal, with the 
specific ability to recognize and destroy neoplastic cells both in vitro 
and in vivo, while leaving normal cells unharmed by a non-
immunological reaction mechanism that requires cell-to-cell contact 
(Tucker et al. 1981). 
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Table. 1.2.2: List of Antigens with which liposomes have been used as 
immunoadjuvants 
Antigen 
Influenza subunit antigen 
Bacterial polysaccharide 
Rabies glycoprotein 
Polio virus peptides 
Cholera toxin 
Toxoid of B, pertussis 
Tetanus toxoid 
Diptheria toxoid 
Herpes simplex virus 
Hepatitis B virus surface antigen 
Liposome / Effect 
Intranasal, protects animals from virus 
Superior immunoadjuvants 
Ag specific IL-2 enhancement 
Enhanced Ab level 
Superior immunoadjuvants 
Very effective vaccine 
Mannose-mediated liposomal targeting, 
increased antibody titre 
Higher Ab response 
MLV with lipid A, Enhanced Ab level 
Humoral and cellular immunity 
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Table. 1.2.3: Liposome based vaccines either approved or licensed 
for use in human 
System 
Novasome 
s 
Novasome 
s 
Novasome 
s 
Novasome 
s 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
Components 
Killed new castle 
disease virus 
Killed avian retrovirus 
E.coli0157:H7 (killed) 
Shigella flexneri 
Haemagglutinins/neura 
minidase from influenza 
strains 
Inactivated hepatitis A 
virions 
Genetically engineered 
Hepatitis A and B 
components (HAV) 
Diptheria and tetanus 
toxoids 
Diptheria and tetanus 
toxoids +HAV virions 
Target Disease 
New castle disease 
Retroviral infection 
E. col i0517 
infections 
S. flexneri infections 
Influenza 
Hepatitis A 
Hepatitis A and B 
Diptheria and 
te tanus 
Diptheria, te tanus, 
Hepatitis A and B 
Company 
IGI, Vineland 
Lab, NJ, USA 
IGI, Vineland 
Lab, NJ, USA 
Novavax, 
USA 
Novavax, 
USA 
Swiss serum 
and Vaccine 
Int., Switz. 
Swiss serum 
and Vaccine 
Int., Switz. 
Swiss serum 
and Vaccine 
Int., Switz 
Swiss serum 
and Vaccine 
Int., Switz 
Swiss serum 
and Vaccine 
Int., Switz 
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Liposomes and antitumor therapy 
Most of the medical applications of liposomes that have reached 
preclinical and clinical stages belong to cancer ailments mainly. Table. 
1.2.2, gives some of the important commercially available liposomal 
preparations of antneoplastic drugs. It ha s been demonstrated that 
small-sized and long circulating liposomes can be passively targeted to 
different tumors because of extended circulation and extravasation 
(owing to their small size, 50-150 nm) in t issues with enhanced 
vascular permeability (Gregoriadis et ah 1971, Gabijon and 
Papahadjopoulos 1992). Long-circulating pegylated liposomes were able 
to deliver between 5 to 11 times more doxorubicin to the Kaposi's 
sarcoma lesions than to normal skin, leading to overall response rates 
as high as 80% (Northfelt et ah 1996), and also decreased uptake of 
drug by sensitive tissues such as the hear t (Uziely et ah 1995). 
Preclinical experiments indicate that stealth liposomal delivery of 
anthracyclin.es is effective in decreasing the cardio toxic effect, 
enhancing antitumor activity and improving the overall therapeutic 
index ((iabizon, 2000). 
Targeting strategies using liposomes can be designed in three different 
ways: 
v Natural targeting (lysosomotropism) of conventional liposomes 
(passive vectorization). 
v Use of long -circulatory (stealth) liposomes. 
v Use of ligand mediated targeting (active targeting). 
(a) The use of anti-receptor antibodies or antibodies developed against 
specific surface antigens on the tumor vascular endothelium; 
(b)The use of angiogenic peptides and adhesion molecules as ligands 
against receptors expressed on tumour vascular endothelium. 
v Use of stealth liposomes and ligand mediated targeting in 
combination. 
62 
<Rgview of literature Liposomes 
Sterically stabilized (stealth) l iposomes (SSL) 
The site-specific drug targeting requires proper and smartly 
designed delivery systems that avoid scavenging through receptor-
mediated uptake by mononuclear phagocytic cells of RES-rich organs. 
Moreover, several targeting strategies require the system to be placed 
either into the tumors cells or their extravasation into non-RES cellular 
lineage. As a matter of fact, recently described approaches to avoid 
RES-uptake of the drug carrier composites, lead to the concept of 
ligand- appended system, which resist opsonization and serum protein 
binding to their surface. Sterically stabilized liposomes thus avoid their 
recognition from RES uptake and this "stealthing" effect makes them 
long circulatiry in nature. 
Rational and concept of using stealth liposomes in tumor 
targeting 
Major aims and benefits of sterically stabilized liposomes (SSL) or 
stealth liposomes are as following: 
• Making liposomal systems more stable in bioenvironmental 
conditions. 
• Making them long circulatory (i.e., less recognizable to serum 
proteins specially opsonins and hence less recognizable to 
phagocytic cells of RES). 
• Making the targeted along with long circulatory behaviour by 
anchoring site specific ligands. 
• Making them more sensitive towards external stimuli and 
signals like pH, substrates and temperatures. 
• Making them more suitable for tumor targeting 
The potential of stealth liposome for tumor targeting can be 
realized by following attributes: 
1. Long circulatory liposomes with encapsulated anticancer drugs 
can reach sites other than RES (if tumor belongs to an 
extravascular site), either by extravasation through leaky blood 
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vessels in tumors or directed through surface attached ligands 
(mostly antibodies). 
2. They can serve as the sustained release micro reservoirs for the 
anticancer drugs. This can be either long-circulatory systemic 
application, local injection to body cavities, such as 
intraperitoneal, or intramuscular or subcutaneous drug depot 
with customized permeability or leakage chracterstics. 
3. They may be used in direct applications, such as delivery of free 
redical oxygen to enhance radiotherapy or other photo- and 
radiotherapeutic substances. 
4. Keeping into consideration amplified expression of folate 
receptor in ovarian carcinoma, it has been shown that folate-
derived liposomes have effectively delivered entrapped agents 
into tumor cells via receptor-mediated endocytosis (Pan et al. 
2002). Folate has been coupled to distearoyl phosphatidyl 
ethanolamine (DSPE) using a PEG 2000 linker (Folate-PEG 
2000-DSPE) to deliver liposome encapsulated doxorubicin has 
been reported over that observed for non targeted vesicles (Lee 
and Low 1994). More recently, reports appeared on Arginine-
Glycine-Aspartic acid (RGD) peptide driven targeting of 
liposomes to endothelial cells to block angiogenesis in tumours. 
RGD tripeptide, being a fragment of fibronectin, discourages 
melanoma cells from spreading (metastasis), presumably RGD 
molecules block the receptors that a wandering tumor cell need 
for binding to fibronectin and hence in the extracellular matrix 
of the tissue. 
Fusogenic liposomes 
Fusogenic liposdomes can potentially facilitate the intracellular 
delivery of encapsulated molecules (drugs or antigen) by fusing with the 
target cell. A variety of approaches can be envisioned for constructing 
fusogenic liposomes. Examples include the inclusion of lipids that are 
able to form non-bilayer phases, such as DOPE, which can promote 
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destabilization of the bilayer, inducing membrane-membrane fusion 
(Ellens et al. 1996). Furthermore, alterations in the lipid composition 
can render liposomes pH-sensitive, leading to enhanced tendencies in 
low pH compartments such as endosomes (wang 85 Huang 1989, Tari et 
al. 1993). Non phospholipid fusogenic liposomes composed primarily of 
dioxyethylene acyl ethers and cholestrol have been shown to fuse with 
plasma membranes of erythrocytes and fibroblasts (Baraka et al. 1996). 
Alternatively, efficient fusogenic liposomes can be achieved by 
incorporating fusogenic proteins into the liposome membrane (Fiebre et 
al. 1993, Compagnon et al. 1992, Bron et al. 1994) or entrapped within 
liposomes (Glushakova et al. 1992). The feasibility of this approach has 
been demonstrated for the delivery of the diptheria toxin A (DTA) 
subunit using liposomes produced from influenza virus envelopes (Bron 
et al. 1995). It has been reported that fusogenic liposomes (Sendai virus 
particles) containing DTA showed high cytotoxicity against sarcoma-
180 (S-180) cells in vitro. When these liposomes were administered into 
the abdominal cavity of ddY mice carrying S-180, tumor cells 
completely disappeared in four of six tumour-bearing mice without 
decrease in body weight (Mizuguchi et al. 1996). Furthermore, 
intratumor injections of fusogenic liposomes containing DTA 
significantly inhibited the tumor growth as assessed by the relative 
mean tumor volume, and by the survival time of the mice (Mizuguchi et 
al. 1996). No therapeutic effects were observed when simple liposomes 
containing DTA or empty fusogenic liposomes were administered. 
Fusogenic peptides can be conjugated to the liposomes and may also 
promote intracellular delivery (Lee et al. 1996, Kato et al. 1991, Puyal et 
al. 1994). Thus, fusogenic liposome is a good candidate as a vehicle to 
deliver drugs into the cytoplasm in an endocytosis-independent 
manner. 
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Table 1.2.4: Liposome-based Antibiotics/Antineoplastics 
System 
Liposomes 
AmBisome 
Amphocil 
ABELECT 
AMPHOLTEC 
Mikasome 
Doxil 
Daunoxome 
EVACET™ 
VincaXome 
Liposomes 
Drug 
Nystatin 
Amphotericin B 
Amphotericin B 
Amphotericin B 
Amphotericin B 
Amikacin 
Doxorubicin 
Daunorubicin 
Doxorubicin 
Vincristine 
Anamycin 
Target Disease 
Systemic fungal 
infections 
Systemic fungal 
infections 
Systemic fungal 
infections 
Systemic fungal 
infections 
Systemic fungal 
infections 
Bacterial infections 
Metastatic cancers 
Metastatic cancers 
Metastatic cancers 
Solid tumors 
Kaposi" s sarcoma 
Company 
AroneX, USA 
NeXstar, USA 
SEQUUS, USA 
Liposome Co. USA 
Sequus, USA 
NeXstar, USA 
SEQUUS, USA 
NeXstar, USA 
Liposome Co, USA 
NeXstar, USA 
AroneX, USA 
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Figure 1.2.4: Accumulation of liposomes within solid tumors — 
(right) liposome extravasation from the disorganized tumor 
vasculature and (left) liposomes in normal tissue. 
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Liposomes and Gene therapy 
Gene therapy is a latest approach to treat, cure or prevent disease 
by changing the expression of specific genes. Broadest definition 
includes in vivo (direct administration of gene therapy formulation) and 
ex vivo (transfection of cells in tissue culture followed by administration 
of these cells into Patients). Two fundamental approaches underlie 
basis of gene therapy. In the first, genetic material is introduced into 
cells to alter cellular phenotypes. This is typified by transfer of 
unintegrated DNA, antisense oligomers and ribozymes. Second 
approach seeks permanent alteration of genotype of the cells leading to 
gene addition, excision or replacement; thereby preventing or altering 
the diseased state. One of the most successful gene therapies was 
reported in 2000, when 3 infants with severe combined 
immunodeficiency received ex vivo gene therapy with recombinant 
mouse leukemia viral vector encoding yC receptor gene. Within 10 
months; T, B, NK cell counts and functions reached normal values. 
In many cell types, it is feasible to deliver nucleic acids and genes 
by variety of methods. Viral based vectors include the use of Retrovirus, 
Adenovirus, Herpesvirus etc. Non-viral DNA delivery (using gene gun, 
electroporation, liposomes) is a multistage process consisting of DNA 
condensation, cell entry, endosomal escape, nuclear localization and 
transgene expession. Non-DNA Particles usually consist of a polycation 
core that induces DNA condensation leading to microprecipitaes that 
contain hundreds of DNA molecules per Particle. Advantages of using 
liposomes are low immunogenicity; ease of handling and availability for 
large-scale operations while disadvantages are that transfection 
efficiency is lower than that of viral vector. Some of the gene transfer 
reagents are: 
• The commercially available Lipofectin is often the standard 
formulation to which newer methods of gene transfer are compared and 
the prototype cationic lipid for gene transfer is DOTMA (1,2, -
dioleyloxypropyl- 3-trimethyl ammonium bromide). Lipofectin is a 1:1 
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mixture of DOTMA and a neutral lipid known as DOPE 
(dioleoylphosphatidyl ethanolamine). Other cationic mixtures are also 
being experimented with-these include combining DOTMA with DMRIE 
(1, 2, dimyristoyloxypropyl-3-dimethyl-hydroxyethyl-ammonium 
bromide), DOTAP (l,2-dioleoyloxy-3-trimethylammonio propane), 
polylysine, cholesterol, lipopolyamides and quarternary ammonium 
detergents. 
• Due to negative surface charge of plasma proteins and circulating 
blood cells, cationic lipoplexes are not likely to maintain their surface 
charge and colloidal stability upon intravenous injection. Anionic 
liposomes are an alternative but DNA itself being negatively charged, 
cannot form complexes efficiently. To rectify these problems, a newer 
formulation known as LPD II was created. LDP I and LDP II are made 
by first complexing DNA to a cationic polymer and then mixing with 
fusogenic anionic liposomes to form LPD II particles. LPD I contains 
cationic lipids while LPD II particle possess anionic lipids. These are 
also termed as Liposome-complexed polyplexes (Guo and Lee 2004). 
• DQAsomes are liposome-like aggregates that are formed from 
drug Dequalinium, a dicationic amphiphile. 
• Terplex system is based on balance of surface charge and 
hydrophobicity that exist between searyl-poly (L-lysine) LDL, and 
genetic material. Plasmid DNA is condensed by addition of stearyl-PLL 
and LDL to yield a terplex system of about lOOnm diameter. 
Given that genes regulate every physiological process in the body, 
the potential for targeting genes as a therapeutic approach is all but 
infinite. Most of the human gene transfer trials seek to correct single 
gene defect such as adenosine deaminase deficiency, 
glucocerebrosidase deficiency in Gaucher's disease or mutated chloride 
transport gene in cystic fibrosis. Aerosol delivery of CFTR gene in 
lipocomplexes is very effective. Suicide gene therapy using coupled 
enzyme cytosine deaminase and drug 5-flourocytosine has been studied 
for targeting tumor cells. Vectors encoding thymidine kinase target 
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tumor cells for killing when exposed to prodrug gancyclovir. The 
efficacy of intracranial implantation of an Alzheimer's patient's own 
modified fibroblasts with inclusion of the gene which expresses Nerve 
Growth Factor has also been established. 
However most of the trials are in early Phase I and II studies. 
Future gene therapy studies will capitalize on preclinical efforts to 
improve cellular targeting, gene transfer efficiency and sustained 
expression. 
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Figure 1.2.5: The optimisation off liposomal gene delivery. 
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Liposomes and Enzyme therapy 
While gene therapy deals with delivery of genes to the cells, 
enzyme therapy aims at treatment of disorders by using gene products 
i.e. enzymes. A number of metabolic disorders are caused by either 
presence of non-functional enzyme or due to complete absence of a 
particular enzyme. Enzymes are now being used as drugs and enzyme-
loaded liposomes are regarded as novel and biocompatible biocatalysts. 
Various enzymes have been entrapped inside small or large 
unilamaller, multilamaller and giant vesicles using different methods. 
Imigluceraferase encapsulated liposomes, available under the name 
Cerezyme® was used to treat Gaucher's disease in 2001 . In about 12 
months, all the symptoms like organomegaly, anemia, and 
thrombocytopenia subsided. Still better results are expected in the light 
of new reports concerned with treatment of liposomal storage disorders, 
Fabry disease, AIDS, adenosine deaminase deficiency, multiple 
sclerosis, chronic myeloid leukemia, juvenile arthritis and ovarian 
cancer. 
While enzyme therapy is still in its infancy, newer related terms 
are coming u p the horizon. In Antibody-dependent enzyme prodrug 
therapy (ADEPT), a prodrug is converted only at site where its 
activating enzyme is delivered. Immunoliposomes attached enzymes are 
used for site-specific targeting of the required enzyme. Gene-directed 
enzyme prodrug therapy (GDEPT) is a promising two-step treatment for 
solid malignant tumors. In the first step, the gene for a foreign enzyme 
is administered and directed to the tumor, where it may be expressed 
using specific transcriptional elements. In the second step, prodrugs 
are administered and activated by the foreign enzyme expressed at the 
tumor. A number of approaches are now being used for management of 
diseases previously considered untreatable. Outlook for gene and 
enzyme therapy is promising. 
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Liposomes and Diagnostics 
Liposomes also find a number of uses in diagnostic assays: 
• Annexins are membrane-binding proteins and a highly sensitive 
assay was developed for their determination. It relied on liposomal 
aggregation as monitored by turbidimetry. 
• Several blood-clotting assays rely on colloidal instability of cells 
or different lipid extracts, from rabbit brains. Synthetic optimized 
liposomes utilizing kits are available that produce reliable results. 
• A system intended for whole process quality assurance of nucleic 
acid amplification assays was developed based on the use of liposomes 
as cell-mimicking vehicles for detection of various Pathogens. 
• In ELISA, one antibody typically carries one labeling group. 
However, if the ligand is associated with liposomes, it could carry 
thousands of markers that enhance the signal proportionally. 
• Receptor-ligand interactions can be accompanied by chromatic 
transitions and thus used to detect viruses. For example, a system 
consisting of polyacetylene bilayers fuctionalized by a sialic-acid 
analogue, which is a site-specific ligand for influenza viral 
haemagglutinin, undergoes a colour change from blue to red upon 
binding that is observable to naked eye. 
Liposomes and Ecology 
In large scale, liposomes may be used for cleansing of 
environment. For example, in metal ion detoxification or clearing up 
reactor/oil spills. Metal ions can be bound to liposomes with surface-
attached chelators, which can then be precipitated. In the case of oil 
spills on water the oil tends to spread on water - this is due to 
significantly higher oil -water interfacial tension as compared to the air 
-oil interfacial tension. Due to their ability to reduce the oil-water 
interfacial tension liposomes are effective in stopping the spreading of 
oil on the surface of water. The oil forms condensed, unspreadable 
droplets, which can subsequently be removed mechanically, skimmed 
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or absorbed. Thus making the whole process of cleaning u p much more 
efficient and manageable. In the case of oil spread (or other 
hydrophobic liquid wastes) on soil the reduction in surface tension 
allows oil droplets to detach from the minerals in the soil and exit 
through the capillaries in the soil. Liposomes also increase both the 
number and variety of microorganisms that can get to the oil surface 
and hence facilitate quicker biodegradation of the oil. This is true for oil 
contamination both on land and on water. 
Liposomes and Industries 
Food industry: 
As an emulsifier for the preparation of bread. It is important to 
get proper mixing of ingredients in order to get the bread to rise and 
bake properly. The addition of emulsifiers help in obtaining a good 
mixture. The addition of emulsifiers also helps in the control of flavor, 
texture and other qualities in food products ranging from mayonnaise 
to chocolates. Liposomes are useful in improved control and shortening 
of fermentation time e.g in cheese making and brewing beer. 
Cosmetic industry: 
Liposomes represent a model for biological membranes in 
biological and medical research because they mimic the lipid 
composition and structure of human skin. They are used in cosmetics 
formulations for their ability to dissolve simultaneously both water-
soluble and water-insoluble substances. Now water-insoluble 
compounds can be dissolved in a biocompatible and biodegradable 
lipid-water system without any organic solvents. Additionally, liposome-
based anti-aging topical formulations (skin care lotions, gels, creams 
and sunscreen products) have been formulated and launched in 
cosmetic market in 1986; some of the products are listed in Table 
1.2.5. Liposomes are valuable for regeneration of the skin and resupply 
of lipid molecules (of which liposomes are made) and moisture. They 
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help improve skin elasticity and 'barrier function' which is major 
causes for skin aging. 
Table 1.2.5: Various liposomal products either launched or 
investigated in the field of dermatology and cosmetics 
Vesicular system 
Bioadhesive 
liposomes 
Brookosome 
Capture 
Coatsome 
Dermosome 
Inovita 
Nactosomes 
Plenitude 
Penta 
Sympathik2000 
Marketed by 
— 
Brook's In's; Applied 
Genetics, Inc 
Cchristian Dior 
Nichiya Liposome Co 
Microfluids 
Pharm / Apotheke 
Lancome(L'Oreal) 
L'Oreal 
Pentapharm 
Biopharm GmbH 
Liposome and 
ingredients 
Gelatin or hyaluronic 
acid bearing liposomes 
with Flucanazole 
Genetic engineered 
enzymes (repair DNA) 
in liposomes 
Liposomes in gel with 
ingredients 
Liposomes with 
humectant (polyol, 
sugar and aminoacid) 
Skin care, loaded 
liposomes 
Thymus 
extract,hyaluronic acid 
and vitamin E in 
liposomes 
Vitamins,retinolactetate 
in liposomes 
Tanning agents in 
liposomes 
Humectant pentavitin F 
in liposomes 
Thymus extract, 
vitaminA Pamitate and 
soya phospholipid 
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There are many other industries where liposomes play important 
roles including: 
o Plastic industry 
o Pesticides 
o Paints (most Paints are emulsions) 
Optimistic approach towards development of new strategies has 
enabled man to overpower a number of diseases to a large extent. 
Liposomes have really proved their worth in this respect. Liposome 
technology has established itself in diverse fields such as medicine, 
immunology, diagnostics, cosmetics, etc and the list is ever increasing. 
Such simplicity is inherent in the structure of liposomes and yet such a 
complex array of their applications is, that these are rightly called as 
"Magic Bullets". In spite of the challenges encountered regarding 
reproducibility, stability and up-scaling methodologies; future 
prospects for the uses of liposomes are very bright. 
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2.1 . Introduction
 vy 
Solid tumors such as fibros^com^^bflaag^historicallv provided 
many challenges to anti-cancer therapy. Therapeutic hurdles to drug 
penetration in solid tumors include heterogeneous vascular supply 
and high interstitial pressures within tumor tissue, particularly in 
necrotic zones, lower pH and presence of leaky vasculature leading to 
reduced therapeutic response. Intense efforts are underway worldwide 
to develop newer and more specific strategies to develop effective 
means for treatment of cancer. This requires a better understanding of 
genetic alterations that ensued in transformation of cells to tumors. 
The efforts are contingent upon the identification of appropriate 
molecular targets, development of modalities that address this target, 
and delivery of the target recognizing novel agent to the tumor cells. In 
this regard, tumor microenvironment is considered to be a critical 
factor in this development since it can both influence the tumor cell 
phenotype, and thus the appropriateness of a given molecular target, 
and act a s a barrier for the delivery of effective treatment (Brown and 
Giaccia 1998). 
The sheer size and complexity of the human genome present 
formidable challenges to proliferating cells engaged in the constant 
manipulation of the DNA double helix. Essential cellular functions 
such as DNA replication, transcription, and cell division require the 
frequent packaging and unpackaging of the DNA genome on a regular 
basis. As key facilitators of such cellular transactions, the DNA 
topoisomerase family of enzymes have the unique ability to relax and 
untangle large s trands of intertwined DNA, thereby maintaining order 
within the cell and preserving the structural integrity of the genetic 
code. The topoisomerases literally prevent the cell from becoming 
embroiled in a tangled mess. The fundamental importance of the DNA 
topoisomerases is highlighted by their stringent conservation across 
prokaryotic and eukaryotic species and by their absolute necessity for 
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cell proliferation. Because of these functions, the DNA topoisomerases 
offer formidable target for treatment of various forms of cancer. 
Infact, DNA topoisomerases modulate the topology of DNA by 
modifying the tertiary structure of the double helix without altering 
the primary nucleotide sequence (Wang et al. 2002, Champoux et al. 
2001, Takimoto et al. 2001). They are responsible for relaxing the 
torsional stress that accumulates when the DNA double helix unwinds 
to allow DNA or RNA polymerases access to the genetic code. In the 
absence of topoisomerases, the accumulation of torsionally strained 
supercoiled DNA would ultimately interfere with vital cellular 
functions. During cell division, DNA topoisomerases also function to 
untangle and physically separate the replicated DNA by facilitating the 
passage of an intact DNA strand through a double-strand nick in the 
DNA helix. Thus, two linked circular DNA molecules can be physically 
separated (decatenated) by the action of specific DNA topoisomerases. 
All DNA topoisomerases act by forming temporary single- or double-
strand breaks in the double helix in which the enzyme is covalently 
bound via a tyrosine residue to one of the nicked ends of the 
phosphodiester DNA backbone. This normally transient intermediate, 
called the cleavable complex, allows for the passage of an intact single 
or double strand of DNA through this break, resulting in the 
unwinding or untangling of the DNA molecule. Subsequent relegation 
and release of the enzyme restore the integrity of the DNA double 
helix. All subsequently characterized DNA topoisomerases can be 
categorized into two broad families, types I and II, based on structure 
and function (Wang et al. 2002). Type I DNA topoisomerases generate 
transient single-strand breaks in DNA and type II DNA topoisomerases 
generate transient double-strand breaks in DNA. In higher eukaryotes 
and humans , three groups of topoisomerases have been identified. 
One group includes topoisomerase I and the mitochondrial DNA 
topoisomerase, which are both type IB enzymes. The second group 
includes human DNA topoisomerases Hoc and lip, which are type II 
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enzymes, and the final group consists of human topoisomerases HID 
and Hip, which are both type IA enzymes. The h u m a n enzymes with 
the greatest relevance for cancer chemotherapy are DNA 
topoisomerase I and DNA topoisomerases Ila and lip (Champoux 
2001). The majority of topoisomerase interactive agents cause the 
accumulation of DNA cleavable complexes composed of protein-linked 
DNA strand breaks. The persistence of these lesions in the presence of 
ongoing DNA replication or RNA transcription leads to cytotoxic DNA 
damage, ultimately causing cell-cycle arrest and death by apoptosis or 
cell necrosis. 
2.1 .1 . Etoposide 
The indigenous peoples of North America have a long history of 
using extracts of the mandrake (mayapple) plant, Podophyllum 
peltatum, for medicinal purposes as a cathartic, emetic, and 
anthelmintic (Pommier et al. 2001). However, formal pharmaceutical 
use of the podophyllotoxins in the United States did not begin until 
1820, and clinical studies in oncology were not initiated until 1946 
(Hande et al. 1998). Initially, severe systemic toxicities limited the use 
of podophyllotoxins to the topical treatment of condylomata 
acuminata. Subsequent efforts in the 1960s to develop less toxic 
podophyllotoxins led to the synthesis of its glycoside derivatives 
etoposide (VP-16-213) and teniposide (VP-26; Kellner et al. 2003). 
Clinical testing of these newer epipodophyllotoxins in the 1970s 
demonstrated predictable toxicity profiles and meaningful antitumor 
activity in diseases such as acute myelocytic leukemia, non-Hodgkin's 
lymphomas, and breast, ovarian, gastric, and lung cancers. In 1983, 
etoposide (VePesid) was approved for the treatment of testicular and 
small cell lung cancer, and in 1993, teniposide was approved for 
treating pediatric leukemias and lymphomas. Currently, etoposide is 
commonly used in cancer chemotherapy and is active against multiple 
cell lines such as L929 fibroblasts, HL-60, K562, A549 human lung 
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carcinoma cells (Spurgers et al. 2006, Natalie et al. 2002, Huang et al. 
1997). It is a part of the first-line therapy for small-cell lung 
carcinoma (Smit et al. 1989), malignant lymphoma (Dollery 1999), 
drug-resistant testicular cancer (Williams et al. 1987) etc. 
OCH$ 
Figure 2.1: Chemical structure ofetoposide 
Etoposide (ETP), like other podophyllins, can alter microtubule 
assembly, it does so only at concentrations several fold greater than 
those achieved in vivo. Upon incubation with cells, etoposide caused 
breaks in single-strand and double strand DNA in dose dependent 
manner (Loike et al. 1976). Upon its removal DNA breakage gets 
quickly repaired. Incubation of etoposide with purified DNA does not 
produce DNA strand breaks. However, when etoposide acts well 
isolated nuclei, leading to breaks in DNA (Wozniak et al. 1983). This 
clearly suggests that factors present in the nuclei, in addition to DNA, 
are required to obtain DNA strand breakage. The relationship between 
topoisomerase II inhibition and etoposide's anti tumour activity was, 
in part, delayed as information about this important enzyme was 
being elucidated for quite some time. It was not until 1979 that the 
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presence of enzyme 'DNA topoisomerases' was reported (Liu et al. 
1994). Extensive biochemical analysis of this group of enzymes was 
being undertaken, at the same time ETP was also being brought to 
the clinic. In 1984, several laboratories demonstrated that 
mammalian topoisomerase II was the target for etoposide action. 
Topoisomerase II enzymes are multisubunit proteins, require ATP for 
overall catalytic activity and modulate DNA topology by passing an 
intact helix through a transient double-stranded break created in the 
DNA backbone (Liu et al. 1994, Froelich-Ammon et al. 1995). As a 
result of their double-stranded DNA passage reaction, type II 
topoisomerases are able to regulate over- and under-winding of the 
double helix and resolve nucleic acid knots and tangles. ETP and 
other topoisomerase II inhibitors do not kill cells by blocking 
topoisomerase catalytic function. Rather they poison these enzymes 
by increasing the steady-state concentration of their covalent DNA 
cleavage complexes. This action converts topoisomerases into 
physiological toxins that introduce high levels of transient protein-
associated breaks in the genome of treated cells. The potential 
lethality of these drug-induced cleavage complexes rises dramatically 
when replication machinery or helicases attempt to traverse the 
covalently bound topoisomerase roadblock in the DNA. This disrupts 
the cleavage complex and converts transient single- or double-strand 
breaks into permanent double-stranded fractures, which are no 
longer held together by proteinaceous bridges. These breaks become 
targets for recombination, sister chromatid exchange, the generation 
of large insertions and deletions and the production of chromosomal 
aberrations and translocation. When these permanent DNA breaks 
are present at sufficient concentration, they trigger a series of events 
that ultimately culminates in cell death by apoptosis. 
Ironically, ETP causes dose limiting haematological (Sinkule et 
al. 1984) as well as gastro-intestinal toxicity when administered orally 
(Postmus et aZ.1984). Further, the lipophilic nature of ETP poses 
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difficulty in its use as anti-cancer agent; as a consequence different 
solubilizers are generally used as co-additives to develop suitable ETP 
formulations (Hande et al. 1992). These additives are often associated 
with adverse effects such as hypotension, anaphylaxis, 
bronchospasm, etc. (O'Dwyer et al. 1984 and Sinkule et al. 1984). 
Keeping into consideration toxicity constraints associated with 
most of the available chemotherapeutic agents including ETP, many 
workers have successfully tried to use liposome based delivery 
systems to circumvent these problems (Marina et al. 2002, Batist et 
al. 2001, Chidiac et al. 2000, Gabizon et al. 1997, Gabizon et al. 
1992, Vaage et al. 1992). The higher lipophilicity of etoposide in fact 
may help in its better intercalation in lipid-based liposomal 
formulations (Tyagi et al. 1999, Sengupta 1998). Liposomes 
accumulate in the tumors in a gradual passive fashion due to 
increased 'leakiness' of the tumour vasculature (Yuan et al. 1994). In 
this regard, antineoplastic agents encapsulated in long circulating 
pegylated liposomes are of special significance as they attain higher 
concentrations in tumor interstitium ultimately eliminating tumors 
with great efficiency (Papahadjopoulos et al. 1991). Similarly the 
encapsulation of certain anticancer agents into cationic liposomes 
was also found to enhance their antitumour potential. However, cost 
factor, cumbersome methods of their preparation and more 
importantly intrinsic toxic manifestations of cationic lipids do not 
argue in favor of their usage as suitable drug vehicle. 
It is indisputable that some degree of immune response against 
cancer exists in animals and humans. Components of the immune 
system that are capable of recognizing cancer cells have been 
identified in patients with certain cancers. In the laboratory, cells of 
the immune system can kill tumor cells. Even more convincing are 
clinical results showing that stimulation of the immune system with 
bacterial products or components of the immune system itself can 
82 
Chapter 2 Tuftsin in the treatment offibrosarcoma 
lead to tumor regression in some patients. The link between cancer 
and the immune system is also suggested by the fact that people with 
an impaired immune system, such as AIDS patients, are more likely 
to develop certain cancers, including Kaposi's sarcoma, rectal cancer 
and some specific types of lymphomas (Kiessling et al. 1999). 
2.1 .2 . Macrophage infiltration and molecular mechanisms for 
recognition of tumor cells 
As first line of defense against cancer, the macrophages must 
first infiltrate the lesions. The presence of inflammatory macrophages 
in growing tumors is maintained through recruitment of circulating 
monocytes and in certain tumors, the proliferation of mononuclear 
phagocytes, and ultimately their transformation into macrophages 
play important role in tumor regression (Mantovani 1990, Bugelski et 
al. 1987a,b). In regressing murine sarcomas, tumor-associated 
macrophages (TAMs) are found throughout the tumors, whereas in 
progressing sarcomas, TAMs are confined to the periphery of the 
tumor (Russell and Gillespie 1977). The presence of noncytotoxic 
(nonactivated) macrophages in neoplasms could actually enhance 
tumor growth (Mantovani et al. 1992). Macrophages (and lymphocytes) 
produce many diffusible growth, angiogenic, and cytotoxic factors, 
some of which would be favored tumor growth while others will 
regress tumors (Nathan, 1987). According to the type and level of such 
mediators, TAMs, therefore, may enhance or inhibit the growth of 
neoplasms (Prehn, 1972). 
Activated macrophages can destroy syngeneic, allogeneic, and 
xenogeneic tumor cells, but leave normal nontumorigenic cells 
unharmed, suggesting that histocompatibility and tumor-specific 
antigens are not involved in this recognition (Fidler and Schroit 1988). 
In addition, differences in metastatic potential, chromosome number, 
resistance to chemotherapeutic agents, or the antigenic properties of 
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tumor cells did not appear to be important factors for macrophage 
recognition of tumors cells (Killion et al. 1993, Pak and Fidler 1989). 
The ubiquitous role of macrophages in homeostasis suggests 
that macrophages recognize numerous molecules via a wide variety of 
plasma membrane receptors that interact with extracellular proteins, 
as well as with adhesion molecules such as the integrins (Gordon et 
al. 1988). Although carbohydrates and proteins have long been known 
to play an important role in cell-cell interactions and antigenic 
structures on cell surfaces, an increasing body of evidence suggests 
that phospholipids are also involved in macrophage recognition of 
target cells (Fidler and Schroit, 1988). All cell membranes are 
composed of a phospholipid bilayer containing four major 
phospholipids, the choline phospholipids phosphatidylcholine (PC) 
and sphingomyelin and the aminophospholipids 
phosphatidylethanolamine (PE) and phosphatidylserine (PS). In 
addition, the distribution 
of phospholipids in the bilayer membrane is extremely asymmetric 
(Gordesky and Marinetti 1973, Zwaal and Hemker 1982). In this 
regard, PC and sphingomyelin are preferentially positioned in the 
outer leaflet of the lipid bilayer, whereas PE is preferentially 
distributed in the inner leaflet. PS displays absolute asymmetry in its 
distribution; normal cells contain PS only in the inner leaflet of the 
cell membrane. Experiments based on several lines of evidence now 
suggest that when PS is expressed on the outer leaflet, it serves as a 
recognition molecule for macrophages and is also correlated with their 
increased binding to tumor cells (Schroit et al. 1985, Ratner et al. 
1986). The mechanism for this recognition is nonimmunologic and 
requires cell-to-cell contact. Because activated macrophages can 
destroy phenotypically diverse tumor cells, including cells resistant to 
killing by other host-defense mechanisms and by anticancer drugs, 
macrophage-directed therapy represents a potential strategy for 
elimination of biologically heterogeneous metastatic cells. 
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2.1 .3 . Activation of macrophages to the tumoricidal state 
The activation of macrophages can transform them from 
noncytotoxic stage to acquire tumoricidal properties (Hibbs 1974 a & 
b, Allison 1974). There are two major pathways to produce 
macrophage activation in vivo. Macrophages can become activated 
subsequent to interaction with microorganisms or their products such 
as endotoxins and bacterial cell-wall components. Although this 
interaction is very common, intentional at tempts to activate 
macrophages systemically by administering microorganisms or their 
products were limited by side effects such as allergic reactions and 
granuloma formations (Allison 1974). For this reason, the field did not 
progress until the discovery of muramyl dipeptide (MDP), a defined 
component of the bacterial cell wall (Lederer 1980). MDP is a water 
soluble, low molecular weight synthetic moiety of iV-acetyl-muramyl-L-
alanyl-D-isoglutamine; it has potent effects on a variety of host-
defense cells, including macrophages (Fogler and Fidler 1986). A 
synthetic, lipophilic MDP derivative, JV-acetylmuramyl- L-alanyl-D-
isoglutamyl-L-alanyl-2-(19,29-dipalmitoyl)-sn-glycero-39-phosphoryl-
ethylamide (MTP-PE), was also synthesized (Gisler et al. 1979). 
Although muramyl peptides influence several macrophage functions in 
vitro, comparable effects have not been observed in vivo because they 
are rapidly cleared after parenteral administration (Fogler and Fidler 
1985). Even when injected at very high doses, muramyl peptides fail 
to induce significant macrophage-mediated antitumor activity (Fidler 
1988). 
Macrophages can also be activated by their interaction with 
lymphokines. Mitogen- and antigen-stimulated T-cells release 
diffusible mediators that interact with specific receptors on target 
cells. A family of lymphokines, referred to as macrophage-activation 
factors (MAF) (Fidler and Schroit 1984), can render macrophages 
tumoricidal activity. For example, IFN-y (member of IFN family) prime 
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macrophages for their tumoricidal activity. Besides, IFN-a and IFN-(3, 
can also prime macrophages in a synergistic fashion to that of IFN-y 
(Saiki et al. 1986a, Pace 1988). It has been reported that IFN-y-
mediated priming of macrophages renders them sensitive to 
tumoricidal activation by tumor necrosis factor (TNF) and interleukin 
(IL)-l, suggesting that interactions of lymphocyte and macrophage 
products (IFNs and ILs) with macrophage receptors can lead to both 
transitory and sustained tumoricidal activity (Hori et al. 1989). 
Studies indicated that the priming stimulus delivered to macrophages 
by IFN-y (or complete activation by MAF) involves the binding and 
subsequent internalization of cell-surface receptors (Poste et al. 
1979a), a process that requires a sustained presence of ligand. The 
tumouricidal properties of lymphokine-activated macrophages are 
shortlived, and the cells become refractory to reactivation by free 
lymphokines (Poste et al. 1979b). Recently it has been demonstrated 
that mitogen-activated protein kinases are necessary for activation of 
macrophages (Dong et al. 1993), but diverse gene expression and 
release of cytokines by activated macrophages depend upon the 
immunomodulator, suggesting that intracellular pathways may be 
distinct for different activation signals. For example, human 
monocytes activated with either lipopolysaccharide or a synthetic 
lipopeptide [Ciba-Geigy Protein 31362 (CGP 31362)] secreted IL-1, 
TNF, and prostaglandin E2, whereas monocytes activated with MTP-
PE secreted TNF without the additional presence of IFN-y (Fidler et al. 
1990). These studies indicate that not all macrophages share identical 
phenotypes. 
2.1.4. Activation of macrophages by liposomised 
immunomodulators 
Considerable attention has been focused on the use of synthetic 
phospholipid vesicles, liposomes, to target various drugs to different 
organ sites in vivo (Fidler 1988, Schroit et. al. 1983). Most attempts to 
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target liposomes to solid neoplasms have failed because these 
phospholipid vesicles are unable to extravasate from the circulation 
and are rapidly taken up by circulating and fixed phagocytic cells. 
This natural fate of liposomes can be utilized to target encapsulated 
immunomodulators to cells of the RES, which activate phagocytic cells 
for their tumoricidal properties (Schroit and Fidler 1982). Preferential 
delivery of the liposome-encapsulated substances can be achieved in 
vivo because mainly phagocytic cells are exposed to the liposome-
entrapped agents. This natural localization pattern also allows 
efficient targeting of liposomes and their contents to various 
macrophage compartments in the body. Through the systematic 
evaluation of multilamellar vesicles (MLV) with different phospholipid 
compositions, certain classes of phospholipids have been 
preferentially recognized by macrophages. The inclusion of negatively 
charged phospholipids, such as phosphatidyl serine (PS) or 
phosphatidylglycerol (PG), in phosphatidyl choline (PC) based MLVs 
enhances their uptake by macrophages (Schroit and Fidler 1982). 
Indeed, liposomes composed of PC:PS result in significant 
accumulation by various cells of the RES (Kleinerman et al. 1983, Xu 
and Fidler 1984). Since the lung is a major site of disseminated 
metastatic form of disease, it is possible to identify liposomes with 
increased efficacy for localization to the lung parenchyma using 
intravenous injection of radiolabeled liposomes. Large MLV (>0.1 mm) 
were retained in the lungs more efficiently than small unilamellar 
liposomes of identical lipid composition. In addition, liposomes of the 
same structural class were more efficiently retained in the lungs when 
they contained negatively charged lipids (PS) as compared to neutral 
charge PC containing liposomes (Schroit et al. 1983). 
The intravenous injection of PC:PS MLV containing MDP or 
MTP-PE immunomodulators results in the in situ activation of alveolar 
macrophages (AM). In order to assess whether AM activated by 
liposomised MDP maintained their tumoricidal properties over an 
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extended period of time, the AM were harvested and assayed for 
tumoricidal activity on days 1, 2, 3, or 4 post infusion of a single dose 
of MLV containing MDP, MTP-PE, or a combination of both of these 
agents. 
On day 1, AM harvested from all of the mice that received MLV 
with hydrophilic MDP exhibited less than 20% cytotoxicity against the 
murine tumor target cells. At every other time point, AM harvested 
from mice that received MLV containing MTP-PE consistently 
exhibited significantly higher levels of tumoricidal activity (up to 55% 
cytolysis of target cells) (Fogler and Fidler 1984). 
2.1.5. Tuftsin 
In 1970, Najjar and Nishioka demonstrated that Leukokinnin, a 
leukophilic fraction of Immunoglobulin IgG, splits under the action of 
specific enzyme (Leukokininase) located in the outer membrane of 
neutrophils. The biological activity of leukokinin rests in a peptide 
tuftsin- so called because it was discovered at Tufts University (Najjar 
et al. 1970). Tuftsin is a 289-292 (Thr-Lys-Pro-Arg) sequence in the 
CH2 domain of the Fc fraction of the IgG molecule. 
The tetra-peptide is released physiologically as a free fragment 
after enzymatic cleavage (Najjar et al. 1987). Two enzymes are 
responsible for the production of tuftsin from leukokinin, tuftsin 
endocarboxypeptidase, a specific enzyme that cleaves the heavy chain 
at the Arg-Glu bond between residues 292-293, and the membrane 
enzyme leucikinase acts on the bound leucokinin-S to cleave it at the 
amino end of threonine between residues 288 and 289. Tuftsin is 
known to bind specifically to macrophages, monocytes and PMN 
leukocytes and possess a broad spectrum of activities primarily 
related to the function of immune system (Najjar et al. 1987, Fridkin 
et al. 1989). These include potentiation of various cell functions, such 
as phagocytosis, pinocytosis, motility, immunogenic response, 
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fungicidal, bactericidal and tumoricidal activity (Fridkin et al. 1989). 
The features of tuftsin coupled with its low toxicity make the tetra-
peptide a promising candidate for immunotherapy (Nishioka et al. 
1986; Khare et al. 1997). Tuftsin capacity to augment cellular 
activation is mediated by specific receptors that have been identified, 
characterized and isolated from rabbit granulocytes (Bump et al. 
1986). Tuftsin and many of its analogs have been chemically 
synthesized and studied extensively for structure- function 
relationship (Nishioka et al. 1995, Gershonov et al. 1996). 
The grafting of tuftsin on the liposomal surface would, therefore, 
enable it not only in homing the liposomised-drugs to the cell 
population possessing receptors to recognize it but also stimulate key 
cells of the immune system non-specifically against various infections 
(Singhal et al. 1984). Structure-function studies of tuftsin indicate 
that its binding and consequent MPS activation is dependent upon 
rather strict conservation of its molecular structure. Thus the 
modification of the peptide at its N-terminus or within the chain leads 
to a significant reduction or even loss of biological activity and also 
reduction in its ability to bind to PMN leukocytes (Fridkin et al. 1981). 
As tuftsin is a hydrophilic molecule, it would preferentially reside in 
the aqueous compartment of liposomes and would not have 
accessibility to its putative receptors present on the surface of various 
immune cells. Therefore, the tuftsin was specifically modified to 
facilitate its grafting on liposomal surface by attaching a long 
hydrocarbon fatty acyl residue to the C-terminus through an ethylene-
diamine spacer arm (Thr-Lys-Pro-Arg-NH-(CH2)2-NH-CO-Ci5H3i) 
(Singhal et al. 1984). 
The incorporation of tuftsin at a percentage of >10 mol% tuftsin 
in the egg PC /cholesterol (7:3; mol/mol) liposomes was not possible as 
the resulting mixture could not be dispersed even by the long 
sonication (Singhal et al. 1984). On the other hand, the liposome 
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containing lower mol% of tuftsin was founded to poorly bound to PMN 
leukocytes. It was observed that 7-8 mol% tuftsin in the liposomes 
elicits optimal immunomodulatory effect. The leakage rate of 6-
carboxy fluoroscen (CF) a fluorescent probe from egg 
PC/Cholesterol/tuftsin liposomes in buffer, pH 7.4 at 37 °C was about 
2-4%/hour. This was probably due to binding of the dye with 
positively charged Arg residue in the analogue. Since this amino acid 
residue should be aligned jus t at the bilayer interface, the effect of its 
binding with the 6-CF on the liposomes permeability mus t have been 
mediated through perturbation of the egg PC head group packing in 
liposomes bilayer (Hauser et al. 1981). The binding/uptake of the egg 
PC/Choi/tuftsin liposomes to PMN leukocytes was saturable, time 
dependent and the cell bound liposomes are apparently taken up by 
the cells by receptor-mediated endocytosis without losing their 
structural integrity. This was further supported by the fact that 
endocytosis was inhibited by lowering the incubation temperature to 
0° C (Singhal et al. 1984). The specificity of these liposomes was also 
examined with other blood cells i.e. erythrocytes, lymphocytes and 
found that no binding with erythrocytes was observed but there 
appeared some binding with lymphocytes which was thought to be 
presumably due to the presence of PMN leucocytes/monocytes as 
contamination in the lymphocyte preparation (Singhal et al. 1984). 
It has been demonstrated that tuftsin could enhance non-
specific defense against infections by activating the macrophages 
(Singh et al. 1992). The biological activity of the peptide was due to the 
induction of the macrophage respiratory burs t and activated 
macrophages exhibited enhanced levels of NADPH oxidase, O2, H2O2 
and myeloperoxidase (MPO). Both O2 and H2O2 damage proteins, 
nucleic acids and membranes sufficiently to kill the cell or even the 
whole organism. Nevertheless, for macrophages hypohalous acid 
produced by action of MPO on H2O2, has been identified as the major 
killer agent (Klebanoff et al. 1980). 
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2.1 .5 .1 . Immunopotentiating effect 
The primary effect of tuftsin, after binding to receptors, consists 
of stimulation of macrophages and polymorphonuclear (PMN) cells. 
Specific binding sites of tuftsin are also localized on human 
monocytes. Tuftsin administered to the cell cultures stimulates the 
production of some cytokines. Intraperitoneal (i.p.) injection of tuftsin 
increases the production of TNF-ct in serum and supernatants of 
cultured splenic and peritoneal cells (Wleklik et al. 1987). Robey et al 
showed that tuftsin as well as its analogs, [Gly^-tuftsin, [Leu4]-tuftsin, 
and [Gln4]-tuftsin (all being fragments of human C-reactive protein), 
induce monocytes to produce IL-1 (Robey et al. 1987). Recently, it was 
also found that treatment of mouse peritoneal macrophages with 
tuftsin or tuftsin-THF-y2 chimeras in the presence of antigen 
augments the IL-6 production (Granoth et al. 1997). In this way, 
tuftsin may perform its immunoregulatory functions and may 
influence inflammatory processes by enhancing the IL-2 formation 
induced by IL-1. It was initially found that tuftsin stimulates 
phagocytosis after binding to PMNs. Subsequently phagocytosis 
stimulating activity of tuftsin in monocyte-macrophages was also 
demonstrated by some workers (Coleman, 1986). 
2.1.5 .2 . Anti-tumor activity 
Many workers have reported the anti-tumor activity of tuftsin 
against experimental tumor models (Nishioka et al. 1981; Nishioka et 
al. 1983). Florentin et al stated that tuftsin is able to potentiate 
various types of immune response when injected into mice, and can 
be used as a potent activator of macrophages in cancer therapy 
(Florentin et al. 1978). This was also confirmed by the finding that 
tuftsin treated mouse peritoneal macrophages exert cytostatic activity 
for tumor cell proliferation (Bruley-Rosset et al. 1981). Tuftsin was 
also reported to enhance the cytotoxic response of h u m a n monocytes 
against K562 tumor cell line at the doses of 5 x 1 0 2 to 5 x lCHjig/ml. 
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The natural killing activity of lymphocytes against that particular cell 
line was not affected by tuftsin (Caroll et al. 1982). Tuftsin was also 
used for the treatment of cancer in h u m a n s with corresponding 
experiments in animals (Catane et al. 1983). Tuftsin at the doses 
ranging between 50 and 500|ag/kg of the body weight enhances the 
cytotoxic activity of mononuclear cells in mice and human. The effect 
of tuftsin was accompanied by leucocytosis induction (Catane et al. 
1983). It was also stated that tuftsin significantly increases survival 
rates among Rauscher virus leukemia infected mice and demonstrates 
antitumor activity against murine melanoma in vivo (Knyszynski et al. 
1983; Noyes et al. 1981). 
Earlier attempts have demonstrated usage of liposomised ETP in 
delaying tumour progression, but such treatment failed to regress 
tumor in model animals (Sengupta et al. 1998, Sengupta et al. 2000). 
In the present study, we have evaluated tuftsin-mediated 
augmentation of antitumorogenic potential of ETP against 
fibrosarcoma induced in Swiss albino mice by the carcinogen benzo (a) 
pyrene. Development of tumor was ascertained by measurement of 
tumor volume and confirmed by histopathological examination of the 
tissues. The tumor-bearing animals were treated with free form as well 
as liposomal formulation of ETP with or without tuftsin. The efficacy of 
various formulations was ascertained on the basis of regression of 
tumor volume and survival study. The present study also tries to 
unravel the molecular mechanism involved in the regression of tumor 
by the tuftsin-associated liposomal formulation of etoposide against 
fibrosarcoma. The tumor suppressor p53 is a predominantly nuclear 
transcription factor activated by various stresses including exposure 
to chemotherapeutic (Jimenez et al. 1999) as well as chemopreventive 
agents (Huang et al. 1999; Hsieh et al. 1999). Activation of p53 entails 
cell cycle arrest or apoptosis, both detrimental to the uncontrolled 
growth of tumors; as a result tumor cells are frequently selected for 
defects in the p53 pathway. When cells do respond adequately to p53-
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activating signals, the actual biological outcome may vary greatly. A 
question that has received great attention, in part owing to its 
paramount relevance to the successful application of cancer 
chemotherapy, is how p53 opts between induction of apoptosis versus 
induction of a viable growth arrest. As it appears now, much of the 
choice is not in the hands of p53; rather, it is the cellular context, as 
defined by the balance of intracellular and extracellular signaling 
events, which dictates whether p53 activation will spare the cell or 
lead to its apoptotic demise. This is of particular relevance to cancer 
cells, which often acquire genetic alterations affecting directly or 
indirectly the functional status of p53. The simplest and most 
common event is direct mutational activation of the p53 gene itself, 
which will eliminate all wild-type p53 (p53wt) from the affected cells. 
Any genetic alterations that impact on the competence of these and 
many other proteins associated with apoptosis, cell cycle control and 
DNA damage repair are expected to be capable of modulating the 
likelihood that p53 will be activated in response to particular types of 
stress, as well as the biological outcome of such activation. The 
molecular basis for the differential activation of particular sets of 
target genes by p53 is not fully understood. Most certainly multiple 
molecular mechanisms contribute to p53 target gene selectivity. There 
are ample evidences advocating that covalent modifications on p53 
may play a critical role in its target gene preference. The consequences 
of p53 activation are mostly mediated through the enhanced 
expression of cell cycle regulating proteins such as the p21 Wafl /Cipl 
(CDKN1A) inhibitor of cyclin-dependent kinases (CDKs) and through a 
number of pro-apopotic proteins, among them Bax (Miyashita and 
Reed, 1995), Noxa (APR) (Oda et al. 2000a) and p53AIPl (Oda et al. 
2000b) acting at the mitochondrial membrane, the cell surface death 
receptors Fas/APO-1 (Owen-Schaub et al. 1995) and KILLER/DR5 
(Wu et al. 1997), the IGF-BP3 inhibitor of the IGF-R1 survival receptor 
(Buckbinder et al. 1995), the death domain-containing PIDD protein 
(Lin et al. 2000), endothelial cell nitric oxide synthase (Mortensen et 
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al. 1999), the p85 regulator of the phosphatidyl-3-OH kinase involved 
in oxygen damage-response (Yin et al. 1998), enzymes that can 
produce reactive oxygen species (Polyak et al. 1997), and the plasma 
membrane protein PERP (Attardi et al. 2000). Furthermore, p53 itself 
can be associated with mitochondria in apoptotic cells (Marchenko et 
al. 2000). 
To evaluate the efficacy of various liposomal formulations the in 
vivo study was divided into two phases, short term and long term. In 
short-term study, animals were exposed to with benzo (a) pyrene and 
subsequently treated with single dose various formulations. To study 
the mechanism operative for observed involved in the efficacy of 
various formulations expression of p53wt, p53mut, p21/wafl was 
ascertained at mRNA level by RT-PCR. In long-term study the tumor-
bearing animals were treated with free drug and with liposomal 
formulations of etoposide with or without immunomodulator tuftsin. 
Drug formulations were administered at lOmg/kg b.w/day by 
intravenous route for five consecutive days. The efficacy of various 
formulations was assessed on the basis of tumor size, expression of 
p53wt, p53mut and p21/Wafl, Caspase-9, Bel and Bax at protein and 
mRNA level by performing western blot analysis and RT-PCR 
respectively. 
2.2. Materials and Methods 
2 .2 .1 . Chemicals 
All the reagents used in the study were of the highest purity 
available. Egg PC was isolated and purified from hen egg yolk 
following the published procedure (Owais et al. 1993). Cholesterol was 
bought from Centron Research Laboratory, Mumbai, India and used 
after crystallizing three times with methanol. [Tuftsin was modified at 
C-Terminus by attaching a sufficiently long hydrocarbon fatty acyl 
residue to the C-terminus through an ethylenediamine spacer arm 
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(Thr-Lys-Pro-Arg-NH-(CH2)2-NH-CO-Ci5H3i), which permits almost 
quantitative incorporation into liposomes, following the procedure 
standardized in our lab (Gupta et al. 1986)]. Anti-p53 antibody 
specific for wild-type (wt) protein (clone PAb 1620, Ab-5), Anti-p53mut 
(clone PAb 240), Anti p21/Wafl , Anti Bcl-2, Anti caspase-3, Anti Bax 
and Anti -actin were purchased from Merck India Ltd. The 
horseradish peroxidase-conjugated isotypes were obtained from 
Bangalore Genei (Bangalore, India). 
2.2 .2 . Isolation and purification of egg phosphatidylcholine 
Egg PC was isolated and purified following the published 
procedure (Singleton et al. 1965). Briefly, egg yolks of one dozen eggs 
were separated carefully, and washed with acetone (100 ml) in a mixer 
5-6 times to get rid off the colored impurities. The resulting white solid 
was powdered and dried in vacuum for 2 hr to remove traces of the 
solvent. The extraction was performed by stirring the solid mass with 
one liter of absolute alcohol for 2-3 hours. After filtration, the residue 
was re-extracted with another 500 ml of ethanol. The filtrates were 
mixed and evaporated off at 40-45 °C. The sticky mass t hus obtained 
was dried under high vacuum to remove traces of the solvent, 
dissolved in minimum amount of petroleum ether (b.p.60-80 °C) and 
poured onto chilled acetone to obtain a white sticky precipitate. The 
solvent from the precipitated material was removed by decantation. 
The sticky solid precipitate was redissolved in petroleum ether and 
again poured onto the chilled acetone. The process was repeated 2-3 
times to obtain crude PC. For further purification, it was 
chromatographed on a neutral alumina (grade III) column. The elution 
was performed using increasing amount of methanol in chloroform. 
Fractions obtained with 5-7 % methanol in chloroform corresponded 
to pure PC. It was further purified by chromatography over Sephadex 
LH-20 column (2.5x 100 cm), using chloroform/methanol (1:1 v/v) as 
the eluant. The elution rate was maintained at 60-70 ml per hour. 
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Fractions were collected and checked for the presence of pure PC. The 
purity was ascertained by thin layer chromatography using silica gel 
G-60 TLC plates. The plates were developed using 
chloroform/methanol/water (65:25:4) as the solvent system, and 
stained with iodine vapour followed by molybdenum-blue spray to 
visualize various phospholipid spots. 
2.2.3 . Liposome preparation 
Etoposide bearing unilamellar liposomes were prepared from egg 
PC (49 |amol) and cholesterol (21 jamol) with or without tuftsin (6.66 
mol % of PC) following the published procedure (Owais et al. 1993). 
Briefly, the solution of egg PC and ETP (in ratio of 40:1 w/w) along 
with cholesterol and tuftsin in chloroform was reduced to a thin dry 
film with slow jet of N2 gas. The dried lipid film was hydrated with 
150-mM sterile normal saline, followed by sonication for 1 hour at 4 
°C under N2 atmosphere in bath type sonicator. The sonicated 
preparation was centrifuged at 10,000 g for 1 h at 4 °C to remove un-
dispersed lipid. Finally, liposomal preparation was extensively dialyzed 
against saline for 24 hour at 4 °C in the dark to remove free form of 
the drug from the liposomal preparations. Both tuftsin free as well as 
tuftsin bearing liposomal preparation was found out to be of 
unilamellar type with size range of 80 ± 10 nm as revealed by electron 
microscopy (data not shown). 
2.2.4 . Estimation of liposome intercalated ETP 
The intercalation efficiency of ETP in the liposomes was 
estimated by HPLC method (Khan et al. 2003). Briefly, specific 
volumes of standard drug solution were injected onto a Hypersil 
octyldecyl-silane (5 nm particle size) analytical column (150 X 4.6 
mm). Detection of ETP was accomplished with a UV-visible-light 
detector set at 254 nm. A standard curve of ETP was plotted by 
calibrating peak area versus amount of the drug injected into column. 
The elution buffer was consisting of an isocratic mixture of 0.005 M 
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EDTA and methanol (2: 8 v/v). The flow rate was kept 1.2 ml/min 
and retention time was found out to be 4.5 min. Finally a known 
volume of liposomal formulation was injected and amount present in 
the sample was determined by area under curve. The intercalation 
efficiency of ETP both in plain egg PC and tuftsin bearing liposomes 
was found out to be of the same order (90 ± 4 percent). 
2.2.4 Estimation of liposome intercalated tuftsin 
The tuftsin entrapped in the drug containing liposomes was 
estimated by BCA method as modified in our lab (Owais et al. 2000). 
Briefly, the liposomes (given volume) were lysed with Triton X-100 
solution and incubated with the mixture of solutions A and B of BCA 
reagent. The absorbance of the colored complex formed was measured 
at 600 nm and tuftsin content was determined using a standard curve 
of tuftsin plotted in the presence of Triton X-100. The incorporation of 
tuftsin was found out to be ~ 98% for both sham as well as ETP 
containing tuftsin bearing liposomes. 
2.2.5. In vitro drug release assay 
The release kinetics of etoposide from tuftsin bearing ETP 
liposomes into surrounding phosphate buffer saline (PBS pH 7.4) was 
determined by HPLC method following standardized protocol as 
described above (Khan et al. 2003). The vials containing Lip-ETP and 
Tuft-Lip-ETP were incubated with PBS at 37 °C under continuous 
shaking. An aliquot was withdrawn at two different time points (24h 
and 48h) and mixture was ultracentrifuged at 100,000gr for 15 min. 
Resulting supernatant was analyzed by HPLC method as described 
earlier. The percent in vitro release was calculated with respect to the 
total drug content in liposomes. 
2.2.6. ETP mediated lysis of human erythrocytes 
The human red blood cells (RBCs) were diluted with isotonic 
buffer to get 50 % hematocrit. Etoposide (free as well as liposomised 
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form) was added at the concentration of 10p.g/ml to erythrocyte 
suspension. The free form of the drug was dissolved in 50 \i\ of DMSO 
and final volume was made up to 1 ml with PBS (5 % DMSO). In order 
to study drug induced hemolysis, a suspension of RBCs was 
incubated with 1 ml of free as well as liposomised drug (10 ng/ml) at 
37 °C for 1 hour. The mixture was centrifuged at 1500 g and 
supernatant analyzed for the released hemoglobin by measuring the 
absorbance at 576 nm. 
The percent hemolysis was determined by following equation: 
Percent Hemolysis = 100 (Abs-Abso / Absioo- Abso), 
Where Abs = Absorbance of the sample 
Abso = Absorbance of -ve control (erythrocytes in 5 % DMSO) with no 
ETP 
Absioo = Absorbance of +ve control (erythrocytes in 1% Triton X-100) 
in presence of 10 jig/ml ETP. 
2.2.6. Animals 
Female Swiss albino mice weighing 18 + 2 g were used in the 
whole study. The animals were given a standard pellet diet (Hindustan 
Lever Ltd.) and water ad libitum. Animals were checked daily for their 
mortality and morbidity prior to commencement of the study and only 
healthy animals were included in the experiment. The techniques 
used for bleeding, injection as well as sacrifice of animals were strictly 
performed following mandates approved by the institute's Animal 
Ethics Committee (Committee for the purpose of control and 
supervision of Experiments on Animals, Govt, of India). 
2.2.7. Maximum tolerated dose 
The maximum tolerated dose (MTD) of the tuftsin bearing 
liposomal formulation of ETP (administered intravenously) was 
determined in healthy Swiss albino mice. Doses were escalated in 
increments starting with 0, 10, 20 40, 100, 200, 400 and 500 mg/kg 
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body weight daily for 5 days. After completing the preliminary 
experiments, the approximate MTD was defined using eight groups 
(consisting of 9 mice each). The drug induce toxic menifestations were 
determined by careful surveillance of weight changes and survival of 
the experimental animals. The highest non-lethal dose of ETP causing 
>10 % weight loss within 1 week of cessation from start of the dosing 
schedule was defined as the MTD. Out of total nine animals in each 
group, three mice received free drug, three were given Lip-ETP and the 
remaining three were administered with Tuft-Lip-ETP. 
2.2.8. Hematological toxicity tests 
Swiss albino mice were used to analyze the changes in 
haematological parameters following administration of Tuft-Lip-ETP, 
Lip-ETP and free form of ETP, with respect to time and dose. The mice 
were randomized into four groups. Group I served as controls and 
received vehicle treatment while Gp. II, Gp. Ill and Gp. IV mice were 
treated with free ETP, Lip-ETP and Tuft-Lip-ETP formulations 
respectively, at a dose of 10 mg/kg b.w/day for 5 days. Drugs were 
administered through the tail vein. On the day 7th post last treatment 
dose of analysis, the animals were sacrificed under anesthesia by 
cervical dislocation and blood withdrawn by cardiac puncture. Total 
and differential leukocyte and platelet counts were determined using a 
Sysmex cell counter. 
2.2.9. Short term studies 
To study the effect of various formulations of ETP on the 
expression of p53wt, p53mut and p21/wafl at mRNA level, animals 
were challenged with benzo (a) pyrene subcutaneously (lOmg/kg body 
weight) into the flanks of the left hind limb. Chemotherapy treatment 
(ETP formulations) was given intravenously on day seven post benzo 
(a) pyrene administration with various formulations. The drug and 
vehicle were slowly injected into the tail vein with a 26-gauge needle 
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and the total volume of administration never exceeded 100 \i\ per 
dose. The animals were divided into seven groups consisting of 12 
animals each as given below. 
Groups 
Group I 
Group II 
Group III 
Group IV 
Group V 
Group VI 
Group VII 
(lOmg/kg) 
Treatment 
Normal untreated 
BaP + PBS (Vehicle Control) 
BaP + Sham liposomes 
BaP + Sham tuftsin liposomes 
BaP + Free etoposide (lOmg/kg b.w) 
BaP + Liposomal etoposide (lOmg/kg b.w) 
BaP + Tuftsin bearing liposomal etoposide 
Four animals from each group were euthanized by cervical 
dislocation after 24, 48 and 72 h of treatment with various 
formulations, respectively. The tissues were excised out, cleaned, snap 
frozen in liquid nitrogen and stored at -80 °C until used for further 
experimentation. 
2.2 .10. Long term studies 
2 .2 .10 .1 . In vivo tumor model 
Solid fibrosarcoma was induced in mice according to published 
method with slight modification (Faiderbe et. al, 1992b). Briefly, single 
dose of benzo (a) pyrene 250ng/ animal was administered 
subcutaneously into the flanks of the left hind limbs. The mice were 
observed daily for any change along the dimensions of the two hind 
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limbs. Only those mice that developed palpable tumors between 90 
and 100 days of post-administration of benzo (a) pyrene were included 
in the study. 
2.2.10.2 . Treatment schedule and assessment parameters 
The tumor-bearing mice were pooled and randomized into seven 
groups as follows: Normal untreated mice were included in Gp. I. 
Groups Treatment 
Group I 
Group II 
Group III 
Group IV 
Group V 
Group VI 
Group VII 
Normal Untreated 
PBS (Vehicle Control) 
Sham liposomes (Vehicle Control) 
Tuftsin bearing liposome (No etoposide) 
Free drug (Etoposide) 
Liposomal etoposide 
Tuftsin bearing liposomal etoposide 
The tumors were measured regularly with a Vernier Caliper 
until they reached a volume of 200 mm3. At this juncture the mice 
were treated with 10-mg/kg b.w/day of etoposide for five consecutive 
days, the first day of treatment was considered as the day 0. The drug 
and vehicle were slowly injected into the tail vein with a 26-gauge 
needle, taking care that the total volume of administration never 
exceeded 100 |il per dose. The tumors were measured regularly after 
treatment. Anti-tumor activity was assessed by calculating the tumor 
volume according to the formula 
V= D X d2 X n /6 , where V = tumor volume, D = biggest dimension, and 
d = smallest dimension. 
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2.2 .10 .3 . Reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis 
Total RNA was isolated from the t issues with TRIzol reagent 
(Invitrogen). Tumor tissue samples were homogenized with TRIzol (1 
ml TRIzol per 100 mg of tissue) using a glass-teflon homogenizer and 
RNA was extracted and purified as per the manufacturer 's protocol. 
For RT-PCR reactions, 3 pg of total RNA was combined with 500 ng of 
oligo dT primer (Invitrogen) in a final volume of 12 pi, heated at 70°C 
for 10 min and then placed on ice. Reverse transcription reactions (20 
pi) were then assembled with final concentrations of IX reaction 
buffer, 10 mM DTT, 0.5 mM dNTP's and 100 U of Superscript II 
reverse transcriptase (Invitrogen). Two percent of the RT reaction was 
used as input for each PCR. PCR reactions (50pl) were assembled with 
final concentrations of IX buffer, 1.5 mM MgC12, 0.2 mM dNTPs, 0.2 
pM of each primer and 2.5 U Taq polymerase (Invitrogen). Primers 
were obtained from Sigma-Aldrich and PCR was performed with 
forward (F) and reverse (R) forward primers specific to mouse p53wt, 
p53mut, p21/waf l , caspase-3, bax, bcl2 genes and primers specific 
for glyceraldehydes-3-phosphate dehydrogenase (GAPDH); Table 2.1. 
GAPDH, a housekeeping gene, PCR reaction employing primers for 
GAPDH were used as control. The GenBank accession no. AF051368, 
AB021961, U09507, NM_009810 XM_991820, NM_007527, 
DQ080431, BC145810 for p53wt, p53mut, p21/waf l , caspase-3, bax, 
bcl-2 and GAPDH respectively. PCR cycle parameters were as follows: 
initial step of 95°C for 5 min and then 20-35 cycles of 95°C for 30s, 
annealing temperature of 59-61°C for 30 s, 72°C for 45s and a final 
step of 72°C for 5 min. Cycle number that allows for endpoint analysis 
during linear amplification was determined empirically. The size of the 
PCR amplicon was determined by comparison with 100-bp DNA 
ladder. PCR products of p53wt (723 bp), p53mut (768 bp), p21/wafl 
(595 bp), caspase-3 (668 bp), bax (589), bcl-2 (606 bp) and GAPDH 
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(382 bp) were resolved on a 1.5% agarose gels and observed in UV-
transilluminator. 
Table 2 .1: Forward and reverse primers specific to mouse p53wt, 
p53mut, p21 /waf l , caspase-3, bax, bc!2 and GAPDH. 
p53wt 
p53mut 
p21/wafl 
caspase-3 
bax 
bcl-2 
GAPDH 
F: 5'-TTACCAGGGCAACTATGGCTTCCA-3' 
R: 5'-TCCCGGAACATCTCGAAGCGTTTA-3' 
F: 5'- TTACCAGGGCAACTATGGCTTCCA-3' 
R: 5'-TCCTCTGTAGCATGGGCATCCTTT-3' 
F: 5'-TGGCTGAACTCAACACCCACCTTA-3' 
R: 5'- AGACCAATCTGCGCTTGGAGTGAT-3' 
F: 5'- AGAGCACTGGAATGTCATCTCGCT-3' 
R: 5'-TGAGCATGGACACAATACACGGGA-3' 
F: 5'-TGTCTCCGGCGAATTGGAGATGAA-3' 
R: 5'-ACTCCAGCCACAAAGATGGTCACT-3' 
F: 5'-AAAGCACCCAATCAGGCCAACAAG-3' 
R: 5'- TTTATTGAGCAGAGTCCTGGCGCT-3' 
F: 5'-TAAAGGGCATCCTGGGCTACACT-3' 
R: 5'-TTACTCCTTGGAGGCCATGTAGG-3' 
2.2.10.4. Preparation of cell lysate 
The skin/ tumor tissue (maintained on ice) was removed with 
sharp scalpel blades. The samples were homogenized in lysis buffer 
(containing 20% glycerol, 20 mmol/L HEPES, 10 mmol/L NaCl, 1.5 
mmol/L MgCb, 0 .1% NP40, 0.2 mmol/L EDTA, 1 mmol/L DTT, 1 
Mg/mL pepstatin A, 1 |ug/mL aprotinin, 100 Hg/mL 
phenylmethylsulfonyl fluoride) and processed according to the 
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published method (Serpi et al. 1999). The homogenate was kept for 15 
minutes in lysis buffer on ice and then centrifuged for 15 minutes 
20,000 g at 4 °C and the supernatant was collected. 
2.2.10.5. Western Blotting 
Western blotting was carried out in the cell lysate of skin/ tumor 
tissue following published procedure (Towbin et al. 1979). Protein 
content of each sample was estimated by the routine method using 
bovine serum albumin as a standard (Lowry et al. 1951). Proteins 
(30jig) were resolved on 10 % SDS-PAGE gels and electroblotted onto 
nitrocellulose membranes. The blots were blocked overnight with 3 % 
nonfat dry milk and probed with appropriate antibodies [i.e., anti-
p53wt (clone PAb 1620) and anti-p53mut (clone PAb 240) antibody, 
anti-Bax (clone 5B7/3A2), anti-Bcl-2 (10C4), Anti Caspase-3 (clone 
AM1.4.1-1B)] at dilutions recommended by the suppliers. 
Immunoblots were detected by horseradish peroxidase-conjugated 
anti-mouse IgG using chromogen 3,3'-diaminobenzidine 
tetrahydrochloride. To quantify equal loading, membranes were 
reprobed with p-actin antibody. Data are presented as the relative 
pixel density of each bands normalized to band of P-actin. The 
intensity of the bands was quantitated using Alpha Image Analysis 
software on Alpha Image Gel Documentation System. 
2.3. Results 
While developing a novel formulation of a given therapeutic 
agent, it is desirable to have idea about its in vitro stability profile. The 
in vitro drug release kinetic studies revealed that incubation of 
liposomised ETP in PBS resulted in slow release of the drug. There 
was 12 % and 23 % leakage after 24h and 48h respectively of ETP 
(active component) from tuftsin bearing ETP liposomes. On the other 
hand, there was 19 % and 38 % drug release after 24h and 48h 
respectively in case of Lip-ETP formulation (Fig. 2.2A). 
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The toxicity studies suggest that incorporation of ETP in 
liposomes markedly lowers its toxicity to erythrocytes. Among various 
formulations, free ETP was found to show maximum toxicity resulting 
in significant hemolysis of erythrocytes. The incorporation of ETP in 
conventional as well tuftsin bearing liposomes resulted in diminution 
of its toxic property to a surprisingly low level. Tuft-Lip-ETP 
formulation imparts less toxicity to erythrocytes (~7 % hemolysis) than 
that of conventional liposomal preparation (~12 % hemolysis) of same 
drug (Fig. 2.2B). 
Loss in body weight in response to the administration of 
antineoplastic agent ETP was used as another parameter to assess its 
toxicity. As shown in Fig. 2.3, the maximum tolerated dose (MTD) for 
free, liposomal as well as tuftsin bearing liposomal ETP was found out 
to be 165.53, 279.77 and 413.25 mg/kg, respectively (P value: Lip-
ETP vs free ETP p<0.001; and the animals treated with Tuft-Lip-ETP 
over free as well as liposomal ETP p<0.001). 
Haematological tests were performed to evaluate the effect of 
liposomised ETP on rapidly proliferating hematopoietic cells. The 
immune cell depletion was significantly greater in the group of 
animals treated with free ETP with a mean total leukocyte count of 
1764/mm 3 as compared to 4 ,457/mm 3 counts in the Lip-ETP treated 
group (p<0.001) on day 7 post last dose of ETP. Myelo-suppression 
was significantly lower in the group of animals treated with Tuft-Lip-
ETP with a mean total leukocyte count 7364 /mm 3 a s compared to 
groups of animals treated with free (p<0.001) as well liposomal ETP 
(p<0.001). Control healthy mice had a total leukocyte count of 
12,160/mm3 at the same time point (Fig. 2.4A). No substantial change 
was observed in the differential leukocyte profile following therapy 
suggesting that the proliferation of all the components was equally 
suppressed. A reduction in platelet count was also observed on day 7 
in drug treated groups as compared with control. The mean platelet 
105 
Chapter! tuftsin in the treatment of fibrosarcoma 
counts in the free ETP, Lip-ETP and Tuft-Lip-ETP-treated groups were 
1.4 X 10 5 /mm 3 (p<0.001 vs control), 2.1 X 10 5 /mm 3 (p<0.001 vs free 
ETP) and 2.5 X 10 5 /mm 3 (p<0.001 vs free as well as Lip-ETP) 
respectively. Vehicle treated control animals had a mean platelet 
count of 2.8 X 10 5 /mm 3 (Fig. 2.4B). 
2.3 .1 . Short term studies 
Short-term study at mRNA level after 24h and 48h treatment 
with various formulations revealed low expression of p53wt and 
p21/wafl while upregulation of p53mut in animals subsequent to 
tratmemt with benzo a pyrene (Gp. II) as compared to untreated 
normal mice (Fig. 2.5, 2.6 and 2.7). Tuftsin-bearing liposomal 
formulation of etoposide significantly raised expression of p53wt and 
p21 /Waf as compared to free and liposomal formulation of etoposide 
and this expression profile was maintained even after 72h post 
treatment. No normalization in expression of p53wt and p21 /waf was 
evident in animals treated with tuftsin-bearing liposomes without 
etoposide or free etoposide (Fig. 2.5 and 2.7). 
The data of the present study demonstrate detectable amount of 
p53mut mRNA in normal healthy animals. After 24h post-treatment 
significant decreased in expression of p53mut was observed in the 
animals treated with free etoposide and tuftsin-liposome (sham 
liposomes) devoid of etoposide (Fig. 2.6). In the animals treated with 
liposomal etoposide the expression of p53mut was significantly lower 
in comparison to animals treated with tuftsin liposomes and free 
etoposide (Fig. 2.6). The expression of p53mut in the animals treated 
with tuftsin-bearing liposomal etoposide was jus t only in detectable 
amount and was comparable to that of control animals that were not 
treated with benzo a pyrene. The same level of mRNA expression was 
observed after 48 and 72h post treatment (Fig. 2.6). 
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2.3.2. Long-term studies 
To evaluate in vivo efficacy of various ETP formulations against 
experimental fibrosarcoma, tumors were developed in model animals. 
The treatment with benzo (a) pyrene ensued in development of tumors 
in 90 percent of the animals within 90-100 days (Fig. 2.8). The 
establishment of the tumors was confirmed by histopathological 
examinations of the tissues. The fibrosarcoma was found to be 
accompanied with increased vascularization, large pleomorphic, 
hyperchromatic spindle shaped cells with anisonucleosis and 
irregularly dispersed chromatin (Fig. 2.9). 
Among various formulations tuftsin bearing liposomised ETP 
was found to be most effective as compared to tuftsin free liposomised 
ETP or free form of the drug in treatment against fibrosarcoma. 
Treatment of the animals with Lip-ETP was started when the tumors 
attained the size of approximately 200 mm3 . Chemotherapy with Tuft-
Lip-ETP at a dose of 10 mg/kg b.w/day for 5 days significantly 
reduced the growth of the tumour as compared with Lip-ETP 
(p<0.001), free ETP (p<0.001), Sham-Tuft-Lip (p<0.001) a s well as 
controls treated with sham liposomes (no tuftsin) and PBS (p<0.001). 
Liposomised ETP delayed tumour growth and was superior to free 
form of ETP and sham tuftsin liposomes, however remained unable to 
regress the tumour significantly. On the other hand, tuftsin bearing 
ETP liposomes reduced the growth upto 165.7 ± 2.63 mm 3 from 200 
mm3 within 52 days after the initiation of chemotherapy (Fig. 2.10A). 
Mortality was seen in all benzo (a) pyrene induced tumor, 
however animals treated with appropriate chemotherapy had 
comparatively longer life span. Table 2.1 shows the median day of 
death in each group. Treatment with free form of ETP increased the 
life span of the tumour-bearing mice as compared to those treated 
with PBS and sham liposomes (p<0.001). As depicted in Fig. 2.10B, 
treatment with Lip-ETP was superior to free form of ETP and Sham-
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Tuft-Lip treatment (p<0.001) in increasing the life-span of the tumor-
bearing mice. While the animals treated with Tuft-Lip-ETP 
significantly increase the life span of tumour bearing animals as 
compared to animals treated with Sham-Tuft-Lip, ETP as well as Lip-
ETP (p<0.001). 
The western blot as well as RT-PCR analysis showed 
significantly ;ow level of expression of p53wt protein in tumors of 
animals treated with vehicle controls (PBS and Sham liposomes) in 
comparison to normal untreated healthy mice (Fig. 2.11A, lanes 1, 2 
and 3). As depicted in Fig. 2.11(A), comparatively high expression of 
p53wt protein was recorded in the animals treated with various 
formulations than the animals treated with vehicle controls. 
Treatment with liposomal etoposide ensued in upregulation of p53wt, 
which was superior to the animals treated with sham tuftsin 
liposomes and free etoposide (p<0.001). Significantly higher 
expression of p53wt was recorded in the animals treated with tuftsin-
bearing liposomal etoposide as compared to animals treated with 
liposomal etoposide (p<0.001), indicating that tuftsin-bearing 
liposomal formulation of etoposide regulate expression of p53wt 
protein significant manner and help in inhibition of D MBA-induced 
neoplastic changes. 
Animals not treated with benzo a pyrene had detectable level of 
p53mut. Administration of benzo a pyrene resulted in development of 
fibrosarcoma in the treated animals and also upregulated p53mut 
levels. Treatment with PBS or sham liposomes did not abolish this 
effect (Fig. 2.1 IB, lanes 1, 2, 3). As depicted in the Fig. 2.11 (B), the 
level of p53mut was significantly reduced (p<0.001) in the animals 
treated with liposomal etoposide in comparison to free etoposide as 
well as tuftsin liposomes (sham). In animals treated with tuftsin-
bearing liposomal etoposide, the expression of p53mut was 
significantly low (p<0.01) in comparison to liposomal etoposide 
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(without etoposide). These results clearly show that etoposide 
mediates down-regulation of p53mut, which is more apparent upon its 
intercalation in liposomes along with tuftsin used in the present study 
(Fig. 2.1 IB). 
The effect of various formulations on the expression of p21/wafl 
was also assessed, which is transcriptionally up-regulated in the 
presence of p53wt. Immunoblot as well as RT-PCR analysis showed 
increased expression of p21/wafl in animals treated with various 
formulations of etoposide. Increased expression (p<0.001) was 
observed in the animals treated with liposomised etoposide in 
comparison to free etoposide as well as sham tuftsin liposomes (Fig. 
2.11C). The expression of p21/wafl was significantly higher in the 
animals treated with tuftsin bearing liposomal etoposide in 
comparison to liposomal etoposide. 
Immunoblot as well as RT-PCR analysis showed an increased 
expression of proapoptotic gene bax in liposomal etoposide treated 
groups. The expression of bax was reduced in the animals treated with 
vehicle controls when compared with untreated control animals. The 
expression of bax increased significantly (p<0.01) in the animals 
treated with etoposide in comparison to vehicle controls. In the groups 
of animals treated with tuftsin bearing liposomal etoposide as well 
liposomal etoposide without tuftsin, the expression of bax was similar 
but significantly higher (p<0.001) than those treated with free 
etoposide (Fig. 2.1 ID). However no significant difference in Bax level 
was observed in the animals treated with sham tuftsin liposomes 
when compared with vehicle controls. 
The level of bcl-2 was also found to be significantly low 
(p>0.001) in the groups of animals treated with free etoposide in 
comparison to vehicle controls. As depicted in the Fig. 2 . H E , the level 
of bcl-2 was reduced significantly (p<0.001) but equal to the animals 
treated with liposomal etoposide as well as tuftsin bearing liposomal 
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etoposide in comparison to free etoposide. While no significant 
difference was observed in animals treated with sham tuftsin liposome 
when compared with vehicle controls. These results clearly show that 
immunomodulator tuftsin play not much significant role in down-
regulation of bcl-2, in etoposide mediated chemotherapy against 
fibrosarcoma (Fig. 2. HE) . 
We also studied effect of liposomised etoposide on caspase-3. 
The expression level of caspase-3 was significantly reduced in animals 
treated with vehicle controls (PBS and Sham liposomes) in comparison 
to normal untreated mice (Fig. 2.1 IF, lanes 1, 2 and 3). As depicted in 
Fig. 2.1 IF, comparatively high level of expression of caspase-3 
(p<0.01) was recorded in the animals treated with free etoposide. In 
the groups of animals treated with liposomal etoposide with or without 
tuftsin the expression level of Caspase-3 was identical but 
significantly higher (p<0.001) when compared to free etoposide. No 
significant difference was observed in the animals treated with sham 
tuftsin liposomes in comparison to animals treated with vehicle 
controls, indicating that liposomal formulation of etoposide with or 
without tuftsin plays a determining role in the expression of caspase-3 
protein. 
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24h 48h 
Figure 2.2(A): Leakage of ETP from liposomised formulations in 
surrounding PBS buffer. Data is mean ± SD of three independent 
experimental values. *p<0.001 (Tufts-Lip-ETP) versus Lip-ETP at 24h 
and 48h. 
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Figure 2.2(B): Hemolysis of human erythrocytes induced by 
various formulations of ETP. Data is mean ± SD of three 
independent experimental values. a p<0.001 versus free ETP and 
bp<0.001 versus Lip-ETP. 
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Figure 2.3: Effect of increasing doses of BTP on body weight of 
the treated animals. 
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The dose resulting in the loss of more than 10 % body weight is 
identified as the MTD. Data shown are means of three individual 
animals at each dose point. 
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Figure 2.4(A): Effects of ETP chemotherapy on leukocyte counts 
of the treated animals. Data are means ± SD with n = 5 per group. 
• p< 0.001 versus free ETP and bp<0.001 versus Lip-ETP. 
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Figure 2.4(B): Effects of ETP chemotherapy on platelet counts of the treated 
animals. Data are means ± SD with n = 5 per group.a p< 0.001 versus free ETP 
and bp<0.001 versus Lip-ETP. 
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Figure 2.5: Effect of various formulations on the mRNA 
expression of p53wt after the administration of benzo (a) pyrene 
in Swiss albino mice. 
Treatment with various formulations followed on day 7 after the 
single subcutaneous dose of benzo a pyrene (lOmg/kg). The 
p53wt mRNA expression were analyzed after (A) 24h, (B) 48h as 
well as (C) 72h. GAPDH was used as control. Isolation of total 
RNA, cDNA synthesis and PCR were performed as described in 
Materials and Methods. Lane 1, Untreated (Normal); lane 2, 
Vehicle Control (PBS); lane 3 , Sham liposomes; lane 4, Tuftsin 
liposomes (No ETP); lane 5, Free ETP; lane 6, Liposomal ETP and 
lane 7, Tuftsin bearing liposomal ETP. 
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Figure 2.6: Effect of various formulations on the mRNA 
expression of p53mut after the administration of benzo (a) 
pyrene in Swiss albino mice. 
Treatment with various formulations followed on day 7 after the 
single subcutaneous dose of benzo a pyrene (lOmg/kg). The 
p53mut mRNA expression were analyzed after (A) 24h, (B) 48h as 
well as (C) 72h. GAPDH was used as control. Isolation of total 
RNA, cDNA synthesis and PCR were performed as described in 
Materials and Methods. Lane 1, Untreated (Normal); lane 2, 
Vehicle Control (PBS); lane 3, Sham liposomes; lane 4, Tuftsin 
liposomes (No ETP); lane 5, Free ETP; lane 6, Liposomal ETP and 
lane 7, Tuftsin bearing liposomal ETP. 
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Figure 2.7: Effect of various formulations on the mRNA 
expression of p21/wafl after the administration of benzo (a) 
pyrene in Swiss albino mice. 
Treatment with various formulations followed on day 7 after the 
single subcutaneous dose of benzo a pyrene (lOmg/kg). The 
p21/wafl mRNA expression were analyzed after (A) 24h, (B) 48h 
as well as (C) 72h. GAPDH was used as control. Isolation of total 
RNA, cDNA synthesis and PCR were performed as described in 
Materials and Methods. Lane 1, Untreated (Normal); lane 2, 
Vehicle Control (PBS); lane 3 , Sham liposomes; lane 4, Tuftsin 
liposomes (No ETP); lane 5, Free ETP; lane 6, Liposomal ETP and 
lane 7, Tuftsin bearing liposomal ETP. 
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Figure 2.8: Establishment of fibrosarcoma (A) and (B) upon 
exposure of animals with benzo (a) pyrene. The benzo (a) pyrene 
was administered into the flanks of the animals subcutaneously 
at the dose of 250ug/animal. 
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Figure 2.9: Establishment of fibrosarcoma upon exposure of 
animals with benzo (a) pyrene. 
Administration of benzo (a) pyrene (250ug/animal, s.c.) into the 
flanks of the animals ensued successful tumor induction, in at 
least 90 % of the animals, while 10 % of the animals did not 
develop any tumor. The tumor bearing animals were sacrificed by 
cervical dislocation and fixed in 10 % formaldehyde solution. 
Subsequently tissues were excised and sections were prepared 
following standard HE staining of 12-mm-thin sections. (A) 
Photomicrographs from tumor showing zone of necrosis, 
increased vascularization and hemorrhage. Large number of 
hyperchromatic mesenchymal cells with features of fibrosarcoma 
is present. Some hyperchromatic cells arranged in glandular form 
also. (B) Photomicrograph from tumor showing soft tissue 
sarcoma. It shows large pleomorphic, hyperchromatic spindle 
shaped cells with anisonucleosis and irregularly dispersed 
chromatin. Some inflammatory cells can also be seen. 
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Figure 2.10(A): Effects of chemotherapy with various 
formulations ofETP on tumor development in Swiss mice. 
Treatment of tumor bearing animals was started when the tumor 
size reached a volume of approximately 200 mm3. Free ETP and 
sham tuftsin liposomes significantly delayed tumor growth 
(p<0.05) as compared with controls (PBS and Sham liposomes). 
Liposomal ETP was more superior to free ETP in delaying tumor 
growth (p<0.001). The regressions of tumors were recorded only 
in the group of animals treated with tuftsin bearing liposomal 
ETP. Data are values ± SD (n = 20 at initiation of therapy, the 
number varies at later time points due to mortality). 
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Figure 2.10(B): Effects of ETP chemotherapy on the survival of 
tumor-bearing mice. 
The fibrosarcoma was induced by exposure to benzo (a) pyrene. 
The treatment of tumor bearing animals was started at the time 
point when tumor size reached a volume of approximately 200 
mm3. All the treated mice received a dose of lOmg/kg b.w/day for 
5 days with various formulations of the drug. Free ETP 
significantly enhanced the life span of the mice as compared with 
the control group (PBS and sham liposomes) (p<0.01). Lip-ETP was 
superior to free ETP in increasing the lifespan (p< 0.001). The 
best therapeutic effect was recorded in the group of animals 
treated with tuftsin bearing liposomal ETP (p<0.001). Data shown 
the number of mice surviving at the given time points. 
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Figure. 2 .11: Effect ofvarious formulations on the expression of 
p53wt (A) at protein level as analysed by western blot as well as 
(B) at mRNA level by RT-PCR in mouse fibrosarcoma. 
The treatments were given to the animals for five consecutive 
days when the tumor reached the size of 200 mm 3 with various 
formulations. All the surviving animals were sacrificed after 25 
days from the first administered drug dose. Skin/tumor lysates 
preparation for Immunoblot analysis and isolation of total RNA, 
OT>NA synthesis and PCR were performed as described in Materials 
and Methods. Lane 1, Untreated (Norm**!); lane 2, Vehicle Control 
{PRS}; hsrte 3 , c*»***m 1ip«e;.-.tin!«»«- lane 4, Tuftsin liposomes (No ETP); 
lane 5, free ETP; lane 6, liposomal ETP and lane 7, Tuftsin 
bearing liposomal ETP. 
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Figure. 2.12: Effect of various formulations on the expression of 
p53mut (A) at protein level as analyzed by western blot as well 
as (B) at mRNA level by RT-PCR in mouse fibrosarcoma. 
The treatments were given to the animals for five consecutive 
days when the tumor reached the size of 2 0 0 mm 3 with various 
formulations. AH the surviving animals were sacrificed after 25 
days from the first administered drug dose. Skin/tumor lysates 
preparation for Immunoblot analysis and isolation of total RNA, 
cDNA synthesis and PCR were performed as described in Materials 
and Methods. Lane 1, Untreated (Normal); lane 2, Vehicle Control 
(PBS); lane 3 , sham liposomes; lane 4, Tuftsin liposomes (No ETP); 
lane 5, free ETP; lane 6, liposomal ETP and lane 7, Tuftsin 
bearing liposomal ETP. 
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Figure. 2.13: Effect of various formulations on the expression of 
p21/wafl (A) at protein level as analyzed by western blot as well 
as (B) at mRNA level by RT-PCR in mouse fibrosarcoma. 
The treatments were given to the animals for five consecutive 
days when the tumor reached the size of 2 0 0 nun3 with various 
formulations. All the surviving animals were sacrificed after 25 
days from the first administered drug dose. Skin/tumor lysates 
preparation for Immunoblot analysis and isolation of total RNA, 
cDNA synthesis and PCR were performed as described in Materials 
and Methods. Lane 1, Untreated (Normal); lane 2, Vehicle Control 
(PBS); lane 3 , sham liposomes; lane 4, Tuftsin liposomes (No £TP); 
lane 5, free ETP; lane 6, liposomal ETP and lane 7, Tuftsin 
bearing liposomal ETP. 
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Figure. 2.14: Effect of various formulations on the expression of 
box (A) at protein level as analyzed by western blot as well as (B) 
at niRNA level by RT-PCR in mouse fibrosarcoma. 
The treatments were given to the animals for five consecutive 
days when the tumor reached the size of 2 0 0 mm 3 with various 
formulations. All the surviving animals were sacrificed alter 2 5 
days from the first administered drug dose. Skin/tumor lysates 
preparation for Immunoblot analysis and isolation of total RNA, 
cDNA synthesis and PCR were performed as described in Materials 
and Methods. Lane 1, Untreated (Normal); lane 2, Vehicle Control 
(PBS); lane 3 , sham liposomes; lane 4 , Tuftsin liposomes (No ETP); 
lane 5, free ETP; lane 6, liposomal ETP and lane 7, Tuftsin 
bearing liposomal ETP. 
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Chapter 2 Tuftsin in the treatment of fibrosarcoma 
Figure. 2.15: Effect of various formulations on the expression of 
bcl-2 (A) at protein level as analyzed by western blot as well as 
(B) at mRNA level by RT-PCR in mouse fibrosarcoma. 
The treatments were given to the animals for five consecutive 
days when the tumor reached the size of 2 0 0 mm 3 with various 
formulations. All the surviving animals were sacrificed after 2 5 
days from the first administered drug dose. Skin/tumor lysates 
preparation for Imnranohlnt analjiiii and Isolatioai of total SEA, 
cDHA synthesis and PCR were performed as described in Materials 
and Methods. Lane 1, Untreated OaonaaD; lane 2 , Vehicle Control 
(PBS); lane 3 , sham liposomes; lane 4 , Tuftsin liposomes (Ho ETP); 
lane 5, free ETP; lane 6 , Hpoaoaaal ETP and lane 7, Tuftsin 
bearing liposomal ETP. 
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Chapter! Tuftsin in the treatment of fibrosarcoma 
Figure. 2.16: Effect of various formulations on the expression of 
caspase-3 (A) at protein level as analyzed by western blot as well 
as (B) at mRNA level by RT-PCR in mouse fibrosarcoma. 
The treatments were given to the animate for five consecutive 
days when the tumor reached the size of 200 mm3 with various 
formulations. All the surviving animals were sacrificed after 25 
days from the first administered drug dose. Skin/tumor lysates 
preparation lor ImmunoUot analysis and isolation of total REA, 
cDHA synthesis and PCR were performed as described in Materials 
and Methods. Lane 1, Untreated (lonMQ; lane 2 , Vehicle Control 
(PBS); lane 3, sham liposomes; lane 4, Tuftsin liposomes (No ETP); 
lane 5, free ETP; lane 6, Hponomal ETP and lane 7, Tuftsin 
bearing liposomal ETP. 
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CHAPTER III 
Role of tuftsin in apoptosis 
Chapter 2 Tuftsin in the treatment of fibrosarcoma 
1A. Discuss ions 
Drugs used in t reatment of cancer generally show severe toxic 
manifestations and undesirable side effects. The usage of most of the 
ant icancer drugs including ETP is also limited by an ever-increasing 
t rend of mult i drug resistance displayed by the cancerous cells. This 
resistance is mainly due to the drug efflux mediated by an array of 
t ranspor ters p-glycoproteins such as p-gp4 and other multi drug 
resistance proteins chiefly MRP1, MRP2 and MRP3 etc (Borst et al. 2000, 
Zelcer et al. 2001 and Guo et al. 2002). It is demand of the ordeal to 
develop newer formulations of potential ant icancer agents viz. ETP 
showing least toxicity and also being able to circumvent the problem of 
drug res is tance. In this regard usage of the drug delivery systems that 
can specifically deliver anticancer drugs solely to tumor t i ssues could 
prove to be an acceptable solution. Etoposide entrapped in liposomes h a s 
been found to be much assuring to this end (Sengupta et al. 1998 & 
2000). Liposomes are lipid-based vesicles that enable efficient and 
targeted delivery of drugs to the desired site (Gabizon et al. 1997', Vaage 
et al. 1992). Moreover, liposomised ant icancer formulations can 
circumvent drug efflux and achieve adequate drug concentration in the 
target cell to enable tumor cell killing as they deliver overwhelming 
disposition of the drug that can match well with p-glycoprotein 
t ranspor ters mediated drug efflux (Candoni et al. 2006, Sadva et al. 
2002, Lo et al. 2001 , Lawrence et al. 2001 , Poujol et al. 1999). 
We have attempted to further enhance therapeut ic efficacy of 
liposomal ETP by the incorporation of the immunomodula tor tuftsin. 
Immunomodula tors are biological response modifiers and can also exert 
ant i tumor effects by improving host defense mechan i sms against the 
tumor. Tuftsin h a s been shown to direct anti-proliferative effect on tumor 
cells and also enhance the ability of the host to tolerate damage by toxic 
chemicals tha t may be used to destroy the cancer cells (Knyszynski et al. 
1983, Noyes et al. 1981). Immunomodulatory therapy t h u s provide an 
alternative to conventional chemotherapy for a variety of diseased 
conditions, especially when the host 's defense mechan i sms is impaired 
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and need appropriate activation. To suppress tumors in vivo, 
macrophages must first infiltrate to the desired site. In fact, the presence 
of inflammatory macrophages in growing tumors is retained through 
recruitment of circulating monocytes (Bugelski et al. 1987a, Bugelski et 
al. 1987b, Evans and Cullen 1984, Normann 1985) and in certain 
tumors, the proliferation of mononuclear phagocytes (Mantovani, 1990). 
Activated macrophages can destroy syngeneic, allogeneic, and xenogeneic 
tumor cells, but leave normal nontumorigenic cells unharmed, 
suggesting that histocompatibility and tumor-specific antigens are not 
involved in this recognition (Fidler and Schroit, 1988). In addition, 
differences in metastatic potential, chromosome number, resistance to 
chemotherapeutic agents, or the antigenic properties of tumor cells did 
not appear to be important factors for macrophage recognition of tumors 
cells (Killion et al. 1993, Pak 1989). Successful treatment of metastases 
by the intravenous injection of liposomes containing immunomodulators 
has been reported for several tumor-host models, including mouse 
fibrosarcoma (Fidler 1986b, Deodhar et al. 1982, Eppstein et al. 1986, 
Lopez-Berestein et al. 1984), melanomas (Phillips et al. 1985, Phillips and 
Tsao 1989), lung carcinoma (Brodt et al. 1989) and colon carcinoma 
(Thrombe and Deodhar 1984) etc. Macrophages are believed to migrate to 
local regions of inflammation and the sites of tumor growth where they 
induce further immune reactivity against tumor cells. The treatment of 
tumors could be achieved by first delivering the drug to the RES and 
concomitant activation of their components (cf. macrophages) for their 
tumoricidal activity by a desirable immunomodulator. Being particulate 
in nature, liposomes are avidly taken up by macrophages that act as 
secondary depot of the drug. These macrophages after reaching to the 
tumor site release the drug thereby bring about tumor cell death. At the 
outset, we speculated our novel formulation comprising the 
immunomodulator tuftsin grafted on the surface of liposomes along with 
ETP would be able to eliminate fibrosarcoma in Swiss albino mice. 
In previous studies conducted in our lab, it was demonstrated that 
pretreatment with liposomised tuftsin led to the successful elimination of 
a range of pathogens in leukopenic mice (Khan et al. 2005, Khan et al. 
2004, Khan et al. 2002). Antitumor activity of tuftsin has been known 
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since long but no sincere effort have been made to evaluate therapeutic 
potential of its liposomised form or per se tuftsin bearing liposomal 
preparation of any anticancer agent. In the present study, we evaluated 
anticancer potential of tuftsin bearing liposomal ETP (Tuft-Lip-ETP). 
Since ETP has cytotoxic properties and the immunomodulator tuftsin 
possesses both anti tumor and immunomodulatory properties to co-
activate immune system, we considered it of interest to evaluate 
therapeutic potential of their combination against experimental 
fibrosarcoma. Our results are well in agreement with proposed 
hypothesis as novel formulation of liposomised ETP with tuftsin grafted 
on the surface was found to be more effective than its free form. Median 
day of death (MDD) studies have also demonstrated that animals treated 
with Tuft-Lip-ETP have increased life span. More importantly, significant 
tumor regression was also induced in the animals treated with Tuft-Lip-
ETP. Enhanced efficacy of Tuftsin-bearing ETP liposomes might be due to 
the fact that tuftsin helps in specific targeting to macrophages that will 
subsequently infiltrate to tumor site. Treatment with free ETP and Sham-
Tuft-Lip were not much effective in killing tumor cells. 
The tumor suppressor gene p53 is regarded as a key factor in 
maintaining the balance between cell growth and cell death (Agarwal et 
al. 1998, Mowat et al. 1998). The importance of p53 gene can be drawn 
from the fact that this gene is reportedly mutated in ~80% of all human 
malignancies (Hollstein et al. 1991). Because of its role in regulation of 
cell cycle, alterations in p53 are critical events in carcinogenesis. In 
tumors loss of p53wt prevents the activation of this growth control 
pathway (Burns et al. 1991). The failure to induce transcriptionally active 
p53wt plays a role in the unregulated growth of the tumors and also in 
the failure to respond to chemotherapeutic agents, which normally trigger 
p53wt thus regulating cell cycle arrest or cell death (el-Deiry 1994). 
Because the balance between p53wt and p53mut determines the fate of 
the cell, many chemotherapeutic agents are known to exert their 
anticancer effects by modulating their expression levels (Skvortsova et al. 
2005, Takimoto et al.2002, Bunz et al. 1999). The results of the present 
study showed increased up-regulation of p53wt along with its 
downstream effector p21/Wafl and down-regulation of p53mut by 
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tuftsin-bearing liposomal formulation of etoposide. In fact the intrinsic 
property of etoposide is to act by modulating the balance between wtp53 
and p53mut protein expression by repressing p53mut and enhancing 
tumor suppressor p53 (Takimoto et al. 2002, Natalie et al. 2002, Kevin et 
al. 2006, Huang et al. 1997). The effect of etoposide on p53wt and 
p53mut gets more apparent upon its liposomization along with tuftsin. 
The up-regulation of p53wt by etoposide is also responsible for the 
transcriptional induction of p21/wafl by directly interacting with its 
regulatory elements (el-Deiry et al. 1994). As observed in the present 
study, liposomization of etoposide with or without tuftsin results in up-
regulation of p21/waf 1. The effect is more prominent in tuftsin-bearing 
etoposide liposomes. The p21 protein is a cyclin-dependent kinase (CDK) 
and has multiple functions. It mediates p53-induced growth arrest at the 
Gl or G2 cell cycle checkpoint and can inhibit CDK-cyclin activity and 
directly inhibit DNA replication (Boulaire et al. 2000, Li et al. 1994, Shiyji 
et al. 1994, Chen et al. 1995). The halt offers time for DNA repair before 
replication or mitosis and thus links p21 directly to the tumour 
suppressor function of p53 (Taylor & Stark 2001, Winters 2002, Gartel et 
al. 1996, Colman et al. 2000). Besides activating p21/Wafl the p53 
protein can also selectively repress one or more antiapoptotic genes, with 
an outcome essentially similar to transactivation of proapoptotic genes 
through the process of apoptosis. Genetic changes resulting in loss of 
apoptosis or derangement of apoptosis-signaling pathways in the 
transformed cells are likely to be critical components of carcinogenesis 
(Kastan et al. 1995, Schulte-Hermann et al 1997). The tumor suppressor 
p53 thus very sophistically causes tumor cell death; simultaneously up-
regulating death-promoting genes and turning off protective genes by the 
process of apoptosis. Apoptosis is mediated by caspase-3, one member of 
a family of cysteine proteases (Thornberry et al. 1998) and is thought to 
be regulated by bax and bcl-2. Bcl-2 is the antiapoptotic protein whose 
expression is reportedly transcriptionally blocked by p53 (Haldar et al. 
1994, Miyashita et al. 1994). The expression of caspase-3 and bax was 
increased in the animals treated with various formulations of etoposide. 
Significantly higher expression of caspase-3 was observed in animals 
treated with Liposomised ETP in comparison to animals treated with free 
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etoposide. No significant difference was observed in the animals treated 
with tuftsin-bearing liposomal etoposide in comparison to liposomal 
etoposide devoid of tuftsin. The expression level of bcl-2 also decreased in 
the animals treated with various formulations of etoposide in comparison 
to animals treated with vehicle controls. The bcl-2 level was observed to 
be significantly lower in the animals treated with liposomal formulations 
of etoposide over free etoposide. No significant difference was observed in 
the animals treated with tuftsin-bearing liposomal etoposide in 
comparison to animals treated with tuftsin-free liposomal etoposide. 
These results clearly show that the regression of tumor in the animals 
treated with tuftsin-bearing liposomal etoposide formulations is through 
the activation of apoptosis as well as cell growth arrest mediated by p53. 
These results also show that therapeutic treatment of tuftsin alone or in 
combination with etoposide has no modulatory effect on the mechanism 
of apoptosis. Free as well as liposomal formulations of etoposide effected 
the modulation of the gene involved in the mechanism of apoptosis but 
had no effect on the expression of the inhibitor of cyclin dependent 
kinase that is p21/wafl. Despite these interesting and promising results 
it remains to be found out more precisely whether the higher expression 
of p21/wafl by tuftsin is p53 dependent or independent. Finally we 
conclude that Tuftsin-bearing liposomised etoposide is an effective 
formulation for the treatment of fibrosarcoma and can pave the way for 
treatment of other forms of cancer as well. Formulation of tuftsin-bearing 
liposomes in combination of other anticancer drugs may be equally 
effective against various form of cancer. 
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3 .1 . Introduction 
In biological systems, free radicals or reactive oxygen species 
(ROS) are continuously generated by oxygen and help in killing of 
pathogens (Halliwell et al. 1993, Li et al. 1994). Incidentally, ROS are 
generated through a variety of environmental pollutant like cigarette 
smoke, automobile exhaust fumes, radiation, and exposure to 
xenobiotic compounds. Due to their high chemical reactivity, ROS are 
able to induce cellular damage in a number of ways (Bendich 1990). 
The most deleterious effects of ROS include DNA damage (Richter et 
al. 1988), which can lead to a number of diseased conditions 
including cancer. Although, ROS act as damaging entities, at the same 
time they also carry out some beneficial biological events. ROS has 
been shown to be mediators, triggers or executioners of essential 
protective mechanisms such as apoptosis, phagocytosis and 
detoxification reactions. Increase of ROS concentration by depletion of 
antioxidants, enhances apoptosis and thereby inhibits neoplastic 
growth. Antioxidants decrease ROS level, inhibit apoptosis and 
suppress the elimination of cancer cells (Agostini et al. 2002 and Zhai 
et al. 2002). 
Apoptosis is a highly organized cell death process, characterized 
by loss of plasma membrane phospholipid asymmetry, enzymatic 
cleavage of the DNA into oligonucleosomal fragments, and 
segmentation of the cells into membrane-bound apoptotic bodies (Kidd 
1998). Genetic changes resulting in loss of apoptosis or derangement 
of apoptosis-signaling pathways in the transformed cells are critical 
components of carcinogenesis (Kastan et al. 1995 and Schulte-
Hermann et al. 1997). Interesetingly, induction of apoptosis of cancer 
cells is recognized as a valuable tool for management of cancer 
(kornblau 1998). In general, the cells execute apoptosis by Caspase-3, 
one of a family of cysteine proteases (Thornberry et al. 1998). This in 
turn is thought to be regulated by Bax and Bcl-2. Proapoptotic Bax 
forms pores in the outer mitochondrial membrane, releasing 
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cytochrome c while antiapoptotic Bcl-2 prevents the opening of 
mitochondrial transition pore by binding with Bax (Antonsson et al. 
1997 and Zamzami et al. 1995). ROS have been suggested to act as an 
upstream signal for Caspase-3 activation (Kim et al. 2006, Jacobson 
1995). 
Some recent studies have revealed that the phosphatidylinositol 
3-kinase (PI 3-kinase) and its downstream target, Akt, are responsible 
for the anti-apoptotic activity of insulin against TGF- p (Chen et al. 
1998). PI 3-kinase was reported to suppress apoptotic cell death 
induced by a variety of stimuli (Ahmed et al. 1997, Dudek et al. 1997, 
Kauffmann-zeh et al. 1997, Khwaja et al. 1997, Kulik et al. 1997). 
Anti-apoptotic activity of PI3-kinase is mediated by through the action 
of the serine/threonine kinase, Akt. Recent studies have 
demonstrated that activated Akt can phosphorylate the proapoptotic 
protein BAD (Datta et al. 1997, Del-Peso et al. 1997). This 
phosphorylation facilitates association of BAD with 14-3-3 and 
dissociation from BCL-XL, which is then released to resume its 
function as a suppressor of apoptosis (Zha et al. 1996). 
In the present study, we have tried to elucidate effect of tuftsin 
on dimethyl benz (a) anthracene (DMBA), induced hepatic alterations 
in ROS generation, lipid peroxidation, s ta tus of the antioxidant 
enzymes, mitochondrial membrane potential etc. The study is ought to 
help u s understanding the mechanism for the inhibition of apoptosis 
by liposomised tuftsin in the liver of Swiss albino mice. 
3.2. Materials and Methods 
3 .2 .1 . Chemicals 
DMBA, egg phosphatidyl choline, dichlorodihydroflourescien 
diacetate dye (DCFH-DA), Rhodamine 123, propidium iodide (PI), p-
actin (clone AC-74) and nitrocellulose membrane were purchased from 
Sigma (St Louis, USA). The Bcl-2 (polyclonal anti-rabbit IgG), Bax 
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(polyclonal anti-rabbit IgG), and Caspase-3 (anti-mouse IgG) antibody 
were puchased from serotech. The anti-mouse and anti-rabbit 
horseradish-peroxidase conjugate secondary antibodies were obtained 
from Banglore Genei (India). Cholesterol was bought from Centron 
Research Laboratory, Mumbai, INDIA and used after crystallizing it 
three times with methanol. Tuftsin was modified at C-Terminus by 
attaching a sufficiently long hydrocarbon fatty acyl residue to the C-
terminus through an ethylenediamine spacer arm (Thr-Lys-Pro-Arg-
NH-(CH2)2-NH-CO-Ci5H3i), which permits almost quantitative 
incorporation into liposomes, following published procedure (Gupta et 
al. 1986). The rest of the chemicals were of analytical grade of purity 
and procured locally. 
3.2 .2 . Preparation of tuftsin bearing liposomes 
Tuftsin bearing liposomes were prepared from egg PC (49 nmol) 
and cholesterol (21 (amol) with tuftsin (7-8% by PC weight) following 
published procedure as standardized in our lab (Owais et al, 1993). 
3.2.2 . Estimation of liposome intercalated tuftsin 
The amount of the tuftsin entrapped in the drug containing 
liposomes was estimated by BCA method as modified in our lab (Khan 
et al 2007). 
3.2 .3 . Animals and treatment 
Female, Swiss albino mice average body weight (25 ± 2 gms 
body weight) were used in the study. They were randomly selected & 
housed in polycarbonate boxes with steel wire tops and rice husk 
bedding with free access to rodent diet. Experiments were conducted 
following mandates approved by the Animal Ethics Committee 
(Committee for the purpose of control and supervision of Experiments 
on Animals, Govt, of India). The animals were divided into five groups 
(Gps.), each comprising of 6 animals. The animals in Gp. I and II were 
given PBS and sham liposomes were administered in the animals of 
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Gp. Ill, whereas the animals of Gp. IV and V were given liposomised 
tuftsin (50|ag/ animal) intraperitonially for five consecutive days. 
Single dose of DMBA (50 mg/kg b. wt. dissolved in 0.2 ml corn oil) 
was given by gavage to the Gps. II, III and IV on day 6 after 24h from 
the last dose of tuftsin. Animals from all the Gps. were examined every 
day for gross morphological changes during the study period. All the 
animals were sacrificed humanly by cervical dislocation 24h after 
single dose of DMBA. Liver from each animal was excised and 
immediately washed with ice-cold saline and stored at -80 °C till 
further analysis. 
3.2.4. Biochemical estimations 
The liver tissue was homogenized individually in ice-cold 
phosphate buffer (pH 7.4) containing 0.15 M KC1. The homogenate 
centrifuged at 9,000 x g for 10 minutes and supernatant was taken as 
enzyme source. SOD was analyzed as described elsewhere (Kakkar et 
al. 1984). Briefly, the assay mixture in a final volume of 3 ml 
contained 0.052 M sodium pyrophosphate buffer (pH 8.3), 186 JIM 
PMS, 300 nM NBT, 780 nM NADH, enzyme source and Milli Q water. 
The reaction was initiated by addition of NADH followed by incubation 
at 37 °C for 90 seconds. The reaction was stopped by addition of 1.0 
ml of glacial acetic acid and the contents were shaken vigorously with 
4.0 ml of n-butanol, allowed to stand for 10 minutes, centrifuged and 
butanol layer was separated. The color intensity of chromogen in 
butanol was measured against butanol using a spectrophotometer. A 
reaction mixture devoid of enzyme served as control. A single unit of 
enzyme activity is defined as the quantity of SOD required for 50 % 
inhibition of reaction. The activity of CAT was analyzed according to 
the method described elsewhere (Sinha 1972) using H202as substrate. 
In brief, the reaction in a final volume of 3 ml consisted of phosphate 
buffer (pH 7.0), 0.2 M H2O2 and enzyme protein. The enzyme activity 
measured following the disappearance of H2O2 at 570 nm and was 
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expressed as |i moles of H2O2 consumed/min /mg protein. Glutathione 
reductase (GR) activity was determined by the published protocol 
(Carlberg and Mannervic, 1985). Briefly, the assay mixtures in a final 
volume of 3.0 ml contained 0.067M phosphate buffer (pH 6.6), 
NADPH, 7.5 X IO-3 GSSG (pH 6.6) enzyme and water. The reaction was 
initiated with enzyme preparation. The difference in optical density per 
30 second was measured for 3 minutes at 340 nm against a reference 
cuvette devoid of GSSG and NADPH. The activity was expressed in 
nmoles /min/mg protein. Glutathione S-transferase (GST) was 
analyzed by the method as described elsewhere (Habig et al. 1974). 
The assay mixture in a final volume of 3.0 ml contained 0.2 M 
phosphate buffer (pH 6.5), GSH, CDNB, enzyme and water. The 
reaction was initiated by addition of CDNB. The difference in optical 
density per 30 seconds was measured at 340 nm for 3 minutes 
against a reference cuvette devoid of enzyme. The activity was 
expressed as nmoles CDNB-GSH conjugate/min/mg protein. Lipid 
peroxidation was analyzed by the method as described elsewhere 
(Ohkawa et al. 1974). The reaction mixture in a final volume of 3.0 ml 
contained enzyme, 100 jil of 10% sodium dodesyl sulphate (SDS), 600 
\x\ of 20% glacial acetic acid, 600 \A of 0.8% TBA and water. The 
mixture was placed in boiling water bath 1 hour and immediately 
shifted to crushed ice bath for 10 minutes. The mixture was 
centrifuged at 2500 X g for 10 minutes. The amount of thiobarbituric 
acid reactive substances (TBARS) formed was assayed by measuring 
OD of supernatant at 535 nm against a blank devoid of enzyme. The 
activity was expressed as n moles of TBARS/mg of tissue protein 
using TMP as standard. The protein content of the tissue was 
determined by the method of (Lowry et al. 1951) using bovine serum 
albumin as standard. 
3.2.5. Flow cytometric analysis of apoptosis 
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Single cell suspension of liver tissue was prepared by using 
madimixer and pelleted at 2,000 rpm for 10 min at 4 °C. The cell 
pellet resuspended in 50 ^1 cold PBS and fixed in 2 ml of 70 % ice-cold 
ethanol. Cells were washed followed by treatment with 0 .1% Triton X-
100 for 5 min. After incubation, cells were again centrifuged and 
resuspended in 1 ml of PBS, ribonuclease (100 |j.g/ml) was added, and 
the cells were incubated at 37 °C for 30 min. After pelleting, cells were 
resuspended in 1 ml of PBS and 50 |^g/ml PI and incubated for 18 h 
at 4 °C. The 10,000 cells were acquired and analyzed on a flow 
cytometer using 'Cell Quest 2.0' software (Nicoletti et al. 1991). 
3.2.6. Measurement of ROS generation 
ROS production was monitored by flow cytometrically (Becton-
Dickinson, San Jose, CA, USA) using DCFH-DA dye as described 
elsewhere (Esposti and McLennan 1998). Briefly, single cell 
suspensions were prepared as described above in PBS supplemented 
with 50 mM glucose and incubated with 10 ^M DCFH-DA at 37 °C for 
1 hour. The fluorescence increase, due to the hydrolysis of DCFH-DA 
to dichlorodihydrofluroscein (DCFH) by some nonspecific cellular 
esterases and its subsequent oxidation by peroxides was measured. 
Values were given in terms of mean fluorescence intensity (MFI) using 
software 'Cell Quest 2.0'. 
3.2.7. Mitochondrial membrane potential (uim) analysis 
Mitochondrial membrane potential was assessed by using 
Rhodamine 123. Rhodamine 123 accumulates in normal mitochondria 
and decline of ipm will lead to leakage of Rhodamine 123 from 
mitochondria, while its fluorescent intensity is reduced. The single cell 
suspensions were incubated with rhodamine 123 (5^g/ml) for 60 min 
in dark at 37 °C, harvested and suspended in PBS. Prior to 
Rhodamine 123, a mitochondrial uncoupler FCCP added for 10 
minutes in one sample of control. The mitochondrial membrane 
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potential was measured using flow cytometry (Becton- Dickinson, San 
Jose, CA, USA) by the fluorescence intensity (FL-1) of 10,000 cells (Bai 
et al. 1999). 
3.2.8 . Western Blotting 
Western blotting was carried out as described elsewhere (Towbin 
et al. 1979) in the liver tissue homogenate. Briefly, protein content of 
the homogenate was estimated by the routine method using bovine 
serum albumin as a standard (Lowry et al. 1951). Proteins (30 \ig) 
were resolved on 10% gel followed by electroblotted onto nitrocellulose 
membranes. The blots were probed with appropriate antibodies (i.e., 
Bcl-2, Bax, Caspase-3, PI 3-K and Akt at dilutions recommended by 
the suppliers. To quantify equal loading, membranes were re-probed 
with P-actin antibody. Data were presented as the relative pixel 
density of each bands normalized to band of p-actin. The intensity of 
the bands was quantitated using Alpha Image Analysis software on 
Alpha Image Gel Documentation System. 
3.3. Results 
3 .3 .1 . Activities of antioxidant enzymes 
Administration of liposomised tuftsin in the model animals 
resulted in a significant protection against DMBA-induced alteration 
in antioxidant enzymes activities. Table 3.1 depicts the level of 
antioxidants SOD, CAT, GR and GST in the liver of control and 
experimental mice. The extent of the oxidative stress in the liver of 
animals upon exposure to DMBA (Gp. II) was evident from the 
significant reduction in the activities of antioxidant enzymes. The 
activities of SOD, CAT, GR and GST were decreased upto an extent of 
39.4 %, 44.5 %, 44.1 % and 48.4 % respectively in comparison to 
control animals not exposed to DMBA. The pretreatment with tuftsin 
protect against DMBA induced reduction in antioxidant enzymes. 
There was 55.8 %, 66.5 %, 61.8 %, 74.8 % residual activity of SOD, 
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CAT, GR and GST respectively in the animals pretreated with 
liposomised tuftsin (p<0.001) when compared with animals treated 
with DMBA only (Gp. II). In the group of animals pretreated with sham 
liposomes (Gp. Ill), the activities of SOD, CAT, GR and GST increased 
but it was not significantly different from the group of animals 
exposed to DMBA only with no pretreatment with sham liposomes. 
These results clearly demonstrated that tuftsin could effectively 
counteract oxidative stress induced by DMBA in liver, the major site of 
metabolism. 
3.3.2 . Lipid peroxidation level 
Estimation of lipid peroxidation is a reliable marker for 
xenobiotic induced oxidative stress. As depicted in Table 3.1, DMBA 
administration resulted in a significant (p<0.001) increase in the 
TBARS upto an extent of 87% over untreated control group animals 
(Gp. I). The animals pretreated with sham liposomes (Gp. Ill) did 
reduce the level of lipid peroxidation but not to any significant degree 
when compared with the group of animals exposed to DMBA and not 
treated with liposomised tuftsin (Gp II). Pretreatment with liposomised 
tuftsin resulted in significant reduction in level of TBARS, upto an 
extent of 52 % (p<0.001) when compared with animals treated with 
DMBA only (Gp. II). 
3.3.3 . Cell death inhibition 
In order to evaluate ability of tuftsin to protect against DMBA 
induced cell death, we observed appearance of sub Gl peak in liver 
cells. In general, ROS produced in DMBA metabolism led to the 
apoptotic cell death (Gp. II), which was observed a s appearance of sub 
Gl peak, whereas no such peak was observed in control healthy 
animals that were not exposed to DMBA (Gp. I) and also in the group 
of animals that were treated with tuftsin alone (Gp. V). As depicted in 
Fig. 3.1, the considerable reduction in cell death events was recorded 
in the animals pretreated with liposomised tuftsin (Gp. IV). In the 
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upon administration of DMBA (Ft/Fu 2.05) (p< 0.05) in comparison to 
untreated control healthy animals (Ft/Fu 4.2). The loss of 
mitochondrial membrane potential was restored in the group of 
animals (Gp. IV) that were pretreated with liposomised tuftsin (Ft/Fu 
3.22) (p< 0.05). However, no significant changes were observed in the 
animals pretreated with sham liposomes (Ft/Fu 2.08) in comparison 
to DMBA treated animals (Gp. II). 
3.3.5. Tetrapeptide tuftsin modifies the expression of PI-3K, Akt, 
Bcl-2, Bax and Caspase-3. 
The exposure of animals to DMBA induced reduction in the 
expression level of PI-3K, Akt and Bcl-2 (Fig. 3.4B, 3.4D, 3.4E). On the 
other hand, DMBA ensued in significant upregulation of Bax and 
Caspase-3 in exposed animals comparison to untreated control animal 
(Fig. 3.4A, 3.4C). The treatment with liposomised tuftsin resulted in 
upregulation of PI-3 K, Akt and Bcl-2 levels. While same treatment 
ensued in decreased expression of Bax and Caspase-3. Treatment of 
healthy animals with liposomised tuftsin did not induce any 
significant change in expression level of any protein (Gp. V). The 
pretreatment with sham liposomes, did not induce any significant 
change in expression of any proteins, and were almost same to that of 
DMBA treated animals (Gp. II). These results, supporting our 
contention that increased expression of PI-3K, Akt, Bcl-2 and 
decreased expression of Bax and Caspase-3 deactivated the DMBA 
induced apoptotic pathway in Swiss mice. 
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Table 3 .1 . Activities of antioxidant enzymes and lipid peroxidation 
induced by tuftsin against DMBA in liver of Swiss albino mice. 
Treatment 
Untreated 
DMBA 
DMBA + 
Sham 
liposomes 
DMBA + 
Tuftsin 
bearing 
liposomes 
(50ng) 
Tuftsin 
bearing 
liposomes 
(50ug) 
Superoxide 
dismutase 
(U/mg 
protein) 
7.1 ± 0 . 4 3 
4.3 ± 0.29 
(39.4%)» i 
4.6 ± .24 
(7 %) 
6.7 ± 0 . 3 4 
(55.8 %)«>| 
7.3 ± 0 . 4 2 
Catalase 
(nmoles/min/ 
mg protein) 
290.4 ± 
14.7 
161.2 ± 12.2 
(44.5%)»| 
173.2 ± 8 . 3 
(7.5) 
268.5 ± 15.5 
(66.5 %)•>* 
302.4 ± 16.2 
Glutathione 
reductase 
(nmoles/min 
/mg protein) 
74.9 ± 5.6 
41.9 ± 2 . 8 
(44.1%)»| 
45.7 ± 2.6 
(9 %) 
67.8 ± 4 . 1 
(61.8 % M 
77 .6±4 .13 
Glutathione 
S-transferase 
(nmoles/min/ 
mg protein) 
25.4 ± 1.4 
13.1 ± .87 
(48.4%)" | 
14.2 ± .78 
(8.4 %) 
22.9 ± 1. 4 
(74.8 %)•> | 
26.2 ± 1.3 
Lipid 
peroxidation 
(nmoles 
TBAKS/mg 
protein) 
1.40 ± 0 . 1 
2.62 ± 0 . 1 8 
(87.1%)«=| 
2.43 ± .13 
(7.25) 
1.52 1 0 . 8 
(52%)«« | 
1.38±0.72 
Values are expressed as mean + SD of six animals, represent 
significant decrease over untreated control group (Gp.I), while 
•represent significant increase over DMBA treated group (Gp. II). 
Similarly, represent significant increase over untreated control group 
(Gp. I), while drepresent significant decrease over DMBA treated group 
(Gp. II). 
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Figure 3.1: Effect of liposomised tuftsin on cell cycle as revealed by 
flow cytometric analysis in. DMBA exposed animals 
Single cell suspension of liver tissues from all treated animals were 
prepared as described in Materials and Methods. PI fluorescence was 
measured using a flow cytometer with FL-2 filter and were expressed 
as histogram. The effect of liposomised tuftsin was expressed by the 
reduction in sub Gl peak that was induced by the treatment of 
DMBA indicating increased cell death. (A) Untreated, (B) DMBA. (C) 
sham liposomes + DMBA, (D) Lip-Tufts + DMBA and (E) Lip-Tufts. 
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Figure 3.2: Effect of liposomised tuftsin pretreatment by flow 
cytometric analysis on ROS level in DMBA treated animals. 
ROS production was monitored flow cytometrically using DCFH-DA 
as described I Materials and Methods. The fluorescence increase, 
due to the hydrolysis of DCFH-DA to dichlorodihydrofluroscein 
(DCFH) by some nonspecific cellular esterases and its subsequent 
oxidation by peroxides was measured. Values were given in terms of 
mean fluorescence intensity (MFI) using software 'Cell Quest 2.0*. 
(A) Untreated, (B) DMBA, (C) sham liposomes + DMBA, (D) Lip-Tufts + 
DMBA and (E) Lip-Tuft. 
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Figure 3.3: Effect of liposomised tuftsin on mitochondrial 
membrane potential in the animals exposed to DMBA. 
Rhodamine 123 fluorescence was measured using a flow cytometer 
with FL-1 H filter. (A) Untreated, (B) DMBA, (C) sham liposomes + 
DMBA, (D) Lip-Tufts + DMBA and (E) Lip-Tufts. Values are expressed 
as mean + S.E of six animals. 
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Figure 3.4: Effect of liposomised tuftsin on the expression level of 
(A) Bcl-2, (B) Box, (C) Caspase-3, (D) PI3K and (E) Akt in DMBA treated 
animals. Lysates were prepared as described in Materials and 
Methods and proteins (30-50 ug) were employed for Western blots. 
Lane 1, Untreated control; Lane 2, DMBA; Lane 3 , sham liposomes; 
Lane 4, Lip-Tufts + DMBA; Lane 5, Lip-Tufts. Equal loading was 
confirmed by reprobing the membrane with p-actin. The bands 
shown here are from a representative experiment repeated three 
times with similar results. Data were expressed as mean values ± SD 
of four separate sets of experiment. 
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3.4. Discussion 
The carcinogen DMBA has been shown to form free radicals, 
which play a critical role in induction of various forms of cancers 
(Cavalieri et al. 1978). DMBA is metabolized by cytochrome P4501A1 
and cytochrome P4501B1 in liver microsomes to form diol epoxides 
and other toxic ROS such as peroxides, hydroxyl and superoxide 
anion radicals. In the present study we have shown that DMBA 
exposure increases the ROS level during its in vivo metabolism. These 
results are in concurrence with the earlier studies performed on liver 
and other tissues in other laboratories (Kalra et al. 2005). The 
metabolites of DMBA including diol epoxides are capable of binding to 
adenine residues of DNA causing chromosomal damage (Guerin 1978). 
ROS play pivotal role in triggering apoptosis, the antioxidant 
deplete them to halt their activity (Schnabel et al. 2006 and Labriola 
1999). Our data demonstrate that apoptosis induced by DMBA, is 
accompanied by an increase in ROS generation. The observed 
inhibition of apoptosis in DMBA induced mouse hepatocytes is 
consistent with the view that tetrapeptide tuftsin deactivates apoptosis 
machinery. It seems, liposomised tuftsin induces Bcl-2 on one hand 
and suppression of Bax and Caspase-3 on other. The tuftsin 
treatment was found to be associated with the increase in the 
expression level PI3K and Akt, which inhibit the DMBA induced 
apoptosis. 
Mitochondrial transmembrane potential is often employed as an 
indicator of cellular viability, and its disruption has been implicated in 
a variety of apoptosis phenomena (Marchetti et al. 1996). 
Mitochondria outsource ROS during apoptosis and reduction of their 
membrane potential leads to increased generation of ROS and 
apoptosis (Zamzami et al. 1995). In the present study tuftsin restored 
the DMBA induced reduced mitochondria membrane potential and 
found to prevent normal cell death. 
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It has been shown that the Bcl-2 family plays an important 
regulatory role in apoptosis, either as activator (Bax) or as inhibitor 
(Bcl-2) (Liu et al. 2006, Green et al. 1998, Adams et al 1998). Since 
BC1-XL can bind to Bax and prevent Bax insertion into the outer 
membrane of mitochondria, the decrease in total and mitochondrial 
BC1-XL promotes the changes of Aipm. It has also been demonstrated 
that the gene products of Bcl-2 and Bax play important roles in 
apoptotic cell death (Jacobson et al. 1995, Jacobson et al. 1994, Oltvai 
1993). In the present study, inhibition of DMBA induced cell death by 
tuftsin in mouse liver can be associated with increased level of PI3K, 
AKT, Bcl-2, and decreased level of Bax and Caspase-3. Analysis of 
data indicates that tuftsin may increase the PI-3K and Akt level 
presumably by the activation of IL-6 inhibiting TGF-p that ultimately 
disturb the Bcl-2 and Bax level and, therefore, lead to decrease in 
apoptosis (Chen et al. 1999, Grannoth et al. 1997). 
Oxidative stress due to increased ROS levels coupled with 
deficiency of host antioxidant defense mechanism, might be a 
determining factor contributing in the development of cancer. To 
protect cells from oxidative stress, radical and non-radical reactive 
species including peroxides and superoxides need to be inactivated 
enzymatically by CAT, SOD, and GPx (Vang et al. 1993). Antioxidant 
enzymes provide the cellular defense against the intermediates of 
dioxygen reduction (superoxide radical, hydrogen peroxide and 
hydroxyl radicals). For example, SOD converts superoxide radicals 
into hydrogen peroxide, which in turn has to be removed by CAT and 
GPx. Thus, CAT and GPx protect SOD against inactivation by 
hydrogen peroxides. Reciprocally, SOD protects CAT and GPx from 
inhibition by superoxide radicals (Pigeolet et al. 1990). There was a 
significant decline in the activities of SOD and CAT after DMBA 
administration, indicative of oxidative stress. The reduced antioxidant 
enzyme activities in liver were prevented by the pretreatment of tuftsin 
liposomes (Table. 1). The protection provided by tuftsin liposomes is 
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possible through radicals scavenging of superoxide radicals and 
peroxyl radicals. GST perform functions ranging from catalyzing the 
detoxification of electrophilic species including metabolites of DMBA 
via spontaneous enzyme catalyzed conjugation reaction to protect the 
cells against peroxidative damage (Ishikawa et al. 1986). The reduced 
activity of GST observed upon DMBA administration may be partly 
due to the lack of its substrate (GSH) (Bhuvaneswari et al. 2005), 
which usually occurs due to reduced activity of GR. 
Lipid peroxidation is one of the main manifestations of oxidative 
damage initiated by ROS and it has been linked to the altered 
membrane structure and enzyme activation. It is initiated by the 
elimination of a hydrogen atom from the side chain of polyunsaturated 
fatty acids in the membrane (Bergendi et al. 1999). The present data 
reveal that DMBA exposure causes a marked oxidative impact as 
evident from the significant increase in lipid peroxidation. The 
increase in lipid peroxides might result from increased production of 
free radicals on one hand and a fall in antioxidant s ta tus on the other. 
Tuftsin liposomes significantly lowered lipid peroxidation and the 
values were comparable with that of the control animals. 
Finally, we can conclude that the present study may open novel 
prospective in cancer chemoprevention, mostly because of the fact 
that the central mechanism of apoptosis is evolutionarily conserved, 
and that ROS and Caspase activation is an essential step in this 
complex apoptotic pathway. The data also imply that mitochondrial 
cell death pathway can be used as target for studies on prevention of 
different type of cancer and that tuftsin merits further investigations 
for developing strategies for chemoprevention and chemotherapeutics. 
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Chemoprevention by liposomal DAS 
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4.1 . Introduction 
In contrast to dark skinned people whites are more prone to 
skin cancer and normally, one in five whites develops skin cancer 
during his or her life, and more than 97% of these are non-melanoma 
skin cancer (NMSC). Although NMSC has a low mortality, it is more 
common than all other cancers and has a higher incidence than lung 
cancer, breast cancer, prostate cancer, and colon cancer combined 
(American Cancer Society 2004). This "epidemic" h a s economic 
significance as well: The total cost of NMSC care in the United States 
is more than 600 million dollars per year (Chen et al. 2001). The rising 
incidence of NMSC is probably due to a combination of increased sun 
exposure, more frequent outdoor activities, changes in clothing style, 
increased longevity, and ozone depletion etc. Some studies suggest 
that development of NMSC, including basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC), may indicate increased risk for 
internal malignancy (Spratt 1999, Karagass et al. 1999). The use of 
alternatives to the medicines in the form of food and food products is 
an effective approach for the treatment of chronic diseases, including 
cancer. Thus, the intervention of chemopreventive strategies for 
controlling genetic diseases using dietary constituents provides a valid 
rationale to arrest or reverse the process of carcinogenesis before 
invasion and metastasis occur. During the past few years, cancer 
chemoprevention by dietary constituents has received a great deal of 
attention and as a means of effective cancer control (Pezzuto 1996). 
Studies on the tumor inhibitory compounds of plant origin have 
yielded an impressive array of novel chemical agents. Besides, 
epidemiological studies suggest that consumption of diets constituting 
fruits and vegetables may reduce the risk of cancer development (El-
Bayoumy et al. 1997, Reddy et al. 1997, Gescher et al. 1998). A 
number of dietary agents are also known to possess the anticancer 
properties against cancer cell lines and rodent bioassays at various 
sites including breast, prostate, colon and lung (Pezzuto 1996, 
158 
Chapter 4 Cbemoprevention 6y Rposomat<DflS 
Wargovich 1997, Gescher et al. 1998, Greenwald et al. 2001). These 
include green and black tea polyphenols, I3C, sulforaphane, vitamin 
D, vitamin E, selenium and calcium, pomegranate etc (Kelloff et al. 
1999). 
In the recent past, a great deal of attention has been devoted to 
organosulfur compounds from garlic for their potential 
chemopreventive properties (Fukushima et al. 1997, Pinto & Rivlin 
2001). Among these, diallyl sulfide (DAS) a sulfur containing volatile 
compound from garlic (Allium satiimm) has received considerable 
emphasis. Laboratory investigations provide sufficient evidence that it 
reduces the incidence of a multitude of chemically induced lung, skin, 
colon, esophageal and forestomach neoplasia (Wargovich et al. 1992; 
Hu et al. 1996a, Singh & Shukla 1999, Singh & Shukla 1998, Yang et 
al. 2001). It has also been shown to inhibit aflatoxin Bl and NDMA 
induced liver preneoplastic foci in rats (Haber-Mignard et al. 1996). 
Several in vitro studies have also demonstrated its inhibitory effects on 
the tumor cells (Hageman et al. 1997, Hong et al. 2000). It has been 
reported that the topical application of DAS inhibit the development of 
tumors in both complete and two-stage model of mouse skin 
carcinogenesis (Singh 85 Shukla 1999, Singh & Shukla 1998). DAS 
has also shown to possess antiproliferative effects on the growth of 
transplantable Ehrlich ascetic tumor cells and inhibit angiogenesis in 
Swiss albino mice (Shukla et al. 2002). A deeper insight revealed that 
DAS achieves its anticancer properties by modulating phase I and II 
detoxifying enzymes, scavenging of free radicals and abrogating their 
mutagenic potential (Prasad et al. 2006, Shukla et al. 2003, Smith et 
al. 2000, Yang et al. 2001 and Guyonnet 1999). 
Of the various options available for administration of medicaments, 
topical application is the most promising approach for treating skin 
tumors as it leads to localized effect at desired site with minimal side 
effects. However, retention of drugs administered by this mode is low 
because of extensive diffusion that is more apparent in case of small 
159 
Chapter 4 CHemoprevention by GposomaC<DJlS 
sized molecule such as DAS. This warrants development of 
formulations that can modulate pharmacokinetics as well as 
pharmacodynamic properties of DAS thereby making it more 
efficacious. 
Among various novel drug delivery systems, micro-particulate-
based carrier systems viz. micro-emulsion (Spiclin et al. 2003), nano-
emulsion (Jia-You et al. 2004), nanoparticles (Muller et al. 2002), 
liposomes (Betz et al. 2005, Kirjavainen et al. 1999), etc. have been 
reported to improve delivery of drug to the skin. Interestingly, 
liposome-based formulations, when employed for topical delivery, have 
been shown to be extremely promising for enhancement of drug 
penetration (Betz et al. 2005; Maestrelli et al. 2005, Cevc 1996), 
improved pharmacological effects (Sharma et al. 1994, Skalko et al., 
1998), decreased side effects, controlled drug release (Jia-You et al. 
2004) and above all their own biodegradable nature (Bhatia et al. 
2004, Drummond et al. 1999, Bally et al. 1998). 
(A) 
(B) 
CH2=CH-CH2-S-CH2-CH=CH2 
2 H C w ^TCH 2 
Figure 4 . 1 : (A) Garlic and (B) Chemical structure of diallyl 
sulfide (DAS) 
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The aim of the present study was to evaluate chemo-preventive 
action of liposome-based topical formulations of DAS against dimethyl 
benz (a) anthracene (DMBA)-induced skin cancer. DMBA, a polycyclic 
aromatic hydrocarbon (PAH), is a ubiquitous environmental pollutant 
that is generated during incomplete combustion of organic substances 
and known to have cytotoxic, mutagenic and carcinogenic effects in 
experimental animals as well as in humans (Guerin 1978, Dipple et al. 
1984). We incorporated DAS in lipid bilayer of egg phosphtidyl-choline 
(PC) liposomes to achieve its slow release for prolonged duration at the 
site of application (Harasym et al. 1997). To the best of our knowledge 
no report is available till date regarding usage of liposome-based 
formulation of DAS against any disease including skin cancer. The 
efficacy of DAS against cancer was further enhanced by incorporating 
it in pH-sensitive liposomes, which have potential to deliver 
encapsulated drug to the cytosol of the cancer cells. The data of the 
present study also revealed that liposomal DAS was found to regulate 
cell cycle factors more efficiently and eventually helped in increasing 
the chemo-preventive properties of DAS. 
4.2. Materials and Methods 
4 .2 .1 . Chemicals 
All the reagents used in the study were of the highest purity 
available. Cholesterol was bought from Centron Research Laboratory 
(Mumbai, India) and used after crystallizing it three times with 
methanol. Egg phosphtidyl-choline (PC) was isolated and purified 
following the published procedure (Singleton et al. 1965). DMBA, DAS, 
dioleoyl phosphatidyl ethanolamine (DOPE) and cholesteryl 
hemisuccinate (CHEMS) were purchased from Sigma Chemical Co (St. 
Louis, USA). Anti-p53 antibody specific for wild-type (wt) protein 
(clone PAb 1620, Ab-5), Anti-p53mut (clone PAb 240) and monoclonal 
p21/Wafl (Ab-1) antibody were purchased from Merck India Ltd. The 
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horseradish peroxidase-conjugated isotypes were obtained from 
Bangalore Genei (Bangalore, India). 
4.2.2. Preparation of DAS bearing PC as well as pH sensitive 
liposomes 
Egg PC liposomes were prepared from egg PC (49 |amol) and 
cholesterol (21 jimol), while pH-sensitive liposomes were prepared 
from DOPE (54 ^mol) and CHEMS (36 jmiol) liposomes using 
published method with some modifications as standardized in our lab 
(Owais et al. 1993). Briefly all the ingredients along with DAS 
(Drug:Lipid :: 1:40) were dissolved in a minimum volume of chloroform 
: methanol (1:1, V/V). The solvents were carefully evaporated under 
reduced pressure to form a thin lipid film on the wall of the round 
bottom flask. Finally, the traces of the organic solvents were removed 
by subjecting the flask to high vacuum overnight at 4 °C. 
Subsequently, the dried lipid film was hydrated with 2.0 ml of 150 
mM sterile saline with intermittent vigorous stirring followed by 
sonication (1 h, 4 °C) in a bath type sonicator under N2 atmosphere. 
The sonicated preparation was dialysed against normal saline for 24 
hour at 4 °C in the dark, and then centrifuged at 10,000 g for 1 h at 4 
°C to remove un-dispersed lipid. The liposomal preparations of DAS 
were used in treatment of DMBA induced skin cancer. 
4.2.3. Determination of intercalation efficiency of DAS in 
liposomes 
The intercalation efficiency of DAS in various formulations of 
liposomes was estimated by HPLC method (Khan et al. 2003). A 
standard curve of the drug was plotted at 271 nm by determining the 
area under curve corresponding to known (increasing) amount of the 
drug. The extent of DAS entrapped in liposome was calculated from 
the standard curve of the drug solution that was plotted for area 
under curve against corresponding amount of the DAS. The 
162 
Chapter 4 Cdemoprevention by bposoma[(DflS 
intercalation efficiency of DAS in egg PC liposome (Lip-DAS), pH-
sensitive liposome (pH-Lip-DAS) and escheriosomes (EC-Lip-DAS) 
formulations was found out to be 90 ± 4 percent and 96.4 ± 2.6 and 
98.2 ± 3 . 1 respectively. 
4.2.4. Animals 
Female Swiss albino mice of weight 22 ± 2 g were obtained from 
the institute's animal facility. The animals were kept in quarantine for 
the period of 1 week on a 12:12-h light-dark cycle and were given a 
standard pellet diet and water ad libitum. Animals were checked daily 
for their mortality and morbidity prior to commencement of the study 
and only healthy animals were included in the experiment. The 
techniques used for drug administration as well as sacrifice of animals 
were strictly performed following mandates approved by the Animal 
Ethics Committee (Committee for the purpose of control and 
supervision of Experiments on Animals, Govt, of India). 
4.2.4. Treatments 
Animals in the resting phase of hair cycle were taken for the 
study. Hairs of the animals were removed from the interscapular 
region over an area of 2cm2 using electric clippers that were not 
lubricated with any oil or grease. The skin of the shaven dorsal 
portion of the mice was exposed to DMBA (52 Dg in 200 ul acetone) 
that was applied topically three times a week for 12 weeks. All the 
formulations of DAS (250dg) were applied within 1 hour after 
exposure with DMBA three times a week for 12 weeks. The animals 
were divided into 9 groups each comprising 15 animals as follows: 
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Groups Treatment 
Group I Untreated Control (Normal) 
Group II DMBA + Acetone 
Group III DMBA + Cream 
Group IV DMBA + Sham PC liposomes in cream (Sham-Lip) 
Group V DMBA + Sham pH-sensitive liposomes in cream 
(Sham-pH-Lip) 
Group VI DMBA + Free DAS (DAS) 
Group VII DMBA + PC-DAS liposomes in cream (Lip-DAS) 
Group VIII DMBA + pH-sensitive-DAS liposomes in cream (pH-
Lip-DAS) 
Group IX Cream + (No DMBA) 
4.2.5 . Tumor measurements 
The diameters of the tumors were measured using a Vernier 
Caliper and the tumor volume was determined by the formula: 
V= D X d2 X 71/6, where V = tumor volume, D = biggest dimension, and 
d = smallest dimension. 
4.2.5. Preparation of nuclear fraction 
The skin/ tumor tissues were removed from experimental mice 
with sharp scalpel blades. The tissue samples were placed on ice and 
fat was scrapped off before further processing. Finally, the samples 
were homogenized and the nuclear fraction was prepared according to 
published method (Serpi et al. 1999). 
4.2.6. Western Blotting 
The nuclear fraction was analyzed for the presence of p53wt as 
well as p53mut using western blotting method (Towbin et al. 1979). 
Briefly, protein content of the homogenate was estimated by the 
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routine method using BSA as a standard (Lowry et ah 1951). Proteins 
(30(ag/well) were resolved under nondenaturing conditions on PAGE 
for p53wt and on 10 % SDS-PAGE gels for p53mut and electroblotted 
onto nitrocellulose membranes. The blots were blocked overnight with 
5% nonfat dry milk and probed with appropriate antibodies [i.e., anti-
p53wt (clone MAb 4H5), anti-p53mut (clone PAb 240) and monoclonal 
anti-p21/Wafl (Ab-1) antibody] at dilutions recommended by the 
suppliers. Immunoblots were detected by horseradish peroxidase-
conjugated anti-mouse IgG using chromagen 3, 3'-diaminobenzidine 
tetrahydrochloride. To quantify equal loading, membranes were 
reprobed with (3-actin antibody. Data are presented as the relative 
pixel density of each bands normalized to band of (3-actin. The 
intensity of the bands was quantitated using Alpha Image Analysis 
software on Alpha Image Gel Documentation System. 
4.3. Results 
In the present study we evaluated anticancer properties of 
various liposomal preparations of DAS. Both pH-sensitive as well as 
conventional egg PC liposomal formulations of DAS inhibited 
significant number of DMBA induced tumors incidences as compared 
to free form of DAS in model animals (Fig. 4.2). The liposomal DAS 
formulations were also successful in delaying onset of tumorogenesis. 
As depicted in Fig. 4.3, the onset of tumorogenesis was delayed for a 
period of more than one week in the mice treated with liposomal 
formulations (Lip-DAS or pH-Lip-DAS) formulations in comparison to 
animals that were treated with free form of DAS (p<0.01). Besides 
delaying onset of tumorogenesis, the treatment with both pH-sensitive 
as well as egg PC liposomes ensued in significant reduction in total 
numbers of DMBA induced papillomas. As shown in Fig. 4.4(A), the 
mean numbers of tumors per mouse were significantly reduced in the 
group of animals treated with Lip-DAS, (mean value 5.84, p<0.001) 
165 
Chapter 4 Chemoprevention by GposomaC<DjlS 
and pH-Lip-DAS, (mean value 3.91, p<0.001) in comparison with the 
animals treated with free form of DAS (mean value 10.6). 
We also measured regression in the tumor volume after 
treatment with various forms of DAS. The mean tumor volume per 
mouse was significantly lower in pH-Lip-DAS treated animals (62.42 
mm3 p<0.001) while it was 168.60 mm 3 (p<0.001) in Lip-DAS treated 
animals. The treatment with free form of DAS reduced mean tumor 
volume to 309.61 mm 3 (p<0.001). The mean tumor volumes recorded 
in the control animals (Gps II and III) were 1048.98 mm 3 and 1041.37 
mm3 respectively (Fig. 4.4B). The animals treated with Sham-Lip and 
Sham-pH-Lip (Gps. IV and V) had tumor dimensions of 984.99 and 
945.88 mm 3 respectively. 
Tumor growth inhibition was used as another parameter to 
assess efficacy of liposomised DAS against DMBA induced papilloma 
formation. The tumor growth inhibition, in comparison to the DMBA 
exposed untreated group, was 94 % (p<0.001) in the group of animals 
treated with pH-Lip-DAS, while it was 84 % in Lip-DAS treated 
animals. Free form of DAS could cause 70 % inhibition in tumor 
growth (Fig. 4.4C). 
The Kaplan-Meier curve (Fig. 4.5) shows the augmentation of 
anticarcinogenic effects of liposomised DAS against DMBA induced 
tumorogenesis in terms of survival of tumor free animals at different 
time intervals. Treatment with acetone, cream base, Sham-Lip, Sham-
pH-Lip and free DAS could not prevent tumor incidence in DMBA 
exposed animals. The liposomised DAS showed tremendous increase 
in chemo-preventive efficacy over its free form against DMBA induced 
tumorogenesis. The treatment caused -23 % and 34 % of animals 
completely free of tumor incidences upon treatment with Lip-DAS and 
pH-Lip-DAS respectively. 
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4.3 .1 . Western Blot analysis 
Exposure to carcinogen DMBA induced down-regulation of 
p53wt protein in the treated animals (Gp. II and Gp. Ill) in comparison 
with normal healthy mice (Gp. I, Fig. 5a, lanes 1, 2 and 3). Treatment 
with Sham-Lip and Sham-pH-Lip (Gp. IV and V) reduced DMBA 
induced downregulation of p53wt (although not significantly) in 
comparison to animals that were treated with acetone and cream (Gp. 
II and III). As depicted in Fig. 4.6(A), a comparatively high expression 
of p53wt protein was recorded in the animals treated with liposomal 
as well as free formulations of DAS (147 % increase in expression in 
the group of animals treated with pH-Lip-DAS, 84 % in the animals 
treated with Lip-DAS liposomes and 23 % in the animals treated with 
free form of DAS) over the group of animals treated with acetone and 
cream. This directly suggests that liposomal formulation of DAS plays 
a determining role in regulation of the expression of p53wt protein and 
inhibition of DMBA-induced neoplastic changes. The neat cream, used 
as a base in the preparation of various formulations, could not 
normalize p53wt expression in DMBA exposed mice. This observation 
was same in animals not given any kind of chemo-preventive 
treatment and hence rules out any ameliorating role of the cream 
base. Exposure of animals to DMBA ensued in upregulation of 
p53mut protein (Fig. 4.6B, lanes 2 and 3). Treatment with various 
forms of DAS aborted DMBA induced upregulation of p53mut. As 
depicted in the Fig. 4.6(B), the level of p53mut was reduced to normal 
level in the animals treated with pH-Lip-DAS. The treatment with Lip-
DAS ensued in 64 % reduction of p53mut level, while there was 40 % 
reduction in the animals treated with free form of DAS (Gp. IV). 
Surprisingly, treatment with Sham-Lip and Sham-pH-Lip (without 
DAS) also nullify DMBA induced over-expression of p53mut although 
not significantly. These results clearly show DAS mediated down-
regulation of p53mut, which was more apparent upon its intercalation 
in various forms of the liposomes used in the present study. 
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We also studied the effect of liposomised DAS on the expression 
of p21/Wafl , which got transcriptionally up-regulated in the presence 
of p53wt. Immunoblot analysis showed increased expression of 
p21/Wafl in liposomal DAS treated groups. As shown in Fig. 4.7, 
there was 93 % increase in the expression of p21/wafl in the group of 
animals treated with pH-Lip-DAS, while 66 % increment recorded in 
the animals treated with Lip-DAS liposomes (Gp. V), and 46 % 
increase occured in the group of animals treated with free form of DAS 
when compared with the DMBA exposed animals that were treated 
with acetone and cream. 
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Figure 4.2: Swiss albino mouse (Shaved dorsal skin) 
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Figure. 4.3.1: Skin with tumors in mice exposed to DMBA 
followed by Acetone. 
Figure. 4.3.2: Skin with tumors in mice exposed to DMBA 
followed by Cream. 
Figure. 4.3.3: Skin with tumors in mice exposed to DMBA 
followed by Sham-Lip. 
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Figure. 4 .3 .4: Skin with tumors in mice exposed to DMBA followed 
by Sham-pH-Lip 
Figure. 4 .3 .5: Skin with tumors in mice exposed to DMBA followed 
by Free DAS. 
Figure. 4.3.6: Skin with tumors in mice exposed to DMBA followed 
by Lip-DAS. 
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Figure. 4.3.7: Skin with tumors in mice exposed to DMBA followed 
by pHLip-DAS. 
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Figure. 4 .4 : Chemo-preventive effect of various formulations of DAS 
on onset of mouse skin tumorogenesis. 
I, Un t r ea t ed Cont ro l (Normal); II, DMBA + Ace tone ; III, DMBA + 
Cream; IV, DMBA + Sham-Lip; V, DMBA + Sham-pH-Lip; VI, DMBA + 
Free DAS; VII, DMBA + Lip-DAS; VIII, DMBA + pH-Lip-DAS; IX, Cream 
base only. a p<0.01 (free DAS), b p<0.001 (Lip-DAS and pH-Lip-DAS) 
v e r s u s vehicle control groups (II-V), c p<0.001 (pH-Lip-DAS a n d Lip-
DAS) v e r s u s free DAS (VI). 
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Figure. 4.5(A): Effect of liposomised DAS mediated chemo-
prevention on the development of average number of tumors per 
mouse. 
I, Untreated Control (Normal); II, DMBA + Acetone; III, DMBA + 
Cream; IV, DMBA + Sham-Lip; V, DMBA + Sham-pH-Lip; VI, DMBA + 
Free DAS; VII, DMBA + Lip-DAS; VIII, DMBA + pH-Lip-DAS; IX, Cream 
base only. »p<0.001 (free DAS, Lip-DAS, pH-Lip-DAS) versos vehicle 
control groups (II-V), *p<0.001 (Lip-DAS and pH-Lip-DAS) versus free 
DAS, cp< 0 .01 (pH-Lip-DAS) versus Lip-DAS. 
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Figure. 4.5(B): Chemo-preventive effects of various formulations of 
DAS on average tumor size. 
The chemo-preventive efficacy of various forms of DAS was 
assessed by measuring size of the tumors using a caliper. I, 
Untreated Control (Normal); II, DMBA + Acetone; III, DMBA + Cream; 
IV, DMBA -i- Sham-Lip; V, DMBA + Sham pH-Lip; VI, DMBA + Free 
DAS; VII, DMBA + Lip-DAS; VIII, DMBA + pH-Lip-DAS; IX, Cream base 
only. *p<0.001 versus vehicle controls (II-V), bp<0.001 (Lip-DAS and 
pH-Lip-DAS) versus free DAS. cp<0.001 (pH-Lip-DAS) versus Lip-DAS. 
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Figure. 4.5(C): Percent-inhibition of tumor growth by various 
formulations of DAS. 
The tumor growth inhibition was calculated by comparing the 
average size of the tumor induced in animals that were treated with 
vehicle controls. ap<0.001 versus (Free DAS). bp<0.001 versus Lip-
DAS. 
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Figure. 4.6: Effect of various formulations of DAS on survival of 
tumor-free animals. 
Kaplan-Meier curve showing effect of various formulations of DAS 
in terms of percentage of tumor free animals at different time 
intervals. The analysis was made on weekly basis. 
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Figure. 4.7(A): Effect of various formulations of DAS on the 
expression of p53wt in mouse skin tumors. 
Lane 1, untreated; lane 2 , DMBA + Acetone; lane 3 , DMBA + Cream; 
lane 4 , DMBA + Sham-Lip; lane 5, DMBA + Sham-pH Lip; lane 6, 
DMBA + Free DAS; lane 7, DMBA + Lip-DAS; lane 8, DMBA + pH-Lip-
DAS and lane 9, Cream base only with no DMBA. 
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Figure. 4.7(B): JS#ect o / various formulations of DAS on the 
expression of p53mut in mouse skin tumors. 
Lane 1, untreated; lane 2, DMBA + Acetone; lane 3, DMBA + Cream; 
lane 4, DMBA + Sham-Lip; lane 5, DMBA + Sham-pH Lip; lane 6, 
DMBA • Free DAS; lane 7, DMBA + Lip-DAS; lane 8, DMBA + pH-Lip-
DAS and lane 9, Cream base only with no DMBA. 
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Figure. 4.8: Effect of various formulations of DAS on the expression 
ofp21/Wafl in mouse shin tumors. 
Lane 1, untreated; lane 2, DMBA + Acetone; lane 3, DMBA + Cream; 
lane 4, DMBA + Sham-Lip; lane 5, DMBA + Sham-pH-Lip; lane 6, 
DMBA + Free DAS; lane 7, DMBA + Lip-DAS; lane 8, DMBA + pH-Lip-
DAS and lane 9, Cream base only with no DMBA. 
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4.4. Discussions 
A considerable emphasis is being laid upon the use of dietary 
constituent DAS, an organosulphur compound of garlic, to prevent 
and cure cancer in rodent tumor models (Arora et al. 2006, Prasad et 
al. 2006, Arora et al. 2004, Yang et al. 2001, Pinto et al. 2001, Singh 
et al. 1999, Singh et al. 1998, Haber et al. 1996, Wargovich et al. 
1988, Sparnins et al. 1988). Although effective, the chemo-preventive 
properties of DAS are far from ideal to make it a potential future 
chemo-preventive agent against skin cancer. The small size of the 
molecule probably results in poor accumulation and did not allow 
attainment of effective therapeutic concentration at the tumor site. 
Earlier studies showed that localized drug delivery to the site of skin 
tumor could be significantly enhanced through the use of liposome-
based drug carriers (Betz et al. 2005; Maestrelli et al. 2005, Cevc 
1996). The present study focuses on evaluation of chemo-preventive 
efficacy of DAS upon its incorporation in egg PC as well as pH-
sensitive liposomes and their potential against skin cancer in model 
animals. 
The data of the present study establish higher efficacy of both 
Lip-DAS (conventional egg PC) and pH-Lip-DAS (pH-sensitive) 
liposomes, which was assessed on the basis of their ability to delay 
onset of tumor induction, reduction in total numbers of tumor 
papilloma formation and survival of the treated animals etc. Lip-DAS 
liposomes showed an efficient (84%) suppression of tumor growth, 
while its pH-sensitive liposomal formulation was found to be more 
effective and induced around 94 % tumor suppression (as comparison 
to the untreated control group). This clearly suggests that 
liposomisation offers a new and effective option to increase the chemo-
preventive and anticarcinogenic potential of DAS in cancer therapy. 
The increased efficacy of liposomised DAS could be attributed to the 
fact that liposomes act as sustained release system allowing greater 
accumulation of drug molecules at the tumor site than that achieved 
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by its free form (Fang et al. 2005, Dayan et al. 2000, El et al. 2001 and 
Harasym et al. 1997). 
The liposomised diallyl sulfide exerts its chemo-preventive 
action by modulating apoptotic factors present in the cytosol of the 
cancer cells therefore its access to the cytosol is crucial for anticancer 
activity. The pH-sensitive liposomes were found to be more effective as 
compared to egg PC liposome as former release their contents into 
cytoplasm of the target cells following their degradation in endo-
lysosomal compartment. In fact, pH sensitive liposomes undergo 
phosphatidyl-ethanolamine (main constituent of these liposomes) 
mediated phase transition at acidic pH, thereby delivering their 
content to the cytosol of the tumor cells. The polar head group of PE 
gets less hydrated as compared to repulsive hydration layer associated 
with the head group of PC. Thus PE provides a more hydrophobic 
bilayer surface that is susceptible to energetically more favorable 
interbilayer interactions. The phospholipid not only facilitate the close 
approximation of bilayers, it may also be directly involved in the 
merging process. In this context PE can form the hexagonal Hn phase, 
the formation of which involves the development of non-lamellar 
structure an intermediate in membrane fusion. The operative 
mechanism seems to form the basis of the observed higher efficacy of 
pH sensitive liposomes over egg PC neutral liposomes (Sergio et al. 
2001, Yatvin et al. 1980). Moreover the higher effectiveness of pH-
sensitive liposome can also be justified on the premise that sites of 
greatest acidity in tumors are often most distant from the tumor 
microvasculature, incidentally conventional liposomes often fail to 
reach such locations (Huang et al 1992, Dellian et al 1996 and 
Helmlinger et al. 1997), while pH-sensitive liposomes overcome this 
problem. 
The usage of liposomes as carrier of anticancer agents including DAS 
has added advantage as fatty acyl chains of phospholipids may also 
impart anticancer effect against various cancers. For example, 
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liposomes composed of phosphatidylcholine (PC) with 18:0 in the sn-1 
position and one of the following fatty acids in the sn-2 position: 18:0, 
18:1 omega 9 (oleic), 18:3 omega 3 (alpha-linolenic), 20:4 omega 6 
(arachidonic), 22:6 omega 3 (docosahexaenoic) have been shown to 
possess antitumor effects in vivo, leading to enhanced longevity of the 
tumor-bearing host (Jenski et al 1995). It has been reported that 
polyunsaturated phosphatidylcholine (PC) and phosphatidylserine (PS) 
induce growth inhibition, differentiation and apoptosis in Caco-2 cells 
(Hossain et al. 2006). Our preliminary studies show that egg PC used 
in the present study is having 18: 0, 18: 1 and 16: 0, 16: 1 fatty acid 
analogs (data not shown). Similarly, pH-sensitive liposomes also 
contain 18: 1 oleic acids. Besides intrinsic anticancer effect of DAS, 
presence of unsaturated fatty acids in liposomes could also be 
considered as potential component to enhance anticancer property of 
DAS liposome formulation. The data of the present study shows some 
level of anticancer activity by sham liposome preparation (with no 
DAS). However the effect was not substantial and could be attributed 
to the fact that amount of the anticancer fatty acids present in various 
phospholipids used for preparation of liposomes never touched 
optimum threshold levels required for their anticancer effect, had we 
used phospholipids that were exclusively consisted of fatty acyl chains 
with potent anticancer activity. Nevertheless, the present study clearly 
advocates the notion that in future studies we can always use tailor-
made phospholipids which are equipped with desired fatty acyl chains 
having intrinsic anticancer properties. This will certainly make 
liposome-based formulations potential candidate for drug delivery 
system against cancer including skin papilloma. 
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Figure 4.9: Potential fate of pH-sensitive liposome upon 
interaction with target cell. 
Upon approaching to a target cell, liposomes can remain bound at the 
cell surface, accumulate in coated or non-coated invaginations or 
internalized by receptor mediated uptake. In acidic environment of 
endo-lysosomal compartment, pH sensitive phospholipids of liposome 
undergo phase transition (bilayer to Hn form) and fuse with endo-
lysosome membrane thereby releasing their contents directly into the 
cytoplasm of the target cell, (a), liposomes can be delivered to 
lysosomes (c) where they and their contents may be degraded by 
lysosomal peptidases and hydrolases. Following acidification of the 
endosomal lumen, pH-sensitive liposomes are designed to either fuse 
with the endosomal membrane (e), releasing their contents directly into 
the cytoplasm, or become destabilized and subsequently destabilize the 
endosomal membrane (d) resulting in leakage of the endosomal 
contents into the cytosol. Receptors may be recycled back to the cell 
surface (b) or targeted for degradation in the lysosome (c). enhance 
anticancer property of DAS liposome formulation. The data of the 
present study shows some level of anticancer activity by sham liposome 
preparation (with no DAS). However the effect was not substantial and 
could be attributed to the fact that amount of the anticancer fatty 
acids present in various phospholipids used for preparation of 
liposomes never touched optimum threshold levels required for their 
anticancer effect, had we used phospholipids that were exclusively 
consisted of fatty acyl chains with potent anticancer activity. 
Nevertheless, the present study clearly advocates the notion that in 
future studies we can always use tailor-made phospholipids which are 
equipped with desired fatty acyl chains having intrinsic anticancer 
properties. This will certainly make liposome-based formulations 
potential candidate for drug delivery system against cancer including 
skin papilloma. 
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In the next phase of study, we deliberated effect of liposomised DAS 
on various cell cycle regulating factors. The tumor suppressor gene 
p53 is regarded as a key factor in maintaining the balance between 
cell growth and cell death (Agarwal et al. 1998, Mowat et al. 1998). We 
have earlier reported DAS mediated modulation of p53 in DMBA-
induced skin tumors in Swiss albino mice (Arora et al. 2004). The 
importance of p53 gene can be drawn from the fact that this gene is 
mutated in -80% of all human malignancies (Hollstein et al. 1991). 
Because of its role in regulation of cell cycle, alterations in p53 levels 
are critical in carcinogenesis. High levels of activated and stabilized 
p53 protein accumulate in the nucleus in response to various forms of 
cell stresses, including DNA damage (Vousden et al. 2002, Levine et al. 
1991). Several nuclear localization signals in the C-terminus of p53 
facilitate its transport to the nucleus where it is required in regulation 
of transcription. Having entered the nucleus, regulatory mechanisms 
exist to control the export of p53 back out to the cytoplasm, which is 
required for the degradation of p53 (Stommel et aZ.1999). Activated 
p53 can induce cell cycle arrest, DNA repair processes, and apoptosis. 
These cellular outcomes are thought to minimize the accumulation of 
deleterious mutations that could eventually contribute to a given 
malignant phenotype (Lane 1992). Keeping above facts into 
consideration the role of p53 in the cytoplasm is clearly secondary to 
its nuclear function, and nuclear localization is essential for p53 
activity. Indeed failure of wild type p53 to localize to the nucleus, 
either due to defects in the ability to enter the nucleus or hyperactive 
nuclear export, appears to contribute to the inactivation of p53 in a 
number of tumors (Stommel et al. 1999, Sengupta et al. 2000 and Lu 
et al. 2000). In tumors, loss of p53wt prevents the activation of this 
growth control pathway (Burns et al. 1991). The failure to induce 
transcriptionally active p53wt plays a role in the unregulated growth 
of the tumors (el-Deiry 1994). Because the balance between p53wt 
and p53mut determines the fate of the cell, many chemo-preventive 
agents are known to exert their anticancer effects by modulating 
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expression level of these molecules (Schwartz et al. 1999 and Schwartz 
et al. 1993). The results of the present study showed liposomal 
formulations of DAS in increased up-regulation of p53wt and down-
regulation of p53mut. In fact, it is the intrinsic property of DAS to 
modulate the balance between wild and mutated p53 protein 
expression. The effect of DAS on p53wt and p53mut gets more 
apparent upon its liposomisation in neutral as well as pH-sensitive 
liposomes. 
The up-regulation of p53wt by chemo-preventive agents is also 
responsible for the transcriptional induction of p21/Wafl by directly 
interacting with its regulatory elements (el-Deiry et al. 1994). As 
observed in the present study, liposomisation of DAS in egg-PC or pH-
sensitive liposomes ensued in up-regulation of p21/Waf 1 as 
compared to free form of the drug. The effect is more prominent in pH-
sensitive liposomes as compared to neutral egg PC liposomes. 
As the composition of the liposome is similar to the components of cell 
membranes, they are likely to get absorbed by skin (Gregoriadis 1994). 
To further increase the effect, we formulated cream-based liposomal 
formulations of DAS, which ought to impart better retention and 
penetration of the compound. When a liposome-bearing gel or cream 
is applied to the skin, the deposited liposomes begin to merge with the 
cellular membranes. In the process, the liposomes release their 
payload of active materials into the cells. As a consequence, not only 
does this ensue in specific drug delivery of the active form of the drug 
directly into the target cells, the delivery also takes place over a longer 
period of time (Padamwar et al. 2006). 
The observed better efficacy of liposomised DAS can be attributed to 
the liposome-mediated enhanced penetration, retention and 
accumulation of the drug at the tumor site. Finally we conclude that 
liposomal formulations of DAS can be a promising strategy for cancer 
treatment. Liposomal formulations not only overcome higher 
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elimination of the drug from tumors, rather ability of liposome to 
accommodate several thousand molecules in single vesicle entity that 
in turn help in maintaining the effective drug concentration at the 
tumor site. 
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5.1. Introduction 
Besides limiting the boundary of cell, the plasma membrane 
plays many important biological functions (Voet et al. 1999). Several 
evidences advocate that the composition of membrane is crucial for 
various physiological activities that rely on membrane-membrane 
fusion viz., fertilization, phagocytosis, exocytosis, and cell division etc. 
(White 1992, Voet et al. 1999). In fact, the membranous organelles 
present in the cytoplasm are part of a dynamic network where 
molecules are shuttled back and forth from one part of the cell to 
another. Most of these shuttling pathways involve the process of 
membrane-membrane fusion. For instance, the secretory or exocytic 
pathways in which materials are synthesized in endoplasmic 
reticulum or Golgi complex, and are transported to various 
destinations like plasma membrane, lysosomes or vacuoles etc. and 
the endocytic pathways, which operate in opposite direction where 
materials move from exterior of the cell to sub-cellular compartments 
such as endosomes or lysosomes (Andrews and Johnson, 1996, Emr 
and Malhotra 1997), there is crucial role of bilayer lipid structure. 
Inter-compartmental transport has been extensively studied in 
cell free system (Vidal and Hoekstra 1995). Most of these studies 
suggest that biological molecules such as proteins and nucleotides 
take active part in the distinct interaction steps that are crucial for 
various transport events (Sztul et al. 1992, Takizawa et al. 1993, Pley 
et al. 1993). Intracellular trafficking is governed by heterotrimeric G-
proteins, SNAP, NSF, and SNARE etc. (Sollner et al. 1993). 
Investigations into the molecular events involved in the membrane-
membrane fusion have mainly focused on the role of proteins in the 
process and no effort has been made in revealing involvement of lipid 
components in the fusion events. Inspite of the fact that proteins 
determine the specificity of biomembrane fusion, their role in the 
induction of membrane fusion is doubtful. This could be justified on 
the premise that the central event during membrane fusion is the 
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merger of two membranes which requires a transient reorganization of 
membrane lipids into highly curved fusion intermediates. Importantly, 
the local-point fusion concept also applies to pure lipid model 
membrane fusion, where electron micrographs revealed the presence 
of very small fusion intermediates, 'lipid particles', suggesting a 
common lipidic intermediate in model and biological membrane fusion 
(Verkleij et al. 1979, Verkleij 1986). The fact, that membrane fusion is 
a local point event implies that fusion events also require a local 
restructuring of the interacting lipid bilayers, and that relatively few 
lipid molecules (hundred to a few thousand), are directly involved in 
the fusion process. Moreover, the marked variation in lipid 
compositions of the primitive and evolved organisms on one hand, and 
energy driven intricate mechanisms operative in the maintenance of 
membrane lipid asymmetry in higher eukaryotes on the other, 
suggests the important role of lipids in various membrane related 
processes (c/. membrane-membrane fusion). For example, the 
asymmetric distribution of lipids between two leaflets of the plasma 
membrane of erythrocytes is quite apparent, where outer leaflet 
contains the bulk of sphingomyelin and PC (both bilayer forming 
neutral lipids) while the inner leaflet has preponderance of PS, PI and 
PE (Sollner et al. 1993, Williamson et al. 1985, Kumar and Gupta 
1983). 
Membrane fusion requires close apposition and coalescence of a 
small area of the lipid bilayers. A progressive force is required to drive 
two bilayers closer than 3 nm together (Helm and Israelachvili, 1993). 
According to the proposed models, at the membrane fusion site, two 
forces dominate, a repulsive hydration force arising from water, tightly 
bound to the lipid headgroups, and an attractive hydrophobic force 
between the hydrocarbon interiors of the membranes. At a pressure of 
about 100 atm, the attractive hydrophobic force locally bypasses the 
repulsive hydration force resulting in the semi-fusion of the bilayers. 
Introduction of membrane defects exposes more of the membrane 
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interior and substantially reduces the pressure required for semi-
fusion. This is likely to be a general theme in most of the membrane 
fusion events. During biomembrane fusion, defects in membrane lipid 
packing could arise from extreme membrane curvature, local changes 
in lipid composition, or the insertion or de-insertion of a stretch of 
hydrophobic amino acids (Blumenthal et al. 1998, White 1992, Bentz 
2000). 
With few exceptions (Shangguan et al. 1996, Bonnafous and 
Stegmann 2000), membrane fusion is envisaged as a 'non-leaky' 
process that involves three distinct stages: membrane adhesion, semi-
fusion, and pore formation (Fig. 5.1). At the semi-fusion stage of 
membrane fusion, the outer (cis-) lipid monolayers of the two 
membranes are continuous but the inner (trans-) lipid monolayers are 
still separated. Experimental support for the existence of a semi-
fusion intermediate in both model and biological membrane fusion 
has been obtained (Lentz and Lee 1999, Razinkov et al. 1999). Two 
main molecular models have been proposed for the semi-fusion 
intermediate. In both models, the semi-fusion intermediate has a 
strong net negative (concave) monolayer curvature. In the first model, 
two membranes join to form an inverted lipid micelle at the semi-
fusion stage (Verkleij 1984), while the second, and currently prevailing 
model, predicts the formation of a so-called stalk (Markin et al. 1984). 
In a modification of the stalk model (Siegel 1993 8B 1999), the stalk 
develops into a trans-monolayer contact, which is short-lived and 
ruptures resulting in the formation of a small pore (Fig. 5.1). It is 
important to note that the evaluation of the different models of 
membrane fusion is dominated by theoretical considerations, and that 
direct data on the structure and composition of the fusion 
intermediates (in the end in biomembrane fusion) are absolutely 
required before a definite answer concerning the molecular nature of 
the semi-fusion intermediate can be given. Nonetheless, the stalk 
mechanism is compatible with a wide range of observations on model 
membrane fusion, and there is increasing evidence that similar 
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intermediates, with a net negative monolayer curvature, mediate 
biomembrane fusion (Chernomordik 1996). 
5.1.1. The role of lipids in biomembrane fusion 
Patch clamp analysis, reveal that the early fusion pore is often 
reversibly open and close several times. Lipids play a key role in the 
induction of biomembrane fusion for several reasons that leads to 
formation of initial transient pore (Monck and Fernandez 1996, 
Lindau and Aimers 1995). Proteins are not an absolute prerequisite 
for membrane fusion; pure lipid model membranes can be induced to 
fuse in the absence of added proteins. Moreover, important 
characteristics of biomembrane fusion such as capacitance flickering 
are also observed in pure lipid model systems, and the activation 
energies of the molecular rearrangements involved appear to be very 
similar (Lee and Lentz 1998). Finally, low (sublytic) concentrations of 
lysolecithin (LPC) have shown to inhibit model membrane as well as 
biomembrane fusion in an efficient and reversible manner. This 
activity of LPC was also observed in biological systems as different as 
the low pH-induced fusion of virus-infected cells, and exocytosis in 
patch-clamped mast cells or isolated sea urchin cortices 
(Chernomordik 1996). 
Hence, all these examples especially the later suggests that both 
model and biological membrane fusion events involve a lipidic 
intermediate with a net negative monolayer curvature. Together, these 
findings support the notion that the membrane lipid composition is an 
important determinant of the willingness of a membrane to fuse, and 
suggest that specific lipid species may play an active role in the local 
destabilization and fusion of the membranes. For example, it was 
demonstrated earlier that LPC, a micelle-forming ('type-I') lipid, was 
involved in biomembrane fusion (Lucy 1978). However, recent data 
have shown that lysophospholipids do not stimulate but inhibit model 
and biological membrane fusion. Moreover, acidic phospholipids, 
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especially phosphatidic acid (PA) and phosphatidylserine (PS), have 
also been proposed to play a central role in the induction of 
biomembrane fusion but in conjunction with Ca2+ (Papahadjopoulos et 
al. 1990). 
On the other hand, inverted non-bilayer-preferring lipids ('type-
II lipids') have been proposed to play a key role in biomembrane fusion 
(Verkleij et al. 1979). In contrast to type-I lipids, which are virtually 
absent from biomembranes, type-II lipids are present in significant 
amounts in almost every biomembrane (De Kruijff et al. 1985, Epand 
1998). One of the non-bilayer lipid phases formed by these lipids is 
the inverted hexagonal-II (Hn) phase. Almost any biological membrane 
contains lipids that upon isolation will form a Hn-phase under 
physiological ionic strength, pH and temperature. Examples are the 
unsaturated phosphatidylethanolamines (PEs) present in all 
eukaryotic membranes (in the plasma membrane, typically 25 mol% of 
total phospholipid, of which 80% is present in the cytosolic leaflet). 
The lipid molecules in the Hii-phase are organized in hexagonally 
arranged cylinders, with the polar headgroups lining a central 
aqueous channel (Fig. 5.2). The tendency of type-II lipids to form 
inverted non-bilayer lipid structures can be explained by considering 
their overall dynamic shape (Israelachvili et al. 1980, Cullis et al. 
1986). While, 'type-II lipids' are cone-shaped; they have a small 
headgroup area as compared with the cross-sectional area of the acyl 
chains, 'type-I' lipids, such as most lysophospholipids, have an 
inverted cone shape, while bilayer-preferring lipids are best described 
as having the shape of a cylinder. 
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Figure 5.1: Pathway of the fusion of phospholipid bilayer 
membrane. 
After contact, an initial local connection {stalk), composed of 
lipids from the contacting leaflets of each membrane, initiates 
fusion. Thinning of the stalk results in a single bilayer [local 
hemifusion), composed of the distal leaflets of each membrane 
(transmonolayer contact). If there is a reservoir for excess lipid 
and the energy of hydrophobic void spaces where hydrophobic 
sides of lipid monolayers peel apart is not high, local hemifusion 
can extend to form a large, trilaminar structure [extended 
hemifusion). This structure can be stable indefinitely or develop a 
small pore [initial fusion pore). Alternately, the initial fusion pore 
can develop directly from local hemifusion. Once formed, the 
initial fusion pore can close or rapidly widen to form a semi-
stable fusion pore composed of coplanar bilayer membrane. 
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Figure 5.2: Shape-structure of lipid polymorphism. 
Unsaturated fatty acids, ceramide, diacylglycerol and 
cholestrol do not themselves form Hn phase, but 
promote Hn phase formation in mixed-lipid system 
(Israelachvili et at 1980, Cullis et al. 1986) 
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The type-II lipids are forced to remain in the lipid bilayer, in a 
situation which is often referred to as 'frustration'. In prokaryotes 
where the lipid composition of the membrane can be easily 
manipulated, the ratio of bilayer to non-bilayer preferring lipids was 
shown to be under strict metabolic control, indicating that propensity 
of the membrane to form 'type II' structures is of great importance for 
their cellular functions (Rietveld et al. 1993, Osterberg et al. 1995). 
Interestingly, the total lipid extract of several biological membranes 
forms and Hn-phase upon hydration, suggesting that, in vivo, these 
membranes will be eager to form non-bilayer lipid structures such as 
those involved in membrane fusion. Thus, it can be presumed that the 
willingness of a biomembrane to fuse may partly be determined by the 
ratio of bilayer to non-bilayer-preferring lipids present in the 
membrane. Most of the biomembranes contain large amounts of type-
II lipids on one hand, and a correlation exists between their presence 
and membrane fusion activity in model systems on the other. This 
leads to the conclusion that type-II lipids are attractive candidates for 
a direct involvement in biomembrane fusion. By virtue of their low 
headgroup hydration, type-II lipids would be expected to enhance 
membrane adhesion by reducing the hydration repulsion, while their 
negative curvature preference should facilitate the formation of highly 
curved concave semi-fusion intermediates and stimulate membrane 
fusion. The idea that biomembrane fusion may take advantage of the 
phase-preference of type-II lipids is supported by studies on the lipid 
dependency of biomembrane fusion. 
A difference has been observed between the lipid compositions 
of eukaryotic and prokaryotic plasma membranes. While the 
prokaryotic plasma membrane {e.g. in bacteria) is mainly composed of 
amino-phospholipids along with cardiolipin and phosphatidylglycerol 
(Rattray 1988, Krishnan et al. 2000a), eukaryotes contain all classes 
of phospholipids distributed in the outer as well as inner leaflets of the 
bilayer, where the amino phospholipids are mainly confined to the 
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inner leaflet and play a major role in exocytosis, which involves 
membrane-membrane fusion (Voet et at 1999). The unique lipid 
composition in lower organisms could be a strategy to cope with the 
high multiplication rate of the microbes, as such lipids facilitate the 
fusion of the two opposite sites of inner leaflets (e.g. due to Ca2+ 
binding) under physiological conditions and earlier studies revealed 
the fusion potential of lipids from Saccharomyces cerevisiae (Bakers 
yeast) (Owais & Gupta, 2000). Similar to the other lower organisms 
(e.g. yeast), membrane lipid composition of Escherichia coli exhibits a 
great majority of anionic phospholipids that may play a pivotal role in 
membrane-membrane fusion (Pluschke and Overath 1981). Hence, 
the aim of the present study was to find out the fusogenicity of 
liposomes made up of E. coli lipids (escheriosomes) and their ability to 
deliver the entrapped molecules to the cytosol of the target cells. 
In the present study, fusogenic properties of E. coli lipids have 
been demonstrated employing routine membrane fusion assays. The 
liposomes comprised of lipids extracted from Escherichia coli 
(escheriosomes) were found to fuse with the plasma membrane and 
thereby successfully deliver encapsulated substances to the cytosol of 
the target cells. Finally, the study was devised to evaluate chemo-
preventive action of topical cream based formulations of DAS bearing 
escheriosomes (EC-Lip-DAS) against dimethyl benz (a) anthracene 
(DMBA)-induced skin cancer. The data of the present study also reveal 
that EC-Lip-DAS was found to regulate cell cycle factors more 
efficiently and eventually helped in increasing the chemo-preventive 
properties of DAS in comparison to its free as well as egg PC liposome 
(conventional liposome) intercalated form. 
5.2. Materials and Methods 
5.2.1. Animals 
Female Swiss albino mice weighing 18 ± 2 g were obtained from 
institute's animal facility. The animals were given a standard pellet 
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diet (Hindustan Lever Ltd.) and water ad libitum. Animals were 
checked daily for their mortality and morbidity prior to 
commencement of the study and only healthy animals were included 
in the experiment. The techniques used for bleeding, injection as well 
as sacrifice of animals were strictly performed following mandates 
approved by the institute's Animal Ethics Committee (Committee for 
the purpose of control and supervision of Experiments on Animals, 
Govt, of India). 
5.2.1. Chemicals 
All the reagents used in the study were of the highest purity 
available. Egg PC was isolated and purified from hen egg yolk 
following the published procedure (Owais et at 1993). Cholesterol was 
bought from Centron Research Laboratory, Mumbai, India and used 
after crystallizing three times with methanol. Calcein (Alfa division of 
Ventron Corp. Denver, MA) was kind gift from Dr. G.C. Varshney (IMT. 
Chd. India). Peptone and Yeast extract was from Hi Media 
Laboratories, Bombay, while Dextrose was from S.D. Fine Chemicals, 
Boisar, India. DMEM, HBSS and FCS were obtained from Life 
Technologies (Grand Island, NY). Deglycosylated ricin A, Imidazole, 
Percoll, Sephadex G-50, Sepharose 6B, and EDTA were from Sigma 
Chemical Company (St. Louis, MO). ANTS and DPX were bought from 
Molecular Probes, Inc. The fluorescent probes, NBD-PE as well as Rh-
PE (Avanti polar lipids) were kind gift from Dr. Anu Puri (NIH, 
Frederick, MD). Anti-IAd, anti-Mac 2 and anti-L3T4 were the gifts 
from Dr. Gyan Mishra (NCBS, Pune, India). [125I] Sodium-iodide 
(carrier free), [35S] L-methionine and [51Cr] sodium-chromate were 
bought from Bhabha Atomic Research Center, Trombay, India. 
Lysozyme was radio iodinated using the published method (15). J 774 
A.l, a macrophage cell line was procured from American Type Culture 
Collection (Rockville, MD) and was grown in DMEM (pH 7.2) 
containing L-glutamine (4mM), sodium pyruvate (110 mg/1), penicillin 
(100 U/ml), streptomycin sulfate (100 ng/ml) and sodium bicarbonate 
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(3.7 g/1) in 75 ml plastic bottles (Costar, MA, USA) at 37°C under 7.5% 
CO2. Anti-p53 antibody specific for wild-type (wt) protein (clone PAb 
1620, Ab-5), Anti-p53mut (clone PAb 240) and monoclonal p21/Wafl 
(Ab-1) antibody were purchased from Merck India Ltd. The 
horseradish peroxidase-conjugated isotypes were obtained from 
Bangalore Genei (Bangalore, India). 
5.2.2. E. coli lipids 
E. coli K12 was cultured in nutrient broth ( 1 % peptone, 0.3 % 
Beef extract, 0.3 % Yeast extract and 1 % Sodium chloride; pH 7.4 ). 
The cells were harvested from mid-log phase (18-20 h). Phospholipids 
were isolated by the method of Bligh Dyer, as modified by Kumar and 
Gupta (1983). The lipid composition was found to be as follows: PE: 
82±1.2, PG: 13.8±0.8, CL: 4.2±0.6 (Kumar and Gupta 1983). 
5.2.3. Lipids vesicles 
Large unilamellar vesicles (LUVs) were prepared essentially by 
the freeze-thaw method as described previously (Hayward et al. 1985). 
The outer diameter of these vesicles was «160 ± 50 nm as revealed by 
electron procroscopical method. LUVs for RET experiments were 
formed using E. coli lipids (or EPC/chol), NBD-PE and Rh-PE in a 
molar ratio of 98.4 : 1 : 0.6 in the presence of 2mM CaCb. For the 
aqueous content mixing experiments, which involves the fusion of two 
different types of liposomes, LUVs were prepared by hydrating E. coli 
lipids or EPC/chol (15 |imol lipid) with 1.5 mL of 10 mM Tris/HCI (pH 
7.5), containing ANTS (25 mM) and NaCl (40 mM) or DPX (90 mM) and 
2mM CaCl2. The entrapped ANTS (or DPX) from free ANTS (or DPX) 
was separated by gel filtration using a Sephadex G-50 column. 
Dried reconstituted vesicles (DRVs) were formed as described 
previously (Kirby and Gregoriadis, 1984). Finally, free flowing, 
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lyophilized, dried powder was re-hydrated with distilled water and 
reconstituted in phosphate buffer saline (1M PBS, pH 7.2). The 
preparation was centrifuged at 14 OOOx g and the pellet was washed at 
least three times with PBS to remove traces of the un-entrapped 
solute. 
5.2.4. Erythrocyte membrane vesicles 
Erythrocytes from fresh human blood were isolated by removing 
the plasma and buffy coat. The cells were lysed by treating with lysis 
buffer and then resealed after washing three times with the isotonic 
PBS as described elsewhere (Williamson et al. 1985). The prepared 
erythrocyte membrane vesicles were then pelleted at 1200x g (15 min, 
4 °C). After washing several times, the preparation was resuspended in 
PBS for further use. 
5.2.5. Resonance energy transfer (RET) assay 
The lipid mixing between the NBD/rhodamine-labeled E. coli 
lipids (or EPC/chol) LUVs («600 nmoles lipid) and unlabeled E. coli 
lipid (or EPC/chol) LUVs was followed by monitoring RET (Struck et al. 
1981) between NBD (absorption, 470 nm; emission, 520 nm) and 
rhodamine (absorption, 536 nm; emission, 585 nm) in the presence of 
2mM CaCb. The excitation wave length was chosen to be 20 nm below 
the absorption maxima of NBD so as to allow a better resolution 
between the scattered light peak and the NBD emission peak, and also 
to minimize the direct excitation of rhodamine. Finally the 
fluorescence was monitored at 520 nm. The efficiency (E) of RET was 
calculated as follows: 
E = 1 - F/Ft where 'F is the NBD fluorescence in the presence of 
rhodamine, and 'Ft' is the NBD fluorescence at maximal dequenching, 
which was measured after disrupting the vesicles with Triton X-100 
(1% final concentration). 
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5.2.6. Aqueous contents mixing assay 
Quenching of the ANTS fluorescence by DPX was observed in 
order to follow the mixing of the aqueous contents of the vesicles 
undergoing fusion (Ellens et al. 1985). The ANTS-containing LUVs 
were mixed with a 10-fold excess of the DPX-containing LUVs in a 
total volume of 3 mL. The mixture was incubated at 37 °C and the 
ANTS fluorescence was measured at varying periods of time. The ANTS 
fluorescence observed at zero minute was taken as 100% fluorescence, 
while the fluorescence values taken after lysing a mixture of ANTS-
containing and DPX-containing LUVs with Triton X-100 (1% final 
concentration) were taken as 0 % fluorescence. The excitation and 
emission wavelengths used were 380 nm and 540 nm, respectively. 
5.2.7. Macrophage-Escheriosomes interaction 
The interaction of the macrophages with the escheriosomes was 
observed by transfer of fluorescently-labeled membrane markers from 
the vesicles to the macrophages. Membranes of liposomes were 
fluorescently labeled by incorporating calcein in the vesicles (£. coli 
lipid liposomes) in the presence of 2mM CaCfo. The J774 A. 1 cells (1 x 
106) were cultured overnight on a sterile cover slip in complete DMEM 
medium containing 10% foetal bovine serum. The cells were washed 
with incomplete DMEM and incubated at 4 °C for 2 h. After washing 
once with incomplete DMEM, the cells were then pulsed with calcein-
labeled liposomes (600 pmol lipid) and incubated for 60 min in 
incomplete DMEM (FBS free) at 37 °C in the presence of 2mM CaCl2. 
The fixed macrophages were observed under a Leitz fluorescence 
microscope at 100 x magnification, using an 13 filter. 
5.2.8. Intracellular localization of lysozyme 
DRVs loaded with 125I-labeled lysozyme (~4 x 105 c.p.m.Trig 
protein1) were used in these experiments. J774 A.l cells (5 x 106 
cells-well1) were cultured in six-well plates and incubated for 1 h at 37 
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°C with lipid vesicles. The cells were washed with PBS followed by 
fixation with 1% paraformaldehyde solution. The cells were then 
detached off the culture plates using chilled Versene solution. Finally, 
to determine the intracellular distribution of labeled lysozyme, the 
cells were broken by a nitrogen cavitation method using a Parr bomb 
(Wileman et al. 1984) before centrifuging them at 750x g for 15 min. 
The supernatant was further centrifuged at l,00,000x g for one hour 
at 4 °C using Beckman L8-55 M ultracentrifuge. The pellet was 
suspended in 3.0 mL of imidazole buffer (3 mM imidazole, 0.25 M 
sucrose; pH 7.4), and then fractionated into the plasma 
membrane/ nucleus, cytosol, endosome/lysosome, and other 
organelles. The purity of each fraction was determined on the basis of 
enzyme marker assays, as described previously (Wileman et al. 1984). 
5.2.9. Inhibition of the protein synthesis in the macrophages by 
escheriosomes encapsulated ricin A 
J774 A.l cells (1 x 106 cells-well1) were cultured in a 24-well 
plate overnight at 37 °C. Next day cells were incubated separately with 
three different forms of the toxin viz.; free 'ricin A', 'ricin A' 
encapsulated in EPC/chol DRVs or 'ricin A' encapsulated in E. coli 
lipid DRVs at 37 °C for 1 h. The cells were washed, and then pulsed 
with [35S]L-methionine (1 jiCi-welH) in a total volume of 200 liL-well-1 
for 2 h at 37 °C. The cells were washed twice with DMEM including 
2mM CaCb and were treated with 7 M guanidine (50 fiL-well1). The 
final volume was made up to 200 (iL-welH with PBS. The suspension 
was vortexed, and small aliquot (20 nL) from the cell lysate was 
withdrawn in eppendorff tubes. The lysate was treated with 
trichloroacetic acid (25%, 100 JJL) and BSA (1%, 50 |iL) and then 
centrifuged. The precipitate was washed once with 10% 
tricholoroacetic acid and counted for ^-emission in a RackBeta 
Scintillation Counter, after suspending in 10 mL of scintillation fluid. 
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5.2.10. Preparation of DAS bearing PC as well as EC liposomes 
Egg PC liposomes were prepared from egg PC (49 jj.mol) and 
cholesterol (21 ^mol), while escheriosomes using published method 
with some modifications as standardized in our lab (Owais et al. 
1993). Briefly all the ingredients along with DAS (Drug:Lipid :: 1:40) 
were dissolved in a minimum volume of chloroform : methanol (1:1, 
V/V). The solvents were carefully evaporated under reduced pressure 
to form a thin lipid film on the wall of the round bottom flask. Finally, 
the traces of the organic solvents were removed by subjecting the flask 
to high vacuum overnight at 4 °C. Subsequently, the dried lipid film 
was hydrated with 2.0 ml of 150 mM sterile saline with intermittent 
vigorous stirring followed by sonication (1 h, 4 °C) in a bath type 
sonicator under N2 atmosphere. The sonicated preparation was 
dialysed against normal saline for 24 hour at 4 °C in the dark, and 
then centrifuged at 10,000 g for 1 h at 4 °C to remove un-dispersed 
lipid. The liposomal preparations of DAS were used in treatment of 
DMBA induced skin cancer. 
5.2.11. Determination of intercalation efficiency of DAS in 
liposomes 
The intercalation efficiency of DAS in various formulations of 
liposomes was estimated by HPLC method (Khan et al. 2003). A 
standard curve of the drug was plotted at 271 nm by determining the 
area under curve corresponding to known (increasing) amount of the 
drug. The extent of DAS entrapped in liposome was calculated from 
the standard curve of the drug solution that was plotted for area 
under curve against corresponding amount of the DAS. The 
intercalation efficiency of DAS in egg PC liposome (Lip-DAS), pH-
sensitive liposome (pH-Lip-DAS) and escheriosomes (EC-Lip-DAS) 
formulations was found out to be 90 + 4 percent and 96.4 ± 2 . 6 and 
97.8 ± 2.9 respectively. 
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5.2.12. Treatments 
Animals in the resting phase of hair cycle were taken for the 
study. Hairs of the animals were removed from the interscapular 
region over an area of 2cm2 using electric clippers that were not 
lubricated with any oil or grease. The skin of the shaven dorsal 
portion of the mice was exposed to DMBA (52Dg in 200 Dl acetone) 
that was applied topically three times a week for 12 weeks. All the 
formulations of DAS (250Dg) were applied within 1 hour after 
exposure with DMBA three times a week for 12 weeks. The animals 
were divided into 9 groups each comprising 15 animals as follows: 
Groups 
Group I 
Group II 
Group III 
Group IV 
Lip) 
Group V 
Group VI 
Group VII 
Group VIII 
Treatment 
Untreated Control (Normal) 
DMBA + Cream 
DMBA + Sham PC liposomes in cream (Sham-Lip) 
DMBA + Sham EC liposomes in cream (Sham-pH-
DMBA + Free DAS (DAS) 
DMBA + PC-DAS liposomes in cream (Lip-DAS) 
DMBA + EC-DAS liposomes in cream (EC-Lip-DAS) 
Cream + (No DMBA) 
5.2.13. Tumor measurements 
The diameters of the tumors were measured using a Vernier 
Caliper and the tumor volume was determined by the formula: 
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V= DX cP X TI/6, where V= tumor volume, D = biggest dimension, and 
d = smallest dimension. 
5.2.14. Preparation of Nuclear Fraction 
The skin/ tumor tissues were removed from experimental mice 
with sharp scalpel blades. The tissue samples were placed on ice and 
fat was scrapped off before further processing. Finally, the samples 
were homogenized and the nuclear fraction was prepared according to 
published method (Serpi et al. 1999). 
5.2.15. Western Blotting 
The nuclear fraction was analyzed for the presence of p53wt as 
well as p53mut using western blotting method (Towbin et al. 1979). 
Briefly, protein content of the homogenate was estimated by the 
routine method using BSA as a standard (Lowry et al. 1951). Proteins 
(30|ig/well) were resolved under nondenaturing conditions on PAGE 
for p53wt and on 10 % SDS-PAGE gels for p53mut and electroblotted 
onto nitrocellulose membranes. The blots were blocked overnight with 
5% nonfat dry milk and probed with appropriate antibodies [i.e., anti-
p53wt (clone MAb 4H5), anti-p53mut (clone PAb 240) and monoclonal 
anti-p21 /Waf 1 (Ab-1) antibody] at dilutions recommended by the 
suppliers. Immunoblots were detected by horseradish peroxidase-
conjugated anti-mouse IgG using chromagen 3,3'-diaminobenzidine 
tetrahydrochloride. To quantify equal loading, membranes were 
reprobed with p-actin antibody. Data are presented as the relative 
pixel density of each bands normalized to band of p-actin. The 
intensity of the bands was quantitated using Alpha Image Analysis 
software on Alpha Image Gel Documentation System. 
5.3. Results 
5.3.1. Escheriosomes fusion with model membrane systems. 
5.3.1.1. Luv-Luv Fusion 
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The potential of the Escheriosomes to induce membrane-
membrane fusion was assessed by monitoring the mixing of the lipids. 
The fusion efficiency was determined by measuring RET between NBD 
(photon donor, absorption at 470 nm, emission at 520 nm) and 
rhodamine (photon acceptor, absorption at 540 nm, emission at 585 
nm). These probes NBD-PE and Rh-PE were grafted on the LUV 
surface prepared by EPC/chol or E. coli lipids. The LUVs containing 
these two fluorophores (labeled vesicles) were diluted with increasing 
amounts of LUVs free of these fluorophores (unlabeled vesicles). The 
efficiency of RET was calculated by measuring the NBD fluorescence, 
as described in materials and methods. As the efficiency of RET 
between these fluorophores has been shown to depend on their 
concentration in the vesicle bilayer (Duzgunes et al. 1991), it was 
expected that any fusion between the labeled and unlabeled LUVs 
would lead to dilution of the probes and consequently in the reduction 
of the RET efficiency. Unlike the EPC/chol-LUVs, the RET in the case 
of the E. coli lipid LUVs decreased with an increase in the incubation 
time as well as with the ratio of the labeled to unlabeled LUVs. We 
observed that the efficiency decreasing to -40% when the 
unlabeled/labeled ratio was 10 (Fig. 5.3. Furthermore, the repetition 
of the same experiment with the liposomes that were prepared with 
the reconstituted E. coli lipids [the lipids viz. 
phosphatidylethanolamine, phosphatidylglycerol and cardiolipin were 
isolated by preparative thin layer chromatography, and reconstituted 
in the liposomes in the same ratio 
(phosphatidylethanolamine/phosphatidylglycerol/cardiolipin, 82:14:4) 
as that of their abundance in the plasma membrane] produced more 
or less same fusion efficiency as determined by the RET assay (Fig. 
5.3). 
The membrane fusion potential of the bacterial lipids was further 
validated by observing the mixing of the aqueous contents during 
fusion by measuring quenching of the ANTS fluorescence by the water 
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soluble quencher DPX. Incubation of the ANTS containing E. coli lipid 
LUVs with a 10-fold excess of DPX containing LUVs resulted in =60% 
quenching of the ANTS fluorescence in 30 min (Fig. 5.4). However, no 
such quenching of the ANTS fluorescence was observed when ANTS-
containing EPC/chol-LUVs were incubated with a 10-fold excess of the 
DPX-containing EPC/chol-LUVs under identical conditions. 
5.3.1.2. LUVs-erythrocyte membrane fusion 
Fusion of the escheriosomes with the erythrocyte membrane 
vesicles was studied by including a self-quenching concentration (5 
mol %) of NBD-PE (Hoekstra et al. 1984) in the E. coli lipids or 
EPC/chol-LUV's bilayer. The NBD fluorescence dequenching was 
measured by fluorometry, subsequent to the fusion of these LUVs with 
the erythrocyte membrane vesicles. Unlike theEPC/chol -LUVs, E. coli 
lipid LUVs readily fuse with erythrocyte membrane vesicles, leading to 
=60% dequenching of the NBD fluorescence in a time dependent 
manner (Fig. 5.5). 
5.3.2. Escheriosome fusion with the target cells. 
5.3.2.1. Escheriosome mediated transfer of membrane 
fluorescent marker (calcein) to the macrophages. 
The fusion potential of the E. coli lipid was also confirmed by 
observing transfer of fluorescent membrane marker (calcein) from 
escheriosomes to the living cells. For this purpose, the E. coli lipid 
DRVs containing calcein (in the presence of 2mM CaCb) in the 
bilayers were allowed to interact with J774 A. 1 cells. The transfer of 
calcein fluorescence from DRVs to the membranes of macrophages 
was analyzed by fluorescence light microscopy. The results 
demonstrated that interaction with E. coli lipid liposomes resulted in a 
diffuse pattern of fluorescence (Fig. 5.6). 
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5.3.2.2. Intracellular distribution of 125I-Lysozyme. 
To analyze the interactions between escheriosomes and J774 
A. 1 cells, these cells were incubated with 125I-labelled lysozyme-
encapsulated escheriosomes. The intracellular distribution of lysozyme 
was measured as described in materials and methods. Approximately 
18% of the total cell-associated 125I-labelled lysozyme was localized in 
the cytosolic portion of the macrophages that were incubated with the 
E. coli lipids-DRVs loaded with 125I-labelled lysozyme (Table 5.1). In 
contrast, only < 1% of the radioactivity could be detected in the 
cytoplasmic compartment of the cells that received treatment with the 
125I-labelled lysozyme loaded EPC/chol-DRVs. These results suggest 
that the E. coli lipids DRVs possess a strong fusogenic character that 
enables them to deliver the entrapped solutes into the cytosolic 
compartment of the antigen presenting cells. 
5.3.2.3. Inhibition of the macrophage protein synthesis by ricin 
A. 
The J774 A.l cells were incubated with DRVs loaded with the 
toxin 'ricin A'. Without the B chain, 'ricin A' is incapable of entering 
the cytosolic compartment of the target cells (Endo, et al. 1987). Any 
effect on the macrophage protein synthesis of the ricin A-loaded DRVs 
should confirm the membrane fusion as one of the modes of the E. coli 
lipid DRVs-macrophage interactions. Our results indicate that, unlike 
its free or EPC/chol DRVs encapsulated form, 'ricin A' entrapped in 
the escheriosomes effectively inhibited protein synthesis in the 
macrophages in a dose-dependent manner (Fig. 5.7). 
Next we evaluated the efficacy of anticancer properties of DAS in 
escheriosomes (EC-Lip-DAS) in comparison to free as well as Lip-DAS. 
The EC-Lip-DAS formulations inhibited significant number of DMBA 
induced tumor incidences as compared to Lip-DAS in model animals 
(Fig. 5.8). The escheriosomes-DAS formulations were also successful 
in significantly delaying onset of tumorogenesis in comparison to Lip-
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DAS. The onset of tumorogenesis was delayed for a period of more 
than a week in the mice treated with EC-Lip-DAS formulations 
(Fig.5.9) in comparison to animals that were treated with Lip-DAS 
(p<0.01). Furthermore the treatment with EC-Lip-DAS resulted in 
significant reduction in total numbers of DMBA-induced papillomas 
(Fig. 5.10). The mean numbers of tumors per mouse were significantly 
reduced (Fig. 5.10A) in the group of animals treated with EC-Lip-DAS 
(mean value 2.53, p<0.001) in comparison with the animals treated 
with Lip-DAS (mean value 5.84) and free form of DAS (mean value 
10.6). 
The regression in the tumor volume after treatment with various 
forms of DAS was also measured. The mean tumor volume per mouse 
in EC-Lip-DAS treated animals was 38.18 mm3 (p<0.001) while it was 
168.60 mm3 (p<0.001) in Lip-DAS treated animals and in case of 
animals treated with free DAS, 309.60 mm3 (p<0.001). The mean 
tumor volumes recorded in the control animals (Gps II) were 
991.37.648 mm3 (Fig. 5.10B). The animals treated with Sham-Lip and 
Sham-EC-Lip (Gps. IV and V) had tumor dimensions of 984.99 and 
920.68 mm3 respectively. 
We also measured tumor growth inhibition assess efficacy of 
liposomised DAS against DMBA induced papilloma formation. The 
tumor growth inhibition, in comparison to the DMBA exposed 
untreated group, was 96.2 % (p<0.001) in the group of animals treated 
with EC-Lip-DAS, while it was 83 % in Lip-DAS treated animals. Free 
form of DAS could cause 69 % inhibition in tumor growth (Fig. 5.10C). 
The Kaplan-Meier curve (Fig. 5.11) shows the augmentation of 
anticarcinogenic effects of liposomised DAS against DMBA induced 
tumorogenesis in terms of survival of tumor free animals at different 
time intervals. Cream base, Sham-Lip, Sham-EC-Lip and free DAS did 
not prevent tumor incidence in DMBA exposed animals. The EC-Lip-
DAS showed a very high increase in chemo-preventive efficacy over 
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Lip-DAS and free form of DAS against DMBA induced tumorogenesis. 
The treatment caused -23 % and 34 % of animals completely free of 
tumor incidences upon treatment with Lip-DAS and EC-Lip-DAS 
respectively. 
5.3.3. Western Blot analysis 
DMBA induced down-regulation of p53wt protein in animals 
exposed to it (Gp. II) in comparison with normal healthy mice (Gp. I, 
Fig. 4.12A, lanes 1, 2 and 3). Treatment with Sham-Lip and Sham-EC-
Lip (Gp. Ill and IV) reduced DMBA induced downregulation of p53wt 
(although not significantly) in comparison to animals that were treated 
with cream (Gp. II). As depicted in Fig. 5.12A, a comparatively high 
expression of p53wt protein was recorded in the animals treated with 
EC-Lip-DAS in comparison to Lip-DAS as well as free DAS. An 
increase of 165 % was observed in the group of animals treated with 
EC-Lip-DAS, 87 % in the animals treated with Lip-DAS liposomes and 
35 % in the animals treated with free form of DAS) over the group of 
animals treated with acetone and cream. Thus EC-Lip-DAS also 
appears to play a determining role in regulation of the expression of 
p53wt protein and inhibition of DMBA-induced neoplastic changes. 
DMBA caused in upregulation of p53mut protein (Fig. 5.12B, lanes 2 
and 3) in exposed animals. Treatment with various forms of DAS 
aborted DMBA induced upregulation of p53mut. As depicted in the 
Fig. 5.12B, the level of p53mut was reduced to normal level in the 
animals treated with EC-Lip-DAS. The treatment with Lip-DAS ensued 
in 64 % reduction of p53mut level, while there was 40 % reduction in 
the animals treated with free form of DAS (Gp. IV). Surprisingly, 
treatment with Sham-Lip and Sham-EC-Lip (without DAS) could also 
nullify DMBA induced over-expression of p53mut although not 
significantly. These results clearly show DAS mediated down-
regulation of p53mut, which was more apparent upon its intercalation 
in escheriosomes used in the present study. 
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We also studied the effect of various formulations of DAS on the 
expression of p21/Wafl, which gets transcriptionally up-regulated in 
the presence of p53wt. Immunoblot analysis showed increased 
expression of p21/Wafl in liposomal DAS treated groups. As shown in 
Fig. 5.13, there was 108 % increase in the expression of p21/wafl in 
the group of animals treated with EC-Lip-DAS, while 63 % increment 
recorded in the animals treated with Lip-DAS liposomes (Gp. V), and 
43 % increase occured in the group of animals treated with free form 
of DAS when compared with the DMBA exposed animals that were 
treated with acetone a 
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Figure 5.3: Time courses. 
Time dependent effect on the efficacy of RET between NBD and 
rhodamine grafted on the LUVs surface upon mixing the labeled 
LUVs with increasing amounts of unlabeled LUVs (in the presence 
of2mMCaCl2 ). 
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Time (min) 
Figure 5.4: Time courses. 
Time dependent quenching of the ANTS flurescence by mixing the 
ANTS-containing LUVs with DPX-containing LUVs in a ratio of 
1:10 EPC/chol; E.coli lipids LUVs. Values are the mean of three 
independent experiments ± SD. 
214 
Chapter 5 <E. coli lipidr basedfusogenic liposomes: cHemo-preventive potential against cancer 
20 30 40 
Time (mm) 
Figure 5.5: Time dependent interactions of the NBD-labeled E.coli 
lipid LUVs with the erythrocyte membrane vesicles. 
E. coli lipid (or EPC/chol) LUVs (750nmol lipid/ml) containing 5 
mol % NBD-PE in their bilayers were interacted with right side-
out erythrocyte membrane vesicles (~ 108 vesicles/ml) CaCbat 37 
°C for varying periods of time. The NBD fluorescence was 
monitored up to 60 min incubation, using excitation and 
emission wavelengths of 470 nm and 520 nm respectively. The 
percentage of NBD dequenching was calculated as follows: 
Percentage dequenching = 100 x (F - F0) / F t - F0) 
Where F, F0 and Ft are the fluorescence intensities at time *t% 0 
min, and after adding Triton X-100 (1 % final concentration), 
respectively. Time dependent NBD-fluoresce nee dequenching 
upon interaction of NBD-labeled LUVs with erythrocyte membrane 
vesicles. 
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(A) (B) 
Figure 5.6: Fluorescence light micrographs of the macrophages 
(J774 A.l) after their interaction with escheriosome encapsulated 
calcein. (A). Fluorescence light micrograph showing diffuse 
fluorescence pattern and (B) Phase contrast micrograph 
J774 A.1 cells were cultured on sterile coverslips overnight. The 
cells were washed with serum free media and incubated with 
escheriosome encapsulated calcein for 60 min at 37 °C in the 
presence of 2mM CaCb. 
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Table 5 .1: Subcellular distribution of 1 2 5I-lysozyme introduced in 
J 7 7 4 A. l cel ls using E. coli lipid DRVs as carriers. 
Values are means of three different experiments ± SD. 
Lipid ves ic les 
EPC/Chol 
E. coli l ipids 
Percent distribution of radioactivity 
Plasma 
membrane 
/ nucleus 
44.9 ± 1.6 
42.4 ± 2 . 4 
Cytosol 
0.6 ± 0 . 4 
18.2 ± 1.2 
Endosome/ 
lysosome 
48.9 ± 4 . 5 
35.2 ± 1.6 
Other organell-es 
5.8 ± 1.2 
4.2 ± 0.9 
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Figure 5.7: Escheriosomes mediated cytosolic delivery of 'ricin 
A'. 
Inhibition of cellular protein synthesis by 'ricin A" after J774 A. 1 
cells were interacted with ricin A-loaded E. coli lipid DRVs CaCfe. 
Values are the mean of three independent experiments ± SD. 
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Figure. 5.8: Skin with tumors in mice exposed to DMBA followed 
by EC-Lip-DAS. 
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Figure. 5.9: Cherno-preventive effect of various formulations of 
DAS on onset of mouse skin tumorogenesis. 
I, Untreated Control (Normal); II, DMBA + Cream; III, DMBA + 
Sham-Lip; IV, DMBA + Sham-EC-Lip; V, DMBA + Free DAS; VI, 
DMBA + Lip-DAS; VII, DMBA + EC-Lip-DAS; VIII, Cream base only. 
ap<0.01 (free DAS), bp<0.001 (Lip-DAS and pH-Lip-DAS) versus 
vehicle control groups (IITV), «p<0.001 (EC-Lip-DAS and Lip-DAS) 
versus free DAS (VI). 
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Figure. 5.10(A): Effect of liposomised DAS mediated 
chemoprevention on the development of average number of 
tumors per mouse. 
I, Untreated Control (Normal); II, DMBA + Cream; III, DMBA + 
Sham-Lip; IV, DMBA + Sham-EC-Lip; V, DMBA + Free DAS; VI, 
DMBA + Lip-DAS; VII, DMBA + EC Lip DAS; VIII, Cream base only. 
ap<0.001 (free DAS, Lip-DAS, EC Lip-DAS) versus vehicle control 
groups (II V), bp<0.001 (Lip-DAS and EC-Lip-DAS) versus free DAS, 
cp< 0.001 (EC-Lip-DAS) versus Lip-DAS. 
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Figure. 5.10(B): Chemo-preventive effects of various formulations 
of DAS on average tumor size. 
The chemo-preventive efficacy of various forms of DAS was 
assessed by measuring size of the tumors using a caliper. I, 
Untreated Control (Normal); II, DMBA + Cream; III, DMBA + Sham-
Lip; IV, DMBA + Sham-EC-Lip; V, DMBA + Free DAS; VI, DMBA 
+ Lip-DAS; VII, DMBA + EC-Lip-DAS; IX, Cream base only. 
»p<0.001 versus vehicle controls (II-V), bp<0.001 (Lip-DAS and EC-
Lip-DAS) versus free DAS. cp<0.001 (EC-Lip-DAS) versus Lip-DAS. 
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Figure. 5.10(C): Percent-inhibition of tumor growth by various 
formulations of DAS. The tumor growth inhibition was calculated by 
comparing the average size of the tumor induced in animals that were 
treated with vehicle controls. ap<0.001 versus (Free DAS). bp<0.001 
versus Lip-DAS. 
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Figure. 5.11: Effect of various formulations of DAS on survival of 
tumor-free animals. 
Kaplan-Meier curve showing effect of various formulations of DAS 
in terms of percentage of tumor free animals at different time 
intervals. The analysis was made on weekly basis. 
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Figure. 5.12(A): Effect of various formulations of DAS on the 
expression ofp53wt in mouse skin tumors. 
Lane 1, untreated; lane 2, DMBA + Cream; lane 3 , DMBA + Sham-
Lip; lane 4, DMBA + Sham-EC-Lip; lane 5, DMBA + Free DAS; lane 
6, DMBA + Lip-DAS; lane 7, DMBA + EC-Lip-DAS and lane 8, 
Cream base only with no DMBA. 
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Figure. 5.12(B): Effect of various formulations of DAS on the 
expression ofp53mut in mouse skin tumors. 
Lane 1, untreated; lane 2 , DMBA + Cream; lane 3 , DMBA + Sham-
Lip; lane 4, DMBA + Sham-EC-Lip; lane 5, DMBA + Free DAS; lane 
6, DMBA + Lip-DAS; lane 7, DMBA + EC-Lip-DAS and lane 8, 
Cream base only with no DMBA. 
226 
Chapter 5 <E. cod Ctpid-basedfusogenic liposomes: chemo-preventwe potential against cancer 
p21AVafl 
[\ -actin 
8 
» 0.8 
8 0.6 -
Figure. 5.13: Effect of various formulations of DAS on the 
expression ofp21/wafl in mouse skin tumors. 
Lane 1, untreated; lane 2, DMBA + Cream; lane 3, DMBA + Sham-
Lip; lane 4, DMBA + Sham-EC-Lip; lane 5, DMBA + Free DAS; lane 
6, DMBA + Lip-DAS; lane 7, DMBA + EC-Lip DAS and lane 8, 
Cream base only with no DMBA. 
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Discussion 
The existing drug delivery systems are usually associated with 
toxicity, cumbersome preparation methodology and cost factors 
(Wijburg et al. 1998, Holzer et al. 1996). The E. coli lipid liposomes 
(escheriosomes) used in the present study seem to have addressed 
most of these problems and emerged as an alternate delivery system 
capable of inducing desired cytotoxic response to cancer cells. The 
fusogenic potential of escheriosomes was demonstrated by RET assay 
experiments. The 'probe dilution' method is known to be insensitive to 
vesicle aggregation (Duzgunes et al. 1987). Furthermore, the 
fluorescent probes employed (viz. NBD and rhodamine) have been 
shown not to undergo any exchange between the phospholipid vesicles 
(Kok et al. 1991). We infer that the observed decrease in the RET 
efficiency is due to vesicle-vesicle fusion (Fig. 5.3). This was further 
confirmed by a content mixing assay where ANTS-encapsulating 
escheriosomes were shown to undergo membrane-membrane fusion 
with DPX (quencher) containing escheriosomes, which eventually led 
to the mixing of fluorescent probe and quencher resulting in decreased 
fluorescence (Fig. 5.4). Moreover, such a fusion phenomenon is not 
restricted to the model membrane only and natural membranes such 
as erythrocyte vesicles can also fuse with the escheriosomes that 
resulted in transfer of the fluorescent probe to the erythrocyte 
membrane (Fig. 5.5). Finally, the potential of escheriosomes to 
undergo fusion with living cells was demonstrated by epifluorescence 
microscopy. The results shown in Fig. 5.6 demonstrated that transfer 
of the fluorescent probe to the membrane of the target cells after 
interaction with E. coli lipid liposomes follows an endocytosis mode 
and resulted in a diffuse fluorescence pattern. 
To further confirm that membrane-membrane fusion 
constitutes a major role in the escheriosome interaction with the J774 
A.l cells, we studied the effect of 'ricin A' on macrophage protein 
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synthesis. The J774 A. 1 cells were incubated with DRVs loaded with 
the toxin. 'Ricin A' is the A chain of the plant toxin 'ricin' which 
consists of two disulfide-linked polypeptides, A and B. While the B 
chain is responsible for the binding of toxin to virtually all types of the 
cells, the cytotoxic activity resides in the A chain, which after 
translocating into the cytosol, inhibits the cellular protein synthesis by 
an effect on elongation factor 2. Without the B chain, 'ricin A' is 
incapable of entering the cytosolic compartment of the cell (Reddy et 
al. 1991). The observed inhibition of the protein synthesis suggests 
that escheriosome entrapped 'ricin A' readily breaches the membrane 
barrier to gain access to the cytoplasm of J 774 A. 1 cells even in the 
absence of ricin B (figure 5.7). 
To quantify the cytosolic delivery of macromolecules by the 
escheriosomes, we determined the distribution of radio-labeled 
lysozyme in different subcellular compartments. Although the major 
portion of the liposomes was directed to the endo/lysosomal 
compartments (Table 5.1), a substantial amount (»18%) was able to 
reach the cytosol of the interacting cells. On the contrary, using other 
delivery systems (e.g. pH sensitive liposomes) the delivery efficiency 
lies between 1 and 10% (Stegmann et al. 1989). 
The E.coli membrane lipid has preponderance of anionic 
phospholipids, which supposedly play important role in membrane-
membrane fusion (Harding et al. 1991). The phospholipid composition 
of most of the lower organisms have more or less same phospholipid 
contents, incidentally, these lipids were found to possess strong 
fusogenic properties to fulfil certain physiological demands of lower 
organisms, in terms of higher multiplication rate (Harding et al. 1991, 
Hayward et al. 1985, Fraker et al. 1978). The RET experiments 
involving reconstituted lipids clearly validate our hypothesis, that the 
anionic lipids play crucial role in the observed membrane-membrane 
fusion. 
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The next phase of the study focuses on evaluation of chemo-
preventive efficacy of DAS upon its incorporation in Escheriosomes 
and their potential against skin cancer in model animals. 
The data of the present study establish higher efficacy of EC-Lip-DAS 
(Escheriosomes) liposomes, which was assessed on the basis of their 
ability to delay onset of tumor induction, reduction in total numbers 
of tumor papilloma formation and survival of the treated animals etc. 
Lip-DAS liposomes showed an efficient (83%) suppression of tumor 
growth, while its EC liposomal formulation was found to be more 
effective and induced around 96.2 % tumor suppression (as 
comparison to the untreated control group). This clearly suggests that 
liposomisation offers a new and effective option to increase the chemo-
preventive and anticarcinogenic potential of DAS in cancer therapy. 
The observed better efficacy of EC-Lip-DAS over Lip-DAS can be 
attributed to the liposome-mediated enhanced penetration, retention 
and accumulation of the drug at the tumor site delivered into the 
cytosol. The escheriosomes undergo phosphatidyl-ethanolamine (main 
constituent of these liposomes) mediated fusion, thereby delivering 
their content to the cytosol of the tumor cells. The polar head group of 
PE gets less hydrated as compared to repulsive hydration layer 
associated with the head group of PC. Thus PE provides a more 
hydrophobic bilayer surface that is susceptible to energetically more 
favorable interbilayer interactions. The phospholipid not only facilitate 
the close approach of bilayers, it may also be directly involved in the 
merging process. In this context PE can form the hexagonal Hn phase, 
the formation of which involves the development of non-lamellar 
structure an intermediate in membrane fusion. The operative 
mechanism seems to form the basis of the observed higher efficacy of 
escheriosomes over egg PC neutral liposomes (Sergio et al. 2001, 
Yatvin et al. 1980). Finally we can conclude that the present study, 
beside providing a better insight about the evolutionary trend followed 
in distribution of lipids in plasma membrane of the living cells, offers a 
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promising approach for developing liposome based drug formulations 
against various forms of cancer. The data of the present study seems 
to open new vistas for the use of escheriosomes based drug 
formulations against various forms of cancer including skin 
papilloma. 
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Tuftsin Augments Antitumor Efficacy of Liposomized 
Etoposide against Fibrosarcoma in Swiss Albino Mice 
ArifKlmn,1 Aijaz A Khan2 Varun Dioivedi,2, Manzoor G Ahmad,2 Seema Hakeem,2 and Mohammad Ozoais1 
'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India; 2J N Medical College, Aligarh Muslim University, 
Aligarh, India 
Anticancer drugs are generally plagued by toxic manifestations at doses necessary for control of various forms of cancer. In-
corporating such drugs into liposomes not only reduces toxicity but also enhances the therapeutic index. Some antioxidants and 
potent immunomodulators have also been shown to impart significant antitumor activity presumably by nonspecific activation 
of the host Immune system. In the present study, we evaluated augmentation of the antitumor activity of etoposide (ETP) by the 
immunomodulator tuftsin in Swiss albino mice with fibrosarcoma. The efficacies of the free form of ETP, liposomized ETP (Llp-ETP), 
and tuftsin-bearlng liposomized ETP (Tuft-Up-ETP) formulations were evaluated on the basis of tumor regression, effect on ex-
pression level of p53wt and p53mut, and survival of the treated animals. Tuft-llp-ETP, when administered at a dosage of 10 
mg/kg body weight/day for five days, significantly reduced tumor volume, delayed tumor growth, and also up-regulated the 
expression of p53wt. In contrast, although Up-ETP delayed tumor growth, it did not decrease tumor size. The results of the pres-
ent study suggest that tuftsin incorporation in drug-loaded liposomes is a promising treatment strategy for various forms of can-
cers, including fibrosarcoma. 
Online address: http://www.molmed.org 
doi: 10.2119/2007-00018.Khan 
INTRODUCTION 
Etoposide (ETP), a derivative of 
podophyllotoxin, has been successfully 
employed as an antineoplastic agent 
against various forms of cancer. It causes 
cell death by forming a ternary complex 
with topoisomerase II and DNA ensuing 
breakage of DNA (1) and is active 
against multiple cell lines such as L929 
fibroblasts, HL-60/K562, A549 human 
lung carcinoma cells (2^1). It is a part of 
the first-line therapy for small-cell lung 
carcinoma (5), malignant lymphoma (6), 
and drug-resistant testicular cancer (7). 
Unfortunately, ETP causes dose-limiting 
hematological (8) as well as gastroin-
testinal toxicity when administered 
orally (9). Furthermore, the lipophilic 
nature of ETP poses difficulty in devel-
opment of drug formulations; as a con-
sequence different solubilizers are gener-
ally used as co-additives to develop suit-
able ETP formulations (10). These addi-
tives are often associated with adverse 
effects such as hypotension, anaphylaxis, 
and bronchospasm (8,11). 
Taking into consideration toxicity con-
straints associated with most of the avail-
able chemotherapeutic agents, including 
ETP, many workers have successfully 
used liposome-based delivery systems to 
circumvent these problems (12,13-17). 
The higher lipophilicity of ETP offers 
better intercalation in lipid-based liposo-
mal formulations (18,19). Liposomes ac-
cumulate in the tumors in a gradual pas-
sive fashion due to increased "leakiness" 
of the rumor vasculature (20). In particu-
lar, antineoplastic agents encapsulated in 
long circulating pegylated liposomes 
have been found to attain higher concen-
trations in tumor interstitium, ultimately 
eliminating tumors with great efficiency 
(21). Similarly, the encapsulation of cer-
tain anticancer agents into cationic lipo-
somes was also found to enhance their 
antitumor potential. However, cost fac-
tors, cumbersome preparation methods, 
and more importantly, intrinsic toxic 
manifestations of cationic lipids limit 
their usefulness as suitable drug vehicles. 
The immunomodulator tuftsin is a 
terra peptide (Thr-Lys-Pro-Arg) that 
binds specifically to macrophages, mono-
cytes, and polymorphonuclear leuko-
cytes and stimulates them to evoke im-
munomodulatory activity in the host. 
Many reports have also described anti-
tumor activity of tuftsin against experi-
mental tumors in animal models (22,23). 
Because of tuftsin's intrinsic antitumor 
properties and its possible role in activa-
tion and infiltration of tumoricidal 
macrophages, administration of tuftsin 
in combination with a potent antitumor 
agent can successfully suppress various 
forms of cancers. 
Earlier attempts have demonstrated 
usage of liposomized ETP (Lip-ETP) in 
delaying tumor progression, but such 
Address correspondence and reprint requests to Mohammad Owais. Inter-Disciplinary 
Biotechnology Unit. Aligarh Muslim University. Aligarh-202002, India. Phone: + 91-0571-
2720388. Fax: + 91-0571-2721776: E-mail: owais_lakhnawi@yahoomail.com. 
Submitted February 24. 2007; Accepted for publication May 2, 2007. 
266 I KHAN ET A l . I MOL MED 1 3 ( 5 - 6 ) 2 6 6 - 2 7 6 , MAY-JUNE 2 0 0 7 
RESEARCH ARTICLE 
treatment failed to regress tumor in 
model animals (19,24). In the present 
study, we evaluated tuftsin-mediated 
augmentation of the antitumorogenic po-
tential of ETP against fibrosarcoma in-
duced in Swiss albino mice by the car-
cinogen benzo (a) pyrene. Development 
of tumor was ascertained by measure-
ment of tumor volume and confirmed by 
histopathological examination of the tis-
sues. The tumor-bearing animals were 
treated with free-form as well as liposo-
mal*formulation of ETP with or without 
tuftsin. The efficacy of various formula-
tions was ascertained on the basis of 
tumor volume and survival, as well as 
expression of p53wt and p53mut in the 
tumor tissues of the animals. 
MATERIALS AND METHODS 
Chemicals 
All the reagents used in the study were 
of the highest purity available. Egg PC 
was isolated and purified from hen egg 
yolk according to published procedure 
(25). Cholesterol was bought from Cen-
tron Research Laboratory, Mumbai, India, 
and used after crystallizing three times 
with methanol. Tuftsin was modified at 
the C-terminus by attaching a sufficiently 
long hydrocarbon fatty aq'l residue to 
the C-terminus through an ethylenedi-
amine spacer arm (Thr-Lys-Pro-Arg-NH-
(CH,)2-NH-CO-C15H3I), which permits al-
most quantitative incorporation into 
liposomes, following the procedure stan-
dardized in our lab (26). Anti-p53 anti-
body specific for wild-type (wt) protein 
(clone PAb 1620, Ab-5) and anti-p53mut 
(clone PAb 240) were purchased from 
Merck India, Ltd. The horseradish peroxi-
dase-conjugated isotypes were obtained 
from Bangalore Genei (Bangalore, India). 
Animals. Female Swiss albino mice 
weighing 18 ± 2 g were used in the 
whole study. The animals were given a 
standard pellet diet (Hindustan Lever 
Ltd.) and water ad libitum. Animals 
were checked daily for their mortality 
and, morbidity prior to commencement 
of the study, and only healthy animals 
were included in the experiment. The 
techniques used for bleeding and injec-
tion as well as killing of animals were 
performed strictly according to mandates 
approved by the institute's Animal Eth-
ics Committee (Committee for the pur-
pose of control and supervision of Exper-
iments on Animals, Government of 
India). 
Liposome Preparation. Etoposide-
bearing unilamellar liposomes were pre-
pared from egg PC (49 umol) and choles-
terol (21 umol) with or without tuftsin 
(6.66 mol % of PC) following the pub-
lished procedure (25). Briefly, the solu-
tion of egg PC and ETP (in a ratio of 40:1 
w/w) along with cholesterol and tuftsin 
in chloroform was reduced to a thin dry 
film with a slow jet of N2 gas. The dried 
lipid film was hydrated with 150-mM 
sterile normal saline, followed by sonica-
tion for 1 h at 4 °C under N2 atmosphere 
in a bath-type sonicator. The sonicated 
preparation was centrifuged at 10,000 g 
for 1 h at 4 °C to remove undispersed 
lipid. Finally, the liposomal preparation 
was extensively dialyzed against saline 
for 24 h at 4 °C in the dark to remove the 
free form of the drug from the liposomal 
preparations. Both tuftsin-free and 
tuftsin-bearing liposomal preparations 
were found to be of unilamellar type, 
with a size range of 80 ± 10 nm, as re-
vealed by electron microscopy (data not 
shown). 
ESTIMATION OF LIPOSOME 
INTERCALATED ETP 
The intercalation efficiency of ETP in 
the liposomes was estimated by an 
HPLC method (27). Briefly, specific vol-
umes of standard drug solution of an iso-
cratic were injected onto a Hypersil 
octyldecyl-silane (5 urn particle size) ana-
lytical column (150 x 4.6 mm). Detection 
of ETP was accomplished with a UV-visi-
ble-light detector set at 254 nm. A stan-
dard curve of ETP was plotted by cali-
brating peak area versus amount of the 
drug injected into the column. The elu-
tion buffer consisted mixture of 0.005 M 
EDTA and methanol (2: 8 v/v). The flow 
rate was kept at 1.2 mL/min, and reten-
tion time was found to be 4.5 min. Fi-
M O l MED 1 3 ( 5 - 6 ) 2 6 6 - 2 7 6 , 
nally a known volume of liposomal for-
mulation was injected and the amount 
present in the sample was determined by 
the area under the curve. The intercala-
tion efficiency of ETP, both in plain egg 
PC and tuftsin-bearing liposomes, was 
found out to be of the same order of 
magnitude (90% ± 4%). 
Estimation of Liposome Intercalated 
Tuftsin 
The amount of tuftsin entrapped in the 
drug-containing liposomes was esti-
mated by the BCA method, as modified 
in our lab (28). Briefly, the liposomes 
(given volume) were lysed with a Triton 
X-100 solution and incubated with the 
mixture of solutions A and B of BCA 
reagent. The absorbance of the colored 
complex formed was measured at 600 
nm, and tuftsin content was determined 
using a standard curve of tuftsin plotted 
in the presence of Triton X-100. The in-
corporation of tuftsin was found out to 
be -98% for both sham as well as ETP-
containing tuftsin-bearing liposomes. 
In Vitro Drug Release Assay 
Drug release from tuftsin-bearing ETP 
liposomes into surrounding phosphate 
buffered saline (PBS; pH 7.4) was deter-
mined by the HPLC method, following a 
standardized protocol as described above 
(27). The vials containing Lip-ETP and 
tuftsin-bearing liposomized ETP (Tuft-
Lip-ETP) were incubated with PBS at 
37 °C under continuous shaking. An 
aliquot was withdrawn at two different 
time points (24 h and 48 h) and the mix-
ture was ultracentrifuged at 100,000g for 
15 min. The resulting supernatant was 
analyzed by HPLC method as described 
earlier. The percentage of in vitro release 
was calculated with respect to the total 
drug content in liposomes. 
ETP-Mediated Lysis of Human 
Erythrocytes 
The human red blood cells (RBCs) 
were diluted to 50% hematocrit with iso-
tonic buffer. ETP (free as well as Lip-
ETP) was added at a concentration of 
10 ng/mL to erythrocyte suspension. The 
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free form of the drug was dissolved in 
50 mL of DMSO, and the final volume 
was made up to 1 mL with PBS (5% 
DMSO). To study hemolysis, a suspen-
sion of RBCs was incubated with 1 mL 
of free as well as liposomized drug 
(10 ug/mL) at 37 °C for 1 h and cen-
trifuged at 1500#; then the supernatant 
was analyzed for the released hemoglo-
bin by measuring the absorbance at 
576 nm. The percentage hemolysis was 
determined by following equation: 
Percentage Hemolysis = 100 (Abs-Abs0/ 
AbsH10 - Abs0), 
where Abs = absorbance of the sample, 
Abs0 = Absorbance of negative control 
(erythrocytes in 5% DMSO) with 
noETP 
Abs)fl0 = Absorbance of positive control 
(erythrocytes in 1% Triton X-100) 
in the presence of 10 ug/mL ETP. 
Maximum Tolerated Dose 
The maximum tolerated dose (MTD) 
for the tuftsin bearing liposomal formula-
tion administered intravenously was de-
termined in healthy Swiss albino mice. 
Doses were escalated in increments start-
ing with 0,10, 20 40,100, 200, 400, and 
500 mg/kg body weight daily for five 
days. After completing the preliminary 
experiments, we defined the approximate 
MTD using eight groups consisting of 9 
mice of each. The drug effects were deter-
mined by careful surveillance of weight 
changes and survival of the experimental 
animals. The highest nonlethal dose of 
ETP causing > 10% weight loss within 1 
week of cessation from start of the dosing 
schedule was defined as the MTD. Of the 
9 animals in each group, 3 mice received 
free drug, 3 were given Lip-ETP, and the 
remaining 3 were given Tuft-Lip-ETP. 
Hematological Toxicity Tests 
Swiss albino mice were used to ana-
lyze the changes in hematological pa-
rameters after administration of Tuft-
Lip-ETP, Lip-ETP, and the free form of 
ETP, with respect to time and dose. The 
mice were randomized into 4 groups. 
Table 1. Treatment Groups of Tumor-Bearing Mice 
Groups Treatment 
Group I 
Group II 
Group III 
Group IV 
Group V 
Group VI 
Group VII 
Untreated control (normal) 
PBS (vehicle control) 
Sham liposomes (vehicle controQ 
Empty tuftsin liposome without ETP (Sham-Tufr-LIp) 
Free drug (ETP) 
Liposomal ETP (Up-ETP) 
Tuftsln-bearlng liposomal ETP (Tuft-Up-ETP) 
Group I served as controls and received 
vehicle treatment, and group II, group 
III, and group IV mice were treated with 
free ETP, Lip-ETP, and Tuft-Lip-ETP for-
mulations, respectively, at a dosage of 
10 mg/kg body weight/day for 5 days. 
Drugs were administered through the 
tail vein. On day seven after the last 
treatment dose of the analysis, the ani-
mals were killed by cervical dislocation 
while under anesthesia, and blood was 
withdrawn by cardiac puncture. Total 
and differential leukocyte and platelet 
counts were determined using a Sysmex 
cell counter. 
In Vivo Tumor Model 
Solid fibrosarcoma was induced in 
mice according to the published method, 
with slight modification (29). Briefly, a 
single dose of benzo (a) pyrene (250 ug/ 
animal) was administered subcuta-
neously into the flanks of the left hind 
limbs. The mice were observed daily for 
any change along the dimensions of the 
two hind limbs. The mice that developed 
palpable tumors at 90 to 100 d of admin-
istration of benzo (a) pyrene were in-
cluded in tiie study. 
Treatment Schedule and Efficacy-
Assessment Parameters 
The animals were divided into seven 
groups of 20 animals each. The animals 
in group I were used as untreated con-
trols (normal healthy) and did not re-
ceive any treatment. The tumor-bearing 
mice were pooled and randomized into 6 
groups (group 1I-V11) (Table 1). The tu-
mors were measured regularly with a 
Vernier caliper until they reached a vol-
ume of 200 mL. At this juncture the mice 
were treated with 10 mg/kg body 
weight/day of ETP for five consecutive 
days, and the first day of treatment was 
considered day 0. The drug and vehicle 
were slowly injected into the tail vein. 
The tumors were measured regularly 
after treatment, and antitumor activity 
was assessed by calculating the tumor 
volume according to the formula: 
V = DXd2Xn/6, 
where V = tumor volume, D = biggest 
dimension, and d = smallest dimension. 
Using the median day of death 
(MDD), we calculated the percentage in-
crease in host life span according to a 
previously described formula (30): 
Percentage increase in host life span = 
MDD (treated mice) - MDD (tumor-bear-
ing control mice) x 100 MDD (tumor-
bearing control mice) 
Histopathologlcal Examinations 
To assess the development of tumor, 
three mice were killed by cervical dislo-
cation and fixed in 10% formaldehyde 
solution. Subsequently, tumor tissues 
were excised, and sections were prepared 
using conventional paraffin sections and 
hemotoxylin-eosin staining. 
Preparation of Nuclear Fraction 
On day 25 after the administration of 
the first dose of various forms of ETP, the 
skin/tumor tissues were removed from 
experimental mice with sharp scalpel 
blades. The tissue samples were placed 
on ice and fat was scrapped off before 
further processing. Finally, the samples 
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Figure 1. (A) Leakage of ETP from liposomized formulations In surrounding PBS buffer. Liposomized formulations of ETP were incubated In 
PBS for 24 h a n d 48 h. Aliquots were taken from the supernatant to determine released ETP by HPLC as described in Materials and Meth-
ods. Data are mean ± SD of 3 independent experimental values. 'P < 0.001 (Tufts-Up-ETP) versus Llp-ETP at 24 h and 48 h. (B) Hemolysis of 
human erythrocytes induced by various formulations of ETP. Human erythrocytes were incubated with free ETP, Up-ETP. and Tuft-Up-ETP 
for 1 h at 37 °C as described in Materials a n d Methods. Data are mean ± SD of 3 independent experimental values. Various groups were 
compared by one-way ANOVA fo l lowed by Dunnett 's post hoc test. °P < 0,001 versus free ETP; °P < 0.001 versus Up-ETP. 
were homogenized and the nuclear frac-
tion was prepared according to a pub-
lished method (31). 
WESTERN BLOTTING 
Using a Western blotting method (32), 
we analyzed the nuclear fraction for the 
presence of p53wt and p53mut. Briefly, 
protein content of the homogenate was 
estimated by the routine method using 
BSA as a standard (33). Proteins (30-50 ug) 
were resolved under nondena hiring con-
ditions on PAGE for p53wt and on 10% 
SDS-PAGE gels for p53mut and electro-
blotted onto nitrocellulose membranes. 
The blots were probed with appropriate 
antibodies [i.e., anti-p53wt (clone PAb 
1620) and anti-p53mut (clone PAb 240)]. 
Immunoblots were detected by horse-
radish peroxidase-conjugated anti-mouse 
lgG using 3, 3'-diaminobenzidine tetra-
hydrochloride chromogen. To quantify 
equal loading, membranes were reprobed 
with fj-actin antibody. Data were pre-
sented as the relative pixel density of 
each of the bands normalized to band of 
p-actin. The intensity of the bands was 
quantitated using Alpha Image Analysis 
software on an Alpha Image Gel Docu-
mentation System. 
Statistics 
All the data were evaluated with 
SPSS/10.0 software. Multiple groups at 
the same time points were compared 
using ANOVA followed by Dunnett's 
post hoc test. P values <0.05 were consid-
ered statistically significant. 
RESULTS 
When a novel formulation of a given 
therapeutic agent is developed, it is de-
sirable to have some information about 
its in vitro stability profile. In this inves-
tigation, kinetic studies of in vitro drug 
release revealed that incubation of Lip-
ETP in PBS resulted in slow release of 
the drug. After 24 h and 48 h, respec-
tively, leakage of ETP from tuftsin-
bearing ETP liposomes was 12% and 
23%, whereas drug release of Lip-ETP 
was 19% and 38% (Figure la). 
Toxicity study results suggest that in-
corporation of ETP in liposomes mark-
edly lowers its toxicity to erythrocytes. 
Among various formulations, free ETP 
was found to show maximum toxicity, 
resulting in significant hemolysis of ery-
throcytes. The incorporation of ETP in 
conventional as well as tuftsin-bearing 
liposomes resulted in surprising diminu-
tion of its toxicity. The Tuft-Lip-ETP 
formulation imparts less toxicity to ery-
throcytes (-7% hemolysis) than does 
conventional liposomal preparation 
(-12% hemolysis) of the same drug 
(Figure lb). 
Loss of body weight in response to the 
administration of the antineoplastic 
agent ETP was used as another parame-
ter to assess its toxicity. As shown in Fig-
ure 2, the maximum tolerated doses 
(MTD) for free ETP, Lip-ETP, and Tuft-
Lip-ETP were found to be 165.53,279.77, 
and 413.25 mg/kg, respectively (P < 
0.001 for Lip-ETP vs free ETP and for 
Tuft-Up-ETP vs Lip-ETP). 
Hematological tests were performed 
to evaluate the effect of Lip-ETP on rap-
idly proliferating hematopoietic cells. 
The immune cell depletion was signifi-
cantly greater in the free ETP treated 
group than in the Lip-ETP treated group, 
with mean total leukocyte counts of 
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1764/mm3 vs 4457/mm3 counts, respec-
tively, (P < 0.001) on day 7 from the last 
dose. Myelosuppression was signifi-
cantly lower in the group of animals 
treated with Tuft-Lip-ETP (mean total 
leukocyte count 7364/mm3) compared 
with groups of animals treated with free 
(P < 0.001) or Lip-ETP (P < 0.001). Con-
trol healthy mice had a total leukocyte 
count of 12,160/mm3 at the same time 
point (Figure 3a). After therapy, however, 
no substantial change was observed in 
the differential leukocyte profile, a find-
ing that suggests that the proliferation of 
all the components was equally sup-
pressed. A reduction in platelet count 
was also observed on day 7 in drug-
treated groups compared with controls. 
The mean platelet counts in the free ETP, 
Lip-ETP, and Tuft-Lip-ETP treated 
groups were 1.4 xl05/mm3 (P < 0.001 
vs control), 2.1 xl05/mm' (P < 0.001 vs 
free ETP), and 2.5 xlOVmm3 (P < 0.001 
vs free as well as Lip-ETP), respectively. 
Vehicle-treated control animals had a 
mean platelet count of 2.8 xio'/mm3 
(Figure 3b). 
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Figure 3. Effects of ETP chemotherapy on leukocyte and platelet counts of the treated animals. Experimental animals were treated with 
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ETP significantly reduced the total leukocyte count (P < 0.001) compared with controls. Lip-ETP caused lesser myelosuppression com-
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(B) A similar effect was observed on platelet counts as seen for total leukocyte count after treatment with free ETP (P < 0.001). The Up-
ETP group had significantly higher mean platelet counts (P< 0.001) than the free ETP group. The Tuft-Up-ETP group had even higher 
platelet counts than the free (P< 0.001) and Lip-ETP (P < 0.001) groups. Data are means ± SD with n = 5 per group. °P< 0.001 versus free 
ETP; °P < 0.001 versus Lip-ETP. 
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MS. 
Figure 4. Establishment of fibrosarcoma by exposure of animals to benzo (a) pyrene. Ad-
ministration of benzo (a) pyrene (250 ug/animal. subcutaneously) into the flanks of the 
animals resulted in successful tumor induction in at least 90 % of the animals and no 
tumor development in 10 % of the animals. The tumor-bearing animals were killed by cer-
vical dislocation and fixed in 10 % formaldehyde solution. Subsequently tissues were ex-
cised and sections were prepared after standard HE staining of 12-mm-thin sections. 
(A) Photomicrograph from tumor showing zone of necrosis, increased vascularization and 
hemorrhage. Large numbers of hyperchromatic mesenchymal cells with features of fi-
brosarcoma are present. Some hyperchromatic cells are arranged in glandular form. 
(B) Photomicrograph from tumor showing soft tissue sarcoma with large pleomorphic, hy-
perchromatic spindle-shaped cells with anisonucleosis and Irregularly dispersed chro-
matin. Some inflammatory cells can also be seen. 
To evaluate in vivo efficacy of various 
ETP formulations against experimental 
fibrosarcoma, tumors were developed in 
model animals. After treatment with 
benzo (a) pyrene, 90% of the treated ani-
mals developed tumors within 90-100 
days. The establishment of the tumors 
was confirmed by histopathological ex-
aminations of the tissues. The fibrosar-
coma was found to be accompanied by 
increased vascularization and large pleo-
morphic, hyperchromatic spindle-shaped 
cells with anisonucleosis and irregularly 
dispersed chromatin (Figure 4a and 4b). 
Among various formulations, Tuft-Lip-
ETP was found to be more effective that 
tuf tsin-free Lip-ETP or free ETP in treat-
ment of fibrosarcoma. Treatment of the 
animals with Lip-ETP was started when 
the tumors attained the size of approxi-
mately 200 mm3. Mice treated with chem-
otherapy with Tuft-Lip-ETP at a dose of 
10 mg/kg body weight/day for five days 
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Figure 5. (A) Effects of chemotherapy with various formulations of ETP on tumor development in Swiss mice. Treatment of tumor-bearing 
animals was started when the tumor size reached a volume of approximately 200 mm3. Free ETP and sham tuftsin liposomes significantly 
delayed tumor growth (P < 0.05) as compared with controls (PBS and Sham liposomes). Liposomal ETP was superior to free ETP in delay-
ing tumor growth (P< 0.001). The regressions of tumors were recorded only in the group of animals treated with Tuft-Lip-ETP. Data are val-
ues t SD (n = 20 at Initiation of therapy, the number varies at later time points due to mortality). (B) Effects of ETP chemotherapy on the 
survival of tumor-bearing mice. The fibrosarcoma was induced by exposure to benzo (a) pyrene. The treatment of tumor-bearing ani-
mals was started at the time point when tumor size reached a volume of approximately 200 mm3. All the treated mice received a dose 
of lOkig/kg body weight/day for 5 d with various formulations of the drug. Free ETP significantly enhanced the life span of the mice 
compared with the control group (PBS and sham liposomes) (P< 0.01). Lip-ETP was superior to free ETP in increasing the lifespan (P< 
0.001). The best therapeutic effect was recorded in the group of animals treated with Tuft-Lip-ETP (P < 0.001). Data shown are the num-
ber of mice surviving at the given time points. 
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Table 2. Effect of Chemotherapy with Various Formulations on the Progression of Benzo (a) 
Pyrene-lnduced Fibrosarcoma0 
Treatment 
PBS (Vehicle Control) 
Sham liposomes (Vehicle Control) 
Sham-Tuft-Lip 
Free Drug (ETP) 
Lip-ETP 
Tuft-Llp-ETP 
MDD 
22 
23 
31 
29 
50 
88 
Increase In life span % 
— 
40.90 
31.81 
127.27 
300.00 
°AII the ETP-treated mice received 10 mg/kg body weight/day for 5 d of drug as a 
suspension in PBS. The formulations were diluted in PBS so the total volume of 
administration was always 100 uL. Vehicle-treated groups received only PBS (100 uL), or 
sham liposomes in PBS (100 uL). Percentage increase in host life span was calculated by 
the formula as described in Materials and Methods. 
showed significantly reduced tumor 
growth compared with mice treated with 
Lip-ETP (P < 0.001), free ETP (P < 0.001), 
and Sham-Tuft-Lip (P < 0.001) as well as 
controls treated with sham liposomes (no 
tuftsin) and PBS (P < 0.001). Lip-ETP de-
layed tumor growth and was superior to 
the free form of ETP and sham tuftsin li-
posomes but did not cause significant 
tumor regression. On the other hand, 
tuftsin-bearing ETP liposomes reduced 
growth up to 165.7 ± 2.63 mm3 from 
200 mm3 within 52 d after the initiation of 
chemotherapy (Figure 5a). 
Mortality was seen in all mice with 
benzo (a) pyrene induced tumors, but 
animals treated with appropriate chemo-
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Figure 6. (A) Effect of various formulations on the expression of p53wt In mouse fibrosarcoma. Skin/tumor lysates were prepared as de-
scribed in Materials and Methods and 30-50 ng protein was used for Western blot analysis. A diminutive expression of p53wt was re-
corded in the animals treated with vehicle controls. Treatment with various formulations was found to replenish the p53wt expression In fi-
brosarcoma. Lane 1. untreated (Normal); lane 2. vehicle control (PBS); lane 3, sham egg PC liposomes; lane 4, Sham-Tuft-Lip; lane 5, free 
ETP; lane 6, Lip-ETP; and lane 7, Tuft-Lip-ETP. (B) Effect of various formulations on the expression of mutp53 in mouse fibrosarcoma. 
Skin/tumor lysates were prepared as described In Materials and Methods and proteins (30-50 pig) were employed for Western blots. The 
expression of p53mut was induced significantly in the animals treated with vehicle controls; however, treatment with various formulations 
against fibrosarcoma resulted in a decrease in p53mut expression. Lane 1. untreated (normal); lane 2, vehicle control (PBS); lane 3, sham 
liposomes; lane 4. Sham-Tuft-Lip; lane 5. free ETP; lane 6. Lip-ETP; and lane 7, Tuft-Lip-ETP. 
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therapy had comparatively longer life 
spans. Table 2 shows the median day of 
death in each group. Tumor-bearing mice 
treated with the free form of ETP lived 
longer than those treated with PBS or 
with sham liposomes (P < 0.001). Tumor-
bearing mice treated with Lip-ETP lived 
longer than those treated with the free 
form of ETP or with Sham-Tuft-Lip (P < 
0.001) (Figure 5b), and tumor-bearing 
mice treated with Tuft-Lip-ETP lived 
longer than those treated with Sham-
Tuft-Lip-ETP or with Lip-ETP (P < 0.001). 
Exposure to the carcinogenic agent 
benzo (a) pyrene followed by treatment 
with ETP resulted in transient weight 
loss in treated animals. The treatment 
with liposomized ETP mitigated weight 
loss to varying levels depending on the 
ETP formulation used for the treatment 
(data not shown). 
Because p53 is crucial for regulating 
growth and death of cells, its presence 
was used as a parameter to study the an-
titumoricida! effect of the tuftsin. The 
levels of p53wt protein were significantly 
reduced in fibrosarcoma-bearing ani-
mals, which were treated with PBS and 
sham liposomes (vehicle controls), com-
pared with untreated healthy controls 
(Figure 6a, lanes 1, 2 and 3). A compara-
tively high expression level of p53wt 
protein was recorded in the animals 
treated with various formulations of ETP. 
Compared with the animals treated with 
vehicle, p53wt expression increased 
179 % in animals treated with Tuft-Lip-
ETP, 88 % in animals treated with Lip-ETP, 
45 % in animals treated with the free 
form of ETP, and 44 % in animals treated 
with sham tuftsin liposomes (Figure 6a), 
indicating that tuftsin-bearing liposomal 
ETP replenished the expression of p53wt 
protein and abolished benzo (a) 
pyrene-induced neoplastic changes. 
Mice treated with tuftsin-bearing lipo-
somal ETP showed a low level of p53mut 
similar-.to that of the healthy mice not ex-
posed'tb benzo (a) pyrene, whereas up-
tegulation of p53mut occurred in ani-
mals exposed to benzo (a) pyrene and 
subsequently treated with vehicle con-
trols (Figure 6b, lanes 1, 2, 3 and 7). As 
depicted in Figure 6b, 85 % down-regula-
tion in the expression level of p53mut oc-
curred in the animals treated with Tuft-
Lip-ETP compared with the animals 
treated with vehicle only (PBS and sham 
liposomes). In the group of animals 
treated with Lip-ETP, the reduction was 
68 %, and 50 % down-regulation oc-
curred in the animals treated with the 
free form of ETP and 30 % in the animals 
treated with Sham-Tuft-Lip. These results 
clearly demonstrate ETP-mediated 
down-regulation of p53mut, which was 
more marked upon its intercalation 
along with tuftsin in the liposomes used 
in the present study (Figure 6b). 
DISCUSSION 
Drugs used in cancer treatment gener-
ally have severe toxic manifestations and 
undesirable side effects. The use of most 
of the anticancer drugs, including ETP, is 
also limited by an ever-increasing trend 
of multidrug resistance by cancerous 
cells. This resistance is mainly due to the 
drug efflux mediated by an array of 
transporters, p-glycoproteins such as p-
gp4, and other multidrug resistance pro-
teins, chiefly MRP1, MRP2, and MRP3 
(34-36). Thus ongoing development of 
newer formulations of ETP with less tox-
icity that also can circumvent the prob-
lem of drug resistance is crucial. One 
possible solution is the use of drug deliv-
ery systems that can specifically deliver 
anticancer drugs solely to tumor tissues. 
ETP entrapped in liposomes has been 
found to be an effective application of 
this method (19,24). Liposomes are lipid-
based vesicles that enable efficient and 
targeted delivery of drugs to the desired 
site (15,17). Moreover, liposomized anti-
cancer formulations can circumvent drug 
efflux and achieve adequate drug con-
centrations in the target cells to enable 
tumor cell killing, because liposome-me-
diated disposition interacts well with 
drug efflux mediated by p-glycoprotein 
transporters (37-41). 
We attempted to further enhance the 
therapeutic efficacy of liposomal ETP by 
the incorporation of the immunomodula-
tor tuftsin, tmmunomodulators are bio-
MOL MED 1 3 ( 5 - 6 ) 2 6 6 - 2 7 6 , 
logical response modifiers and can also 
exert antitumor effects by improving 
host defense mechanisms against the 
tumor. Tuftsin has been shown to have 
antiproliferative effects on tumor cells 
and also enhance the ability of the host 
to tolerate damage by toxic chemicals 
that may be used to destroy the cancer 
cells (42,43). Immunomodulatory ther-
apy could thus provide an alternative to 
conventional chemotherapy for a variety 
of disease conditions, especially when 
host defense mechanisms are impaired 
and need appropriate activation. To sup-
press tumors in vivo, macrophages must 
first infiltrate to the desired site. It is well 
documented that the presence of inflam-
matory macrophages in growing tumors 
is maintained through recruitment of cir-
culating monocytes (44-47) and in cer-
tain tumors, the proliferation of mononu-
clear phagocytes (48). Activated 
macrophages can destroy syngeneic, allo-
geneic, and xenogeneic tumor cells but 
leave normal nontumorigenic cells un-
harmed, suggesting that histocompatibil-
ity and tumor-specific antigens are not 
involved in this recognition (49). In addi-
tion, differences in metastatic potential, 
chromosome number, resistance to 
chemotherapeutic agents, or the anti-
genic properties of tumor cells did not 
appear to be important factors for 
macrophage recognition of tumor cells 
(50,51). Successful treatment of metas-
tases by the intravenous injection of lipo-
somes containing immunomodulators 
has been reported for several tumor-host 
models, including mouse fibrosarcoma 
(52-55), melanomas (56,57), lung carci-
noma (58), and colon carcinoma (59). 
Macrophages are believed to migrate to 
local regions of inflammation and the 
sites of tumor growth, where they induce 
further immune reactivity against tumor 
cells. The treatment of tumors could be 
achieved by first delivering the drug to 
the RES and concomitant activation of 
their components (eg, macrophages) for 
their tumoricidal activity by a desirable 
immunomodulator. Being particulate in 
nature, liposomes are avidly taken up by 
macrophages that act as secondary de-
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pots of the drug. After reaching the 
tumor site these macrophages release the 
drug and thereby bring about tumor cell 
death. At the outset, we speculated that 
our novel formulation comprising the 
immunomodulator tuftsin grafted on the 
surface of liposomes along with ETP 
would be able to eliminate fibrosarcoma 
in Swiss albino mice. 
In our previous studies, we have 
demonstrated that pretreatment with li-
posomized tuftsin led to the successful 
elimination of a range of pathogens in 
leukopenic mice (27,60,61). The antitu-
mor activity of tuftsin has long been rec-
ognized, but no evaluation has been 
made of the therapeutic potential of its 
liposomized form or a tuftsin-bearing li-
posomal preparation of any anticancer 
agent. In the present study, we evaluated 
the anticancer potential of Tuft-Lip-ETP 
against experimental fibrosarcoma be-
cause ETP has cytotoxic properties and 
the immunomodulator tuftsin possesses 
both antitumor and immunomodulatory 
properties to coactivate immune system. 
Our results are well in agreement with 
our hypothesis, because this novel for-
mulation of liposomized ETP with 
tuftsin grafted on the surface was found 
to be more effective than its free form. 
MDD studies also demonstrated in-
creased life span in animals treated with 
Tuft-Lip-ETP. More importantly, signifi-
cant tumor regression was also found in 
the animals treated with Tuft-Lip-ETP. 
Enhanced efficacy of tuftsin-bearing ETP 
liposomes might be due to the fact that 
tuftsin helps in specific targeting to 
macrophages that will subsequently infil-
trate to the rumor site. Treatment with 
free ETP and Sham-Tuft-Lip were not 
very effective in killing tumor cells. 
The tumor suppressor gene p53 is re-
garded as a key factor in maintaining the 
balance between cell growth and cell 
death (62,63) and is reported to be mu-
tated in -80% of all human malignancies 
(64). Because of its role in regulation of 
the cell cycle, alterations in p53 are criti-
cal events in carcinogenesis. Normally, in 
response to toxic insults p53wt triggers a 
chain of cell cycle regulatory events to 
check the proliferation of altered cells 
and repair or minimize damage (62,63). 
In tumors, loss of p53wt prevents the ac-
tivation of this growth control pathway 
(65). The failure to induce transcription-
ally active p53wt plays a role in the un-
regulated growth of tumors and also in 
the failure to respond to chemotherapeu-
tic agents, which normally trigger p53wt, 
and regulates cell cycle arrest or cell 
death (66). The balance between p53wt 
at\d p53mut determines the fete of the 
cell, and many chemotherapeutic agents 
are known to exert their anticancer ef-
fects by modulating p53wt and p53mut 
expression levels (67-69). The results of 
the present study showed increased up-
regulation of p53wt and down-regulation 
of p53mut by liposomal formulations of 
ETP. ETP acts intrinsically by modulating 
the balance between p53wt and p53mut 
protein expression, suppressing p53mut 
and enhancing tumor suppressor p53wt 
(2-4,68). As evident from the present 
study, the effect of ETP on p53wt en-
hanced and reduced p53mut upon its li-
posomization along with tuftsin (Figure 
6a and 6b). 
On the basis of the data of the present 
study, we conclude that Tuft-Lip-ETP is 
an effective formulation for treatment of 
fibrosarcoma and can pave the way for 
treatment of other forms of cancer. More-
over it is imperative to speculate that for-
mulation of tuftsin-bearing liposomes in 
combination with other anticancer drugs 
may be equally effective against various 
form of cancer. 
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Potential of Diallyl Sulfide Bearing pH-Sensitive Liposomes in 
Chemoprevention Against DMBA-lnduced Skin Papilloma 
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Diallyl sulfide (DAS), an active component of garlic, possesses strong anti-neoplastlc properties against various forms of can-
cer. In the present study, we have evaluated chemo-preventive effects of liposomized DAS (conventional egg PC and pH-
sensitive liposomes) against DMBA-induced skin papilloma. Various liposome-based novel formulations of DAS (250 ug/mouse) 
were applied topically, after one hour of exposure to DMBA (52 ug/mouse/dose), to the animals. The animals were treated thrice 
weekly for the total period of 12 weeks. The efficacy of the various liposomal formulations of DAS was evaluated on the basis of 
parameters such as incidence of tumorogenesis and total numbers and sizes of induced tumor nodules. The liposomized DAS for-
mulations also were assessed for their effect on the expression of p53wt, p53mut, and p21/Wafl. The results of the present study 
showed that liposomized DAS could effectively delay the onset of tumorogenesis and reduce the cumulative numbers and sizes 
of tumor papillomas in treated mice. Treatment of DMBA-exposed animals with the liposomal formulation of DAS ensued In up-
tegulation of p53wt and p21 /Waf 1, while levels of p53mut expression reduced down. The promising chemo-preventive nature of 
liposomal DAS may form the basis for establishing effective means of controlling various forms of cancer, including skin papilloma. 
Online address: http://www.molmed.org 
doi: 10.2119/2006-00111 .Khan 
INTRODUCTION 
Garlic (Allium sativum) has been 
shown to possess potential health bene-
fits (lipid lowering, antimicrobial, 
chemo-preventive, and anticarrinogenic 
properties, for example) since the begin-
ning of recorded history and is probably 
one of the most widely studied medici-
nal plants (1,2). The chemotherapeutic 
and antitumor activity associated with 
garlic has been attributed to the presence 
of various organosulfide-based active 
compounds including DAS (Figure 1), 
(3,4,5,6,7,8). Our lab, as well as other 
investigators, has demonstrated the anti-
carcinogenic properties of DAS against 
chemically induced carcinogenesis in 
model animals (3,9,10). DAS has been 
found to be effective against various 
forms of cancer affecting skin, lung, 
esophagus, colon, liver, and others 
(3,9,10,11). A deeper insight revealed that 
DAS achieves its anticancer properties by 
modulating phase I and phase II detoxi-
fying enzymes, scavenging of free radi-
cals, and abrogating their mutagenic 
potential (4,12,13,14,15). 
Of the various options available for the 
administration of medications, topical 
application is the most promising ap-
proach for treating skin tumors as it 
leads'to a localized effect at the desired 
site with minimal side effects. However, 
retention of drugs administered by this 
mode is low because of extensive diffu-
sion that is more apparent in case of 
small-sized molecules such as DAS. This 
warrants development of formulations 
that can modulate pharmacokinetics as 
well as pharmacodynamic properties of 
DAS, thereby making it more efficacious. 
Among various novel drug delivery 
systems, microparticulate-based carrier 
systems such as micro-emulsion (16), 
nano-emulsion (17), nanoparticles (18), 
liposomes (19,20), and others have 
been reported to improve the delivery 
of drugs to the skin. Interestingly, 
liposome-based formulations, when 
employed for topical delivery, have been 
shown to be extremely promising for en-
hancing drug penetration (19,21,22), im-
proving pharmacological effects (23,24), 
decreasing side effects, controlling drug 
release (17), and, above all, their own 
biodegradable nature (25,26). 
The aim of the present study was to 
evaluate chemo-preventive action of 
liposome-based topical formulations of 
DAS against dimethyl benz (a) anthra-
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Figure 1. Chemical structure of DAS 
cene (DMBA)-induced skin cancer. 
DMBA, a polycyclic aromatic hydrocar-
bon (PAH), is an ubiquitous environmen-
tal pollutant generated during incom-
plete combustion of organic substances 
and known to have cytotoxic, mutagenic, 
and carcinogenic effects in experimental 
animals as well as in humans (27,28). We 
incorporated DAS in a lipid bilayer of 
egg phosphatidyl-choline (PC) liposomes 
to achieve its slow release for prolonged 
duration at the site of application (29). To 
the best of our knowledge, no report is 
available to date regarding usage of lipo-
some-based formulation of DAS against 
any disease including skin cancer. The ef-
ficacy of DAS against cancer was further 
enhanced by incorporating it in pH-sen-
sitive liposomes, which have the poten-
tial to deliver the encapsulated drug to 
the cytosol of the cancer cells. The data 
of the present study also reveal that lipo-
somal DAS was found to regulate cell 
cycle factors more efficiently and eventu-
ally helped in increasing the chemo-
preventive properties of DAS. 
MATERIALS AND METHODS 
Chemicals 
All the reagents used in the study 
were of the highest purity available. 
Cholesterol was bought from Centron 
Research Laboratory (Mumbai, India) 
and used after crystallizing it three times 
with methanol. Egg phosphatidyl-
choline (PC) was isolated and purified 
following the published procedure (30). 
DMBA, DAS, dioleoyl phosphatidyl 
ethanolamine (DOPE), and cholesteryl 
hemisuccinate (CHEMS) were purchased 
from Sigma Chemical Company (St. 
Louis, MO, USA). Anti-p53 antibody spe-
cific for wild-type (wt) protein (clone 
PAb 1620, Ab-5), Anti-p53mut (clone PAb 
240), and monoclonal p21/Wafl (Ab-1) 
antibody were purchased from Merck 
India Limited (Mumbai, India). The 
horseradish peroxidase-conjugated iso-
types were obtained from Bangalore 
Genei (Bangalore, India). 
Animals 
Female Swiss albino mice of weight 
22 ± 2 g were obtained from the insti-
tute's animal facility. The animals were 
kept in quarantine for the period of one 
week on a 12:12 h light:dark cycle and 
were given a standard pellet diet and 
water ad libitum. Animals were checked 
daily for their mortality and morbidity 
prior to commencement of the study and 
only healthy animals were included in 
the experiment. The techniques used for 
drug administration as well as the killing 
of the animals were strictly performed 
following mandates approved by the An-
imal Ethics Committee (Committee for 
the Purpose of Control and Supervision 
of Experiments on Animals, Government 
of India). 
Preparation of DAS-Bearing 
Liposomes 
Egg PC liposomes were prepared 
from egg PC (49 umol) and cholesterol 
(21 umol), while pH-sensitive lipo-
somes were prepared from DOPE (54 
umol) 
and CHEMS (36 umol) using published 
method with some modifications as 
standardized in our lab (31). Briefly all 
the ingredients along with DAS 
(Drug:Lipid 1:40) were dissolved in a 
minimum volume of 
chloroform:methanol (1:1, V/V). The 
solvents were evaporated carefully 
under reduced pressure to form a thin 
lipid film on the wall of the round bot-
tom flask. Finally, the traces of the or-
ganic solvents were removed by sub-
jecting the flask to high vacuum 
overnight at 4°C. Subsequently, the 
dried lipid film was hydrated with 
2.0 mL of 150 mM sterile saline with in-
termittent vigorous stirring followed by 
sonication (one hour, 4°C) in a bath 
type sonicator under N2 atmosphere. 
The sonicated preparation was dialyzed 
against normal saline for 24 h at 4"C in 
the dark, and then centrifuged at 
10,000g for one hour at 4°C to remove 
undispersed lipid. The liposomal prepa-
rations of DAS were used in treatment 
of DMBA-induced skin cancer. 
Determination of Intercalation 
Efficiency of DAS in Liposomes 
The intercalation efficiency of DAS in 
various formulations of liposomes was 
estimated by HPLC method (32). A 
standard curve of the drug was plotted 
at 271 nm by determining the area 
under curve corresponding to the 
known (increasing) amount of the 
drug. The extent of DAS entrapped in 
liposome was calculated from the stan-
dard curve of the drug solution that 
was plotted for the area under curve 
against the corresponding amount of 
the DAS. The intercalation efficiency of 
DAS in egg PC liposome (Lip-DAS) 
and pH-sensitive liposome (pH-Lip-
DAS) formulations was found out to be 
90 ± 4 percent and 96.4 ± 2.6 percent re-
spectively. 
Treatments 
Animals in the resting phase of hair 
cycle were taken for the study. Hairs of 
the animals were removed from the in-
terscapular region over an area of 2 cm2 
using electric clippers that were not lu-
bricated with any oil or grease. The skin 
of the shaven dorsal portion of the mice 
was exposed to DMBA (52 ug in 200 mL 
acetone) that was applied topically three 
times a week for 12 weeks. All the for-
mulations of DAS (250 ug) were applied 
within one hour after exposure with 
DMBA three times a week for 12 weeks. 
The animals were divided into nine 
groups each comprising 15 animals as 
follows: Group I, Untreated Control 
(Normal); Group II, DMBA + Acetone; 
Group III, DMBA + Cream; Group IV, 
DMBA + Sham PC liposomes in cream 
(Sham-Lip); Group V, DMBA + Sham 
pH-sensitive liposomes in cream (Sham-
pH-Lip); Group VI, DMBA + Free DAS 
(DAS); Group VII, DMBA + PC-DAS 
liposomes in cream (Lip-DAS); Group 
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VIII, DMBA + pH-sensitive-DAS lipo-
somes in cream (pH-Lip-DAS); and 
Group IX, Cream + (No DMBA). 
Tumor Measurements 
The diameters of the tumors were 
measured using a Vernier Caliper and 
the tumor volume was determined by 
the formula: 
V = D x rf2 x i t /6, 
where V = tumor volume, D = biggest 
dimension, and d = smallest dimension. 
Preparation of Nuclear Fraction 
The skin/ tumor tissues were removed 
from experimental mice with sharp 
scalpel blades. The tissue samples were 
placed on ice and fat was scraped off be-
fore further processing. Finally, the sam-
ples were homogenized and the nuclear 
fraction was prepared according to pub-
lished method (33). 
Western Blotting 
The nuclear fraction was analyzed for 
the presence of p53wt as well as p53mut 
using the Western blotting method (34). 
Briefly, the protein content of the ho-
mogenate was estimated by the routine 
method using BSA as a standard (35). 
Proteins (30 ug/well) were resolved 
under nondenaturing conditions on 
PAGE for p53wt and on ten percent SDS-
PAGE gels for p53mut and electroblotted 
onto nitrocellulose membranes. The blots 
were blocked overnight with five percent 
nonfat dry milk and probed with appro-
priate antibodies [i.e., anti-p53wt (clone 
MAb 4H5), anti-p53mut (clone l'Ab 240) 
and monoclonal anti-p21/Wafl (Ab-1) 
antibody] at dilutions recommended by 
the suppliers. Immunoblots were de-
tected by horseradish peroxidase-
conjugated anti-mouse IgG using 
chromagen 3,3'-diaminoben7.idine 
tetrahydrochloride. To quantify equal 
loading, membranes were reprobed with 
(B-actin antibody. Data are presented as 
the relative pixel density of each band 
normalized to a band of fi-actin. The 
intensity of the bands was quantitated 
using Image Analysis software on an 
Image Gel Documentation System. 
Statistical Analysis 
One-way ANOVA was used for com-
paring the mean values of tumor num-
bers and tumor volume between differ-
ent treated groups after ascertaining the 
homogeneity of variance between treat-
ments. Post hoc analysis for comparing 
the two groups was done using the Least 
Statistical Difference (LSD) technique. 
The Kaplan-Meier method was used to 
estimate tumor free survival and differ-
ences were analyzed by the log-rank test. 
RESULTS 
In the present study, we evaluated an-
ticancer properties of various liposomal 
preparations of DAS. Both pH-sensitive 
and conventional egg PC liposomal for-
mulations of DAS inhibited a significant 
number of DMBA-induced tumor inci-
dences as compared with the free form of 
DAS in model animals. The liposomal 
DAS formulations also were successful in 
delaying onset of tumorogenesis. As de-
picted in Figure 2, the onset of tumoroge-
nesis was delayed for a period of more 
than one week in the mice treated with 
liposomal formulations (Lip-DAS or pH-
Lip-DAS) in comparison to animals that 
were treated with free form of DAS (P < 
0.01). Besides delaying the onset of tu-
morogenesis, treatment with both pH-
sensitive as well as egg PC liposomes re-
sulted in significant reduction in total 
numbers of DMBA-induced papillomas. 
As shown in Figure 3A, the mean num-
bers of tumors per mouse were signifi-
cantly reduced in the group of animals 
treated with Lip-DAS, (mean value 5.84, 
P < 0.001) and pH-Lip-DAS, (mean value 
3.91, P < 0.001) in comparison with the 
animals treated with the free form of 
DAS (mean value 10.6). 
We also measured regression in the 
tumor volume after treatment with vari-
ous forms of DAS. The mean tumor vol-
ume per mouse was significantly lower 
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Figure 3. A. Effect of liposomized DAS mediated chemo-prevention on the development of average number of tumors per mouse. 
The animals were treated with various forms of DAS after their exposure to carcinogenic agent DMBA. Efficacy of various DAS liposomal 
formulations was assessed on the basis of their ability to prevent development of tumors. °P < 0.001 (free DAS, Lip-DAS, pH-Lip-DAS) 
versus vehicle control groups (groups ll-V), bP < 0.001 (Lip-DAS and pH-Lip-DAS) versus free DAS, CP < 0.01 (pH-Lip-DAS) versus Lip-DAS. 
B. Chemo-preventive effects of various formulations of DAS on average tumor size. The chemo-preventive efficacy of various forms of 
DAS was assessed by measuring the size of the tumors using a caliper. The tumor volume was determined by the formula as described in 
Materials and Methods. °P< 0.001 versus vehicle controls (groups ll-V), bP< 0.001 (Lip-DAS and pH-Llp-DAS) versus free DAS. CP< 0.001 
(pH-Lip-DAS) versus Lip-DAS (group VII). C. Percent-Inhibition of tumor growth by various formulations of DAS. The animals were treated 
with various forms of DAS after exposure to DMBA as described in Materials and Methods. The tumor growth Inhibition was calculated by 
comparing the average size of the tumor induced in animals that were treated with vehicle control (acetone treatment). °P< 0.001 
versus (Free DAS). bP< 0.001 versus Lip-DAS. 
in pH-Lip-DAS treated animals (62.42 
mnv', P < 0.001) while it was 168.60 mnv' 
(P < 0.001) in Lip-DAS treated animals. 
Treatment with the free form of DAS re-
duced the mean tumor volume to 
309.61 mm'1 (P < 0.001). The mean tumor 
volumes recorded in the control animals 
(groups 11 and 111) were 1048.98 mm"1 and 
1041.37 mm3 respectively (Figure 3B). 
The animals treated with Sham-Lip and 
Sham-pH-Lip (groups IV and V) had 
tumor dimensions of 984.99 and 
945.88 mm1 respectively. 
Tumor growth inhibition was used as 
another parameter to assess efficacy of 
liposomized DAS against DMBA-
induced papilloma formation. The tumor 
growth inhibition, in comparison to the 
DMBA-exposed untreated group, was 
94 percent (P < 0.001) in the group of ani-
mals treated with pH-Lip-DAS, while it 
was 84 percent in Lip-DAS treated ani-
mals. The free form of DAS resulted in 
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70 percent inhibition in tumor growth 
(Figure 3C). 
The Kaplan-Meier curve (Figure 4) 
shows the augmentation of anticarcino-
genic effects of liposomized DAS against 
DMBA-induced tumorogenesis in terms 
of survival of tumor free animals at dif-
ferent time intervals. Treatment with ace-
tone, cream base, Sham-Lip, Sham-pH-
Lip, and free DAS could not prevent 
tumor incidence in DMBA exposed ani-
mals. The liposomized DAS showed 
tremendous increase in chemo-preven-
tive efficacy over its free form against 
DMBA induced tumorogenesis. The 
treatment resulted in -23 percent and 
34 percent of animals completely free of 
tumor incidences upon treatment with 
Lip-DAS and pH-Lip-DAS respectively. 
Western Blot Analysis 
Exposure to carcinogen DMBA in-
duced down-regulation of p53wt protein 
in the treated animals (groups II and III) 
in comparison with normal healthy mice 
(group I, Figure 5A, lanes 1, 2, and 3). 
Treatment with Sham-Lip and Sham-pH-
Lip (group IV and V) reduced DMBA 
induced downregulation of p53wt (al-
though not significantly) in comparison 
to animals treated with acetone and 
cream (groups II and III). As depicted in 
Figure 5A, a comparatively high expres-
sion of p53wt protein was recorded in 
the animals treated with liposomal as 
well as free formulations of DAS 
(147 percent increase in expression in the 
group of animals treated with pH-Lip-
DAS, 84 percent in the animals treated 
with Lip-DAS liposomes, and 23 percent 
in the animals treated with the free form 
of DAS) over the group of animals 
treated with acetone and cream. This di-
rectly suggests that liposomal formula-
tion of DAS plays a determining role in 
the regulation of the expression of p53wt 
protein and the inhibition of DMBA-
induced neoplastic changes. The neat 
cream, used as a base in the preparation 
of various formulations, could not nor-
malize p53wt expression in DMBA-
exposed mice. This observation was the 
same as in animals not given any kind of 
chemo-preventive treatment and hence 
rules out any ameliorating role of the 
cream base. Exposure of animals to 
DMBA ensued in upregulation of 
p53mut protein (Figure 5B, lanes 2 and 
3). Treatment with various forms of DAS 
aborted DMBA induced upregulation of 
p53mut. As depicted in the Figure 5B, 
the level of p53mut was reduced to nor-
mal levels in the animals treated with 
pH-Lip-DAS. The treatment with Lip-
DAS yielded a 64 percent reduction of 
p53mut level, while there was a 40 per-
cent reduction in the animals treated 
with the free form of DAS (group IV). 
Surprisingly, treatment with Sham-Lip 
and Sham-pH-Lip (without DAS) also 
nullify DMBA-induced over-expression 
of p53mut although not significantly. 
These results clearly show DAS medi-
ated downregulation of p53mut, which 
was more apparent upon its intercalation 
in various forms of the liposomes used in 
the present study. 
We also studied the effect of lipo-
somized DAS on the expression of 
p21/Wafl, which was transcriptionally 
upregulated in the presence of p53wt. 
Immunoblot analysis showed increased 
expression of p2l/Wafl in liposomal 
DAS-treated groups. As shown in 
Figure 6, there was a 93 percent increase 
in the expression of p21 /wafl in the 
group of animals treated with pH-Lip-
DAS, while a 66 percent increment was 
recorded in the animals treated with Lip-
DAS liposomes (group V), and a 46 per-
cent increase occurred in the group of 
animals treated with the free form of 
DAS when compared with the DMBA-
exposed animals treated with acetone 
and cream. 
DISCUSSION 
A considerable emphasis is being 
placed upon the use of dietary con-
stituent DAS, an organosulphur com-
pound of garlic, to prevent and cure can-
cer in rodent tumor models (3,4,5,7,8,9, 
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Figure 5. A. Effect of various formulations of DAS on the expression of p53wt in mouse skin tumors. Skin/tumor lysates were prepared as 
described in Materials and Methods. Lysates were resolved by electrophoresis and analyzed for p53wt using anti-p53wt antibodies. To 
quantify equal loading, membranes were re-probed with p-actin antibody. The intensity of the bands was quantitated using Image 
Analysis software on an Image Gel Documentation System. Lane 1, untreated; lane 2, DMBA + Acetone; lane 3, DMBA + Cream; lane 4, 
DMBA + Sham-Up; lane 5, DMBA + Sham-pH-Lip; lane 6, DMBA + Free DAS: lane 7, DMBA + Lip-DAS; lane 8. DMBA + pH-Lip-DAS and lane 
9, Cream base only with no DMBA. B. Effect of various formulations of DAS on the expression of p53mut in mouse skin tumors. Skin/tumor 
lysates were prepared as described in Materials and Methods and analyzed for p53mut expression by Western blot analysis using anti-
body to p53mut. To quantify equal loading, membranes were reprobed with p-actin antibody. The intensity of the bands was quanti-
tated using Image Analysis software on an Image Gel Documentation System. Lane 1, untreated; lane 2. DMBA + Acetone; lane 3, 
DMBA + Cream; lane 4. DMBA + Sham-Lip; lane 5, DMBA + Sham-pH-Lip; lane 6, DMBA + Free DAS; lane 7, DMBA + Lip-DAS; lane 8. 
DMBA + pH-lip-DAS and lane 9, Cream base only with no DMBA. 
10,14,36,37). Although effective, the 
chemo-preventive properties of DAS are 
far from ideal to make it a potential fu-
ture chemo-preventive agent against skin 
cancer. The small size of the molecule 
probably results in poor accumulation 
and has not allowed attainment of effec-
tive therapeutic concentration at the 
tumor site. Earlier studies showed that 
localized drug delivery to the site of skin 
tumor could be enhanced significantly 
through the use of liposome-based drug 
carriers (19,21,22). The present study fo-
cuses on an evaluation of chemo-preven-
tive efficacy of DAS upon its incorpora-
tion in egg PC as well as pi l-sensitive 
liposomes and their potential against 
skin cancer in model animals. 
The data of the present study establish 
higher efficacy of both Lip-DAS (conven-
tional egg PC) and pH-Lip-DAS (pH-
sensitive) liposomes, which was assessed 
on the basis of their ability to delay onset 
of tumor induction, reduction in total 
numbers of tumor papilloma formation, 
and survival of the treated animals 
among other factors. Lip-DAS liposomes 
showed an efficient (84 percent) suppres-
sion of tumor growth, while its pH-
sensitive liposomal formulation was 
found to be more effective and induced 
around 94 percent tumor suppression (in 
comparison to the untreated control 
group). This clearly suggests that lipo-
somization offers a new and effective 
option to increase the chemo-preventive 
and anticarcinogenic potential of DAS in 
cancer therapy. The increased efficacy of 
liposomized DAS could be attributed to 
the fact that liposomes act as a sustained 
release system allowing greater accumu-
lation of drug molecules at the tumor site 
than that achieved by its free form 
(29,38,39,40). 
The higher efficacy of pH-Lip-DAS 
over Lip-DAS could be attributed to the 
fact that diallyl sulfide exerts its chemo-
preventive action by modulating apo-
ptotic factors present in the cytosol of the 
cancer cells, therefore its access to the cy-
tosol is crucial for the desired anticancer 
activity. In fact, pH sensitive liposomes 
undergo phosphatidyl-ethanolamine-
mediated phase transition at acidic pH, 
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Figure 6. Effect of various formulations of DAS on the expression of p21 /Waf 1 in mouse 
skin tumors. Skin/tumor lysates were prepared as described in Materials and Methods 
and proteins samples from various groups were employed for Western blots. The level 
of p21/wafl was assessed by Western blotting using anti-p21/Waf 1 antibodies. To 
quantify equal loading, membranes were reprobed with p-actin antibody. The inten-
sity of the bands was quantitated using Image Analysis software on an Image Gel 
Documentation System. Lane 1. untreated; lane 2. DMBA + Acetone; lane 3. DMBA + 
Cream; lane A. DMBA + Sham-Up; lane 5. DMBA + Sham-pH-Up; lane 6, DMBA + Free 
DAS; lane 7, DMBA + Lip-DAS; lane 8. DMBA + pH-Lip-DAS and lane 9. Cream base 
only with no DMBA. 
thereby delivering their content to the 
cytosol of the rumor cells (phosphatidyl-
ethanolamine is the main constituent of 
these liposomes). The polar head group 
of PE gets less hydrated as compared 
with the repulsive hydration layer asso-
ciated with the head group of PC. Thus 
PE provides a more hydrophobic bilayer 
surface that is susceptible to energetically 
more favorable interbilayer interactions. 
The phospholipid PE not only facilitates 
the close approach of bilayers, it may 
also be involved directly in the merging 
process. In this context, PE can form the 
hexagonal H„ phase, the formation of 
which involves the development of a 
non-lamellar structure, an intermediate 
in membrane fusion. The operative 
mechanism seems to form the basis of 
the observed higher efficacy of pH sensi-
tive liposomes over egg PC neutral lipo-
somes (41,42). In addition, the higher ef-
fectiveness of pH-sensitive liposome can 
also be justified on the premise that sites 
of greatest acidity in rumors are often 
most distant from the rumor microvascu-
lature, incidentally conventional lipo-
somes often fail to reach such locations 
(43,44,45), while pH-sensitive liposomes 
overcome this problem. 
The usage of liposomes as carrier of 
anticancer agents including DAS has 
added advantage as fatty acyl chains of 
phospholipids may also impart anti-
cancer effect against various cancers. For 
example, liposomes composed of phos-
phatidylcholine (PC) with 18.0 in the sn-1 
position and one of the following fatty 
acids in the sn-2 position: 18:0,18:1 
omega 9 (oleic), 18:3 omega 3 (a-
linolenic), 20:4 omega 6 (arachidonic), 
22:6 omega 3 (docosahexaenoic) have 
been shown to possess antitumor effects 
in vivo, leading to enhanced longevity of 
the tumor-bearing host (46). It has been 
reported that polyunsaturated phos-
phatidylcholine (PC) and phosphatidyl-
serine (PS) induce growth inhibition, dif-
ferentiation and apoptosis in Caco-2 cells 
(47). Our preliminary studies show that 
egg PC used in the present study is hav-
ing 18:0,18:1 and 16:0,16:1 fatty acid 
analogs (data not shown). Similarly, pH-
sensitive liposomes also contain 18:1 
oleic acids. Besides the intrinsic anti-
cancer effect of DAS, presence of unsatu-
rated fatty acids in liposomes also could 
be considered as a potential component 
to enhance the anticancer properties of 
the DAS liposome formulation. The data 
of the present study shows some level of 
anticancer activity by sham liposome 
preparation (with no DAS). However the 
effect was not substantial and could be 
attributed to the fact that the amount of 
the anticancer fatty acids used in the 
present study never touched the opti-
mum threshold levels required for their 
anticancer effect as opposed to the effects 
possible had we used phospholipids that 
exclusively consisted of fatty acyl chains 
with potent anticancer activity. Neverthe-
less, the present study clearly advocates 
the notion that in future studies we can 
always use tailor-made phospholipids 
which are equipped with desired fatty 
acyl chains having intrinsic anticancer 
properties. This will certainly make lipo-
some-based formulations potential can-
didates for use as drug delivery systems 
against cancer, including skin papilloma. 
In the next phase of study, we deliber-
ated the effect of liposomized DAS on 
various cell cycle regulating factors. The 
tumor suppressor gene p53 is regarded 
as a key factor in maintaining the bal-
ance between cell growth and cell death 
(48,49). We have reported earlier that 
DAS mediated modulation of p53 in 
DMBA induced skin rumors in Swiss al-
bino mice (9). The importance of the p53 
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gene can be drawn from the fact that this 
gene is mutated in -80 percent of all 
human malignancies (50). Because of its 
role in the regulation of the cell cycle, al-
terations in p53 levels are critical in car-
cinogenesis. High levels of activated and 
stabilized p53 protein accumulate in the 
nucleus in response to various forms of 
cell stresses, including DNA damage 
(51). Several nuclear localization signals 
in the C-terminus of p53 facilitate its 
transport to the nucleus where it is re-
quired in the regulation of transcription. 
Having entered the nucleus, regulatory 
mechanisms exist to control the export of 
p53 back out to the cytoplasm, which is 
required for its degradation (52). Acti-
vated p53 can induce cell cycle arrest, 
DNA repair processes, and apoptosis. 
These cellular outcomes are thought to 
minimize the accumulation of deleteri-
ous mutations that could eventually con-
tribute to a given malignant phenotype 
(53). Taking the above into consideration, 
the role of p53 in the cytoplasm is clearly 
secondary to its nuclear function, and 
nuclear localization is essential for p53 
actjvity. Indeed failure of wild type p53 
to localize to the nucleus, either due to 
defects in the ability to enter the nucleus 
or hyperactive nuclear export, appears to 
contribute to the inactivation of p53 in a 
number of tumors (52,54,55). In tumors, 
loss of p53wt prevents the activation of 
this growth control pathway (56). The 
failure to induce transcriptionally active 
p53wt plays a role in the unregulated 
growth of the tumors (57). Because the 
balance between p53wt and p53mut 
determines the fate of the cell, many 
chemo-preventive agents are known to 
exert their anticancer effects by modulat-
ing expression level of these molecules 
(58,59). In fact, it is the intrinsic property 
of DAS to modulate the balance between 
wild and mutated p53 protein expres-
sion. The effect of DAS on p53wt and 
p53mut gets more apparent upon its li-
posomization in neutral as well as pH-
sensitive liposomes. 
The upregulation of p53wt by chemo-
preventive agents also is responsible for 
the transcriptional induction of p21 / 
Wafl by directly interacting with its reg-
ulatory elements (57). As evident from 
the present study, liposomization of DAS 
in egg-PC or pH-sensitive liposomes en-
sued in upregulation of p21/Waf 1 as 
compared with the free form of the drug. 
The effect is more prominent in pH-
sensitive liposomes as compared with 
neutral egg PC liposomes. 
As the composition of the liposome is 
similar to the components of cell mem-
branes, they are likely to get absorbed by 
skin (60). To further increase the effect, 
we formulated cream-based liposomal 
formulations of DAS, which ought to im-
part better retention and penetration of 
the compound. When a liposome-bearing 
gel or cream is applied to the skin, the 
deposited liposomes begin to merge with 
(he cellular membranes. In the process, 
the liposomes release their payload of ac-
tive materials into the cells. As a conse-
quence, not only does this ensue in spe-
cific drug delivery of the active form of 
the drug directly into the target cells, the 
delivery also takes place over a longer 
period of time (61). 
The observed better efficacy of lipo-
somized DAS can be attributed to the 
liposome-mediated enhanced penetra-
tion, retention, and accumulation of the 
drug at the tumor site. Finally, we con-
clude that liposomal formulations of 
DAS can be a promising strategy for can-
cer treatment. Liposomal formulations 
not only overcome the problem of higher 
elimination of the drug from tumors, but 
the ability of liposomes to accommodate 
several thousand molecules in a single 
vesicle entity also helps in maintaining 
the effective drug concentration at the 
tumor site. 
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